

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2008 (12.09.2008)

PCT

(10) International Publication Number
WO 2008/106985 A1

(51) International Patent Classification:

A01K 67/027 (2006.01) C12N 15/85 (2006.01)
C12N 5/10 (2006.01)

(21) International Application Number:

PCT/DK2008/050058

(22) International Filing Date: 7 March 2008 (07.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PA 2007 00349	7 March 2007 (07.03.2007)	DK
PA 2007 00659	1 May 2007 (01.05.2007)	DK
PA 2007 01039	13 July 2007 (13.07.2007)	DK

(71) Applicant (for all designated States except US): AARHUS
UNIVERSITET [DK/DK]; Nordre Ringgade 1, DK-8000
C Århus (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MIKKELSEN,
Jacob Giehm [DK/DK]; Lillehammervej 13, DK-8600
Silkeborg (DK). MOLDT, Brian [DK/DK]; Mindegade
9, 2., DK-8000 C Århus (DK). NIELSEN, Anders Lade
[DK/DK]; Enggårdsvvej 4, DK-8230 Åbyhøj (DK). BOL-
UND, Lars Axel [DK/DK]; Tjørnebakken 7B, DK-8541
Skødstrup (DK). KRAGH, Peter, Michael [DK/DK];
Skelbækvej 43, DK-8240 Risskov (DK). JAKOBSEN,
Jannik Ejnar [DK/DK]; Rudolph Wulffs Gade 10, 4. tv.,
DK-8000 C Århus (DK). JØRGENSEN, Arne, Lund
[DK/DK]; Miltonsvej 13, DK-8270 Højbjerg (DK).

(74) Agent: HØIBERG A/S; St. Kongengade 59A, DK-1264
Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC,

[Continued on next page]

(54) Title: PIG MODEL




Fig. 7

(57) Abstract: The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a porcine embryo, blastocyst, foetus, donor cell and/or cell nucleus, derived from said genetically modified pig. In another aspect, the invention relates to any genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.



LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

Pig model

Field of invention

5 The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a recombinant target vector and uses thereof. Methods are disclosed for the production of genetically modified pigs.

Background of invention

10 Transgenic, non-human animals can be used to understand the action of a single gene or genes in the context of the whole animal and the interrelated phenomena of gene activation, expression, and interaction. The technology has also led to the production of models for various diseases in humans and other animals which contributes significantly to an increased understanding of genetic mechanisms and of genes
15 associated with specific diseases.

Traditionally, smaller animals such as mice have been used as disease models for human diseases and have been found to be suitable as models for certain diseases. However, their value as animal models for many human diseases is quite limited due to
20 differences in mice compared to humans. Larger transgenic animals are much more suitable than mice for the study of many of the effects and treatments of most human diseases because of their greater similarity to humans in many aspects. Particularly, pigs are believed to be valuable as disease models for human diseases.

25 Integration of foreign DNA plays a pivotal role in both genetic manipulation of cell lines and technologies related to therapeutic gene transfer. Current integrations strategies, based upon for example retroviral, lentiviral or DNA transposon-based vector systems allow efficient gene insertion, but all suffer from the fact that gene insertion is not controllable and cannot be directed to predetermined positions in the genomic DNA.

30 The yeast Flp recombinase, in contrast, facilitates sequence-specific integration (1), but the Flp recombination target sequence (FRT) does not exist in mammalian genomes. The site of integration is of great importance for the gene expression profile of the inserted gene. Hence, in some positions the gene will be stably expressed, whereas other positions are unable to support long-term expression due to strong influences
35 from the flanking DNA leading to transcriptional silencing. Such actions upon the

transgene may lead to reduced expression or complete shut-down of expression depending on cell type or tissue. For several purposes it is therefore of great importance to direct insertion towards 'stably' expressing loci. This may have particular importance in genetically manipulated animal models in which continued gene expression in the tissue of interest is essential for genetic studies. As another important example, cell therapies in which genetically altered effector cells are administered to patients (as in some cancer immunotherapy protocols) rely on stable transgene expression from loci that are not silenced over time.

10 The tyrosine recombinases Flp (2) and Cre, derived from yeast and E.coli phages, respectively, and the serine recombinase Φ C31 from S. lividans phages are cherished for their site-specific integrating properties. Φ C31 has been found to facilitate plasmid DNA recombination into pseudo recognition sites in the human genome and therefore has been extensively explored as a tool in gene therapy (3). In case of Flp and Cre, 15 however, the human genome does not contain recombination target sites and these sites need to be introduced in the genome prior to successful gene insertion (1). Although Cre-based recombination has been heavily studied and appears to be a bit more effectful than Flp in human cells, a now widely used Flp-based integration system has been commercialized by Invitrogen (cat. no. K6010-01). This system is based on a 20 FRT sequence contained within a lacZ-Zeocin fusion gene. This FRT-tagged gene is inserted into cells by nonhomologous recombination, an uncontrolled recombination process which is believed often to involve concatamer formation, leading to insertion of more than one copies of the foreign DNA. Characterized cell lines containing this FRT-lacZzeo insert are currently offered by Invitrogen, allowing researchers to insert 25 plasmid DNA containing their gene of interest into the FRT-tagged locus on offer in the particular cell line. This plasmid contains not only the transgene but also a FRT-hygro cassette that does not contain a start codon. By recombination between the two FRT sites (one in the genome and one on the plasmid) the start codon of the lacZzeo fusion is fused to the FRT-hygro cassette, allowing for expression of the hygro gene and 30 subsequent selection for hygromycin B resistance. This technology facilitates insertion of the entire plasmid including the bacterial backbone which is believed to have a negative impact on gene expression in mammalian cells potentially be inducing posttranscriptional silencing.

Transcriptional silencing of foreign genetic material is a fundamental problem in gene transfer and genetic engineering of cells and animals. Due to epigenetic modifications transgenic animal models therefore often suffer from reduced gene expression, or the lack of gene activity in tissues in which transcription is required to develop a desired phenotype. The choice of promoter influences the overall transgene expression profile in a transgenic animal and to a certain degree the level of gene silencing. However, positional effects and spreading of heterochromatin from flanking genomic regions are major contributors to gene silencing, and the site of integration of a transgene is crucial, therefore, for the fate of a foreign gene. In rodents, well-characterized loci supporting long-term gene expression have been identified. Based on these findings transgenic animal models have been generated by inserting genes by homologous recombination into such preferred sites.

The establishment of cloned pig models of genetic disease, is challenged by problems in identifying genomic loci that support ubiquitous or, for some models, tissue-specific expression of an inserted transgene. At present, the information that allows the insertion of genes into well-suited and predefined loci of porcine cells is not available. Moreover, by inserting disease genes at random positions we risk to target genomic sites that are eventually silenced during pig development and growth. Therefore, a need exists for a genetically modified pig harbouring an insertion site that allows for the integration of a transgene at a position in the genome wherein the transgene is stably expressed.

Summary of invention

The present invention concerns a genetically modified pig which allows for integration of transgenes for example disease-causing genes that will allow the study of said diseases. The genetically modified pig harbours a site for integration of a transgene in a stably expressing locus.

The present invention discloses a novel DNA transposon based approach for tagging the chromosomal DNA of cells of interest by introducing one or more recombination sites for site specific recombinases. Genes of interest for example genetic determinants of disease can subsequently be inserted into the genome of the cell by the use of substrates for recombination carrying the gene of interest.

Thus, one aspect of the present invention relates to a genetically modified pig, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

5 A second aspect of the present invention pertains to a genetically modified porcine blastocyst derived from the genetically modified pig model, wherein the genetically modified genome comprises at least one site for integration of at least one transgene, and/or a genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

10

Similarly, a third aspect relates to a genetically modified porcine embryo derived from the genetically modified pig model, wherein the genetically modified genome comprises at least one site for integration of at least one transgene, and/or a genetically modified porcine embryo, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

15

Furthermore, a fourth aspect relates to a genetically modified porcine fetus derived from the genetically modified pig model, wherein the genetically modified genome comprises at least one site for integration of at least one transgene, and/or a genetically modified porcine fetus, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

20

A fifth aspect of the present invention pertains to a genetically modified porcine donor cell and/or cell nucleus derived from the genetically modified pig model, wherein the genetically modified genome comprises at least one site for integration of at least one transgene, and/or a genetically modified porcine donor cell and/or cell nucleus, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

25

30 It is appreciated that in a preferred embodiment of the present invention the at least one site for integration of at least one transgene is a heterologous recombination site.

Embodiments for the present invention comprises mini-pigs for example selected from the group consisting of Goettingen, Yucatan, Bama Xiang Zhu, Wuzhishan and Xi Shuang Banna, including any combination thereof. In a preferred embodiment the pig,

35

embryo, blastocyst, fetus and/or cells thereof is a Goettingen minipig. However, another embodiment relates to pigs that are not a mini-pig, such as the species of *Sus domesticus*, for example where the pig is selected from the group consisting of Landrace, Yorkshire, Hampshire, Duroc, Chinese Meishan, Berkshire and Piétrain, including any combination thereof.

Embodiments of the present invention comprises the genetically modified pig, porcine embryo, blastocyst, fetus and/or cells thereof, wherein the genetically modified genome comprises at least one recombination site for site-specific gene insertion, for example at least one recombination site for Fip and/or Cre recombinase, or at least one recombination site is a recombination site for Fip. Thus the genetically modified pig comprises a transposon tagged genome by a recombinant vector as disclosed herein. The genetically modified pig may further comprise at least one transgene, displaying a phenotype associated with disease.

A sixth aspect of the invention pertains to a genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, wherein the genetically modified genome comprises at least one gene of interest obtained by recombination into the at least one site for integration. Such a genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell is for example obtainable by use of the recombinant vector as disclosed elsewhere herein and/or by the system described elsewhere herein.

A seventh aspect of the invention pertains to a recombinant target vector comprising a DNA transposon construct comprising a bicistronic gene cassette comprising (i) at least one recombination site and ii) an IRES-driven selection gene. Within the scope of the present invention is for example the recombinant vector, wherein said DNA transposon is the Sleeping Beauty (SB) DNA transposon. The DNA transposon is for example selected from the group consisting of the Sleeping Beauty (SB) transposon, Frog Prince (FP) transposon, Piggybac transposon, Tol2 transposon, Himar 1 transposon and passport transposon. In a particular embodiment the DNA transposon is the Sleeping Beauty transposon. The recombinant target vector in one embodiment comprises at least one FRT, attB/P and/or LoxP recombination site. In a preferred embodiment the recombinant target vector comprises at least one recombination site in the form of a FRT and/or LoxP recombination site, more preferably a FRT recombination site. The recombination site is in one embodiment embedded in the coding sequence of a reporter gene and/or selection gene, for example the eGFP gene, for example the FRT recombination site is embedded in a SV40 promoter driven

fusion variant of eGFP. Another embodiment of the present invention relates to the genes driven by the IRES, wherein said gene is a gene conferring resistance to a drug, for example a puromycin resistance gene. The recombinant vector further comprises in another embodiment at least one recognition site for a Cre recombinase., for example wherein said at least one recognition site for Cre recombinase is located between the upper inverted repeat of the vector and the SV40 promoter, for example wherein said at least one recognition site for Cre recombinase is located between the poly A sequence and the lower inverted repeat of the vector.

- 10 A further aspect of the present invention relates to a bi-phase system comprising a recombinant target vector as disclosed herein and a recombination substrate. A recombination substrate comprises a fusion of at least one recognition site for a recombinase and a gene of interest. In one embodiment of this aspect the recombination substrate is present in a plasmid, an in vitro generated plasmid-derived minicircle and/or a lentiviral circle.

- Yet a further aspect of the present invention relates to a mammalian cell comprising a DNA transposon tagged genome containing a recombination target site for site-specific gene integration. In one embodiment of the invention the recombination target site is a heterologous target site not ordinarily found in the genome of the mammalian cell. In one embodiment the cell comprises a DNA transposon tagged genome by a recombinant vector as defined herein. In another embodiment the genome of the cell further contains at least one recognition site for Cre-recombinase. The mammalian cell is a somatic cell, for example of porcine origin, for example a fibroblast, such as a primary somatic cell, for example a porcine primary fibroblast, or a porcine neonatal fibroblast.

- An additional aspect of the present invention pertains to a method for producing a mammalian cell comprising a DNA transposon tagged genome comprising at least one recombination target site for site-specific gene insertion comprising the steps of a) providing a mammalian cell, b) transfecting the cell of a) with a plasmid expressing a transposase and a recombinant vector comprising a DNA transposon construct and a bicistronic gene cassette comprising (i) a recombination site and ii) an IRES-driven selection gene, c) selecting DNA transposon tagged cells. In one embodiment the method further comprises a step of recombination using the recombination substrate as

disclosed herein.. The cell of the method is a somatic cell, for example of porcine origin, for example a fibroblast, such as a primary somatic cell, for example a porcine primary fibroblast.

- 5 A further aspect of the present invention relates to a method for obtaining the genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, wherein the genetically modified genome comprises at least one site for integration of at least one transgene comprising the steps of i) providing a donor cell, ii) genetically modifying the donor cell of i) by inserting the recombinant vector as defined herein into the
- 10 genome of said donor cell, iii) transferring the modified genome of the donor cell obtained in ii) into a host cell, iv) obtaining a reconstructed embryo forming an embryo, v) culturing said embryo; and vii) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus, wherein said genetically modified embryo obtainable by nuclear transfer comprises steps i) to v)
- 15 and/or vi), wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii), wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii)

- Yet a further aspect of the present invention concerns a genetically modified pig model,
- 20 porcine embryo, blastocyst, fetus and/or donor cell, wherein the genetically modified genome comprises at least one site for integration of at least one transgene obtainable by nuclear transfer comprising the steps of i) establishing at least one oocyte having at least a part of a modified zona pellucida, ii) separating the oocyte into at least two parts obtaining an oocyte having a nucleus and at least one cytoplasm, iii) establishing a
- 25 donor cell or cell nucleus with desired genetic properties, iv) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus, v) obtaining a reconstructed embryo,vi) activating the reconstructed embryo to form an embryo; culturing said embryo; and vii) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus, wherein said
- 30 genetically modified embryo obtainable by nuclear transfer comprises steps i) to v) and/or vi), wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii), wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii)

An additional aspect of the present invention pertains to a method for producing a genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, comprising at least one recombination site comprising: i) establishing at least one oocyte, ii) separating the oocyte into at least three parts obtaining at least one cytoplasm, iii) establishing a donor cell or cell nucleus having desired genetic properties, such as at least one heterologous recombination site iv) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus, v) obtaining a reconstructed embryo, vi) activating the reconstructed embryo to form an embryo; culturing said embryo; and vii) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus, wherein said genetically modified embryo obtainable by nuclear transfer comprises steps i) to v) and/or vi) , wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii), wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii)

15

Yet a further aspect relates to a method for producing a genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell comprising:

- i) establishing at least one oocyte
- ii) separating the oocyte into at least three parts obtaining at least one cytoplasm,
- iii) establishing a donor cell or cell nucleus having desired genetic properties, wherein the donor cell is established from a genetically modified pig carrying in its genome at least one site for integration of at least one transgene
- iv) providing a transgene and integrating said transgene into the donor cell of iii)
- v) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus,
- vi) obtaining a reconstructed embryo,
- vii) activating the reconstructed embryo to form an embryo;
- viii) culturing said embryo; and
- ix) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus, wherein said genetically modified embryo obtainable by nuclear transfer comprises steps i) to v) and/or vi) ,

20

25

30

wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii), wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii)

- 5 A further aspect relates to the genetically modified pig model, porcine embryo, blastocyst, fetus and/or donor cell of the present invention obtainable by nuclear transfer comprising the steps of
- i) establishing at least one oocyte having at least a part of a modified zona pellucida,
 - 10 ii) separating the oocyte into at least two parts obtaining an oocyte having a nucleus and at least one cytoplasm,
 - iii) establishing a donor cell or cell nucleus with desired genetic properties, wherein the donor cell is established from a genetically modified pig carrying in its genome at least one site for integration of at least one transgene
 - 15 iv) providing a transgene and integrating said transgene into the donor cell of iii)
 - v) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus,
 - 20 vi) obtaining a reconstructed embryo,
 - vii) activating the reconstructed embryo to form an embryo;
culturing said embryo; and
 - viii) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus, wherein said genetically modified embryo obtainable by nuclear transfer comprises steps i) to v) and/or vi) ,
 - 25 wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii), wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii).
- 30 Embodiments of the aspects comprise one or more of the features as defined herein, wherein the method for activation of the reconstructed embryo is selected from the group of methods consisting of electric pulse, chemically induced shock, increasing intracellular levels of divalent cations and reducing phosphorylation. Further embodiments of the second and third aspects comprise one or more of the features as
- 35 defined above, wherein steps d) and f) are performed sequentially or simultaneously,

and embodiments comprising one or more of the features, wherein the embryo is cultured in vitro. Such embryo may be cultured in sequential culture. The embryo, for example at the blastocyst stage, is cryopreserved prior to transfer to a host mammal. For the methods of the present invention embodiments cover pigs, mini-pigs for example selected from the group consisting of Goettingen, Yucatan, Bama Xiang Zhu, Wuzhishan and Xi Shuang Banna, including any combination thereof. However, another embodiment relates to pigs that are not a mini-pig, such as the species of *Sus domesticus*, for example where the pig is selected from the group consisting of Landrace, Yorkshire, Hampshire, Duroc, Chinese Meishan, Berkshire and Piêtrain, including any combination thereof.

In a final aspect of the present invention the recombinant vector described herein is used for the production of genetically modified mammalian cells, comprising at least one site for integration of a transgene.

Description of Drawings

Figure 1 shows the bi-phased technology of the present invention in which an integrating SB vector, carrying a reporter gene and a selective marker gene, serves as a reporter for continuous gene expression and hence as a target for gene insertion. In a second modification step this vector may serve as a target for insertion of one or more gene expression cassettes in a well-characterized locus.

Figure 2 shows a Sleeping Beauty docking vector system for controlled porcine transgenesis by Flp-directed gene insertion. A) Schematic description of the SB transposon plasmid used in the first step of transgenesis. The pSBT/SV40-FGIP plasmid includes a gene cassette flanked by LIR and RIR elements which enable transposition of the gene insert in the presence of SB transposase. The gene cassette includes the SV40 promoter driving the expression of a transcript encoding eGFP and the puromycin resistance gene. Co-expression of the proteins is achieved by the presence of an internal ribosomal entry site (IRES) after the eGFP coding region. In the 5'-region of the eGFP gene (immediately flanking the start codon) is inserted an FRT site that allows Flp-mediated recombination. After transposase-mediated integration into the host genome, the gene cassette represents an acceptor locus for further transgenesis. The FRT site is located just 3' of the start codon of eGFP and thus

enable a controlled recombination event that separates this start codon from the rest of the eGFP gene and, accordingly, abolishes eGFP translation. B) Schematic representation of the Flp donor plasmid, used in the second step of transgenesis, and the result of Flp-directed transgenesis. The Flp donor plasmid contains the CMV promoter which controls the expression of a transcript encoding the DsRed protein which is used as a marker. In addition, the donor plasmid includes a promoter-free gene cassette including the hygromycin B resistance gene and a polyadenylation signal. The 5'-region of the hygromycin resistance gene is modified to include a FRT recombination site and to lack a translational start codon. The lower part of the figure illustrates Flp-mediated recombination for insertion of the donor sequence into the acceptor locus.

Figure 3 shows the transposition efficiency of pSBT/RSV-GFIP by co-transfecting with pCMV-SB and pCMV-mSB, respectively, in HEK-293 cells. As expected the GFIP transposon was efficiently transposed into the genomic DNA thereby conferring resistance to puromycin. Fig. 3, insert, shows an example of a puromycin-resistant colony generated with two-plasmid transfections, stable eGFP expression was verified by fluorescence microscopy.

Figure 4 shows Sleeping Beauty transposition in porcine fibroblasts. A) Schematic description of the pSBT/PGK-puro plasmid used to examine the potential of SB transposons for transgenesis in neonatal pig fibroblasts (NPFs). A puromycin resistance gene driven by the PGK promoter is flanked by LIR and RIR sequences. B) NPFs support SB transgenesis. 2.6×10^4 NPFs were co-transfected with pSBT/PGK-puro and with plasmid DNA encoding one of the following three variants of SB transposase: mSB which represents an inactive transposase variant, SB10 which is the original SB transposase, and HSB3 which is a hyperactive transposase variant. The experiments were carried out in triplicates and the number of cell colonies was counted after 9 days of puromycin selection.

Figure 5 shows that transgenesis by SBT/SV40-FGIP transposition is dependent of a functional transposase. The pSBT/SV40-FGIP plasmid was transfected together the plasmid DNA encoding mSB, SB10, or HSB3. The number of puromycin-resistant colonies was counted after 9 days of puromycin selection. Representative colonies were analyzed by phase contrast and epi-fluorescence microscopy to determine

homogeneity in eGFP expression. The cell lines analyzed were in A) HEK-293, B) NIH-3T3, and C) NPFs.

Figure 6 shows substitution of transgenes by Flp-mediated recombination. A) and B).
5 Flp-based gene insertion into integrated SB docking vector. NIH3T3 and HEK293 cell lines derived from pSBT/SV40-FGIP-mediated transgenesis (seeded at 8×10^5 cells/dish) were re-transfected with the FRT donor plasmid in the presence (+) or absence (-) of plasmid DNA encoding the Flp recombinase. The number of hygromycin B-resistant colonies was counted. The cell clones used were in A) derived from NIH-
10 3T3 cells and in B) from HEK293 cells. C) Flp-mediated recombination is possible in NPFs. To identify Flp-mediated recombination event in NPFs, cellular DNA was purified from cells co-transfected with the FRT donor plasmid and the Flp expression vector and from control cells with the donor plasmid but lacking Flp expression. A PCR amplification was performed with a forward primer located downstream of LIR in
15 pSBT/SV40-FGIP transposon and a reverse primer at the beginning of the hygromycin B gene located in the donor plasmid. Molecular weight markers are shown to the left. D) Fluorescence analysis of Flp-mediated gene shifting. Cells from HEK-293 clone 4 containing the SBT/SV40-FGIP transposon were re-transfected with the FRT donor plasmid and the Flp expression vector. After the indicated number of days the
20 presence of green fluorescence and red fluorescence was determined by epifluorescence analysis of cell clones obtained under hygromycin B selection. The upper two panels (labelled '-Flp') show the HEK-293 cell clone used in the analysis. In the bottom part, puromycin selection was re-introduced resulting in cellular death. E) Fluorescence analysis of Flp-mediated gene shifting in NPFs. Experimental conditions
25 were as described in D).

Figure 7 shows that transgenic NPFs give rise to viable porcine blastocysts. A) Fluorescence analysis of the NPF colony used for nuclear transfer. The cell clone was derived from NPFs co-transfected with the pSBT/SV40-FGIP vector and the pCMV-
30 HSB3.Topo plasmid coding for the hyperactive SB transposase. After selecting with puromycin for 9 days the cell clone was analyzed by microscopy and the cells subsequently propagated. B) SBT/SV40-FGIP-transgenic NPF cells give rise to viable blastocysts. A representative blastocyst derived by nuclear transfer from the cells shown in A) was analyzed by fluorescence microscopy. The green fluorescent colour is
35 evident in the inner cell mass (ICM) and in the trophoblast (TB) layer in particular.

Figure 8 To facilitate Flp-based gene insertion into integrated SB vectors HEK-GFIP1, HEK-GFIP2, and HEK-GFIP3 were co-transfected with pcDNA/FRT (containing the FRT-hygro fusion gene) and pCMV-Flpx9. Upon subsequent hygromycin B selection
5 312, 53, and 1800 drug-resistant colonies appeared in the three cell lines shown in figure 3.

Figure 9 shows a schematic representation of circular DNA intermediates that are generated during lentivirus infection and which are often considered dead-end reverse-
10 transcribed products of infection. 2-LTR DNA circles are generated by DNA repair and ligation of the full-length linear viral DNA (Fig. 4, left), whereas 1-LTR DNA circles are generated by homologous recombination between the two LTRs of the episomal and linear viral DNA (Fig. 4, right). We hypothesized that these circles, generated during lentiviral vector transduction, may support Flp-based recombination, allowing site-
15 specific integration of DNA circles devoid of bacterial sequences (Fig. 4, bottom)

Figure 10 To maximize circle formation and accumulation we generated integration-defective lentiviral vectors (ID-LVs) which contained a mutated inactive integrase protein. We generated a lentiviral vector, pLV/FRT-hygro.PGK-puro, that contains the
20 FRT-hygro recombination sequence and found in transduction titer assays that this vector was only slightly less efficiently transferred in comparison to the original vector

Figure 11 shows HEK-GFIP3 cells were transfected with pCMV-Flpx9 and on the following day transduced transfected cells with ID-LV/FRT-hygro.PGK-puro at a
25 MOI~100. Based on transfection and transduction of about 10^7 cells, we obtained in triplicate assays on average approximately 20 hygromycin B-resistant colonies (Fig. 6A). Background activity was not registered in cells transfected with pUC19 prior to ID-LV/FRT-hygro.PGK-puro-transduction. PCR amplifications using as template genomic DNA from 10 of the hygromycin B-resistant colonies verified that DNA circles had been
30 inserted site-specifically into SB-tagged loci (Fig. 6B). PCR across the FRT integration site resulted in band sizes indicative of specific gene insertion, whereas primers that amplified sequences containing the LTR region(s) of the integrated circles resulted in amplicons with either one or two LTRs (Fig. 6B)

35 Figure 12 shows triplicate assays using the indicated substrates.

Figure 13 ID-LV co-transduction results in site-specific lentiviral DNA circle insertion.

Figure 14 shows a schematic representation of pSBT/RSV-GFIP.

5

Figure 15 shows transposition of SB vectors in porcine fibroblasts. A standard transposon encoding a puromycin resistance gene (SBT/PGK-puro) was employed and varying levels of transposition were detected, resulting in about 75 drug-resistant colonies in cultures of fibroblasts co-transfected with pSBT/PGK-puro and pCMV-SB, less than 3 colonies appeared after transfection with pSBT/PGK-puro and pCMV-mSB, the latter which encodes an inactive version of the transposase. Interestingly, a mean of almost 140 colonies was obtained using the hyperactive transposase variant HSB3, indicating that HSB3 also in porcine cells mediates higher levels of transposition compared to the original SB transposase.

15

Figure 16 shows efficient insertion of a FRT-tagged SB vector in pig fibroblasts SB-tagged cell clones containing a Flp recombination target site for site-specific gene insertion were co-transfected the pSBT/loxP.SV40-loxP257 plasmid with pCMV-mSB, pCMV-SB, and pCMV-HSB3, respectively. HSB3 again showed the highest activity, resulting in about 30 drug-resistant colonies after transfection of 3×10^4 fibroblasts.

20

Figure 17 shows clone analysis by fluorescence microscopy of isolated and expanded puromycin-resistant colonies demonstrates efficient FRTeGFP expression

25

Figure 18 shows a gene shift with the help of the Sleeping Beauty (SB) DNA transposon technology and Flpe recombination is presented in this example. We inserted into HEK 293 cells a SB transposon containing an eGFP gene and an frt site. The frt site enables gene shifting with a donor plasmid containing the RFP gene as well as an frt site.

30

Figure 20 shows a gene shift in HEK293 cells derived from clone 4. The eGFP gene linked to a puromycin resistant gene is shifted with a RFP gene linked to a hygromycin gene.

Figure 21 top shows the transposase efficiency in fibroblast cells of a mini pig, using a PGK (phosphoglycerate kinase) promoter – puromycin transposon; lower diagram shows the transposase efficiency in fibroblast cells of a mini pig, using a modified GFIP transposon.

5

Figure 22 shows viable cells and blastocysts comprising a transposon tagged genome carrying an eGFP gene.

Figure 23. (a) Oocytes trisection; (b) couplets of fibroblast-oocyte fragment for the first fusion; (c) embryos reconstructed with triplets (note elongation under the AC currency); (d) triplets fusion. Scale bar = 50 μ m.

10

Figure 24 (a) In vitro matured oocytes after partial zona digestion. (b) Delipated oocytes after centrifugation. (c) Bisection of delipated oocytes. (d) Couplets of fibroblast-oocyte fragment for the first fusion. (e) Four-cell stage reconstructed embryos developed from delipated oocytes. (f) Four-cell stage reconstructed embryos developed from intact oocytes. (g) Re-expanded blastocysts from delipated embryos after warming. (h) Hoechst staining and UV illumination of re-expanded blastocysts from delipated embryos after warming. Bar represents 100 μ m.

15

20

Figure 25. Bisection at chemically assisted enucleation. Note the extrusion cone or polar body connected to the smaller part (putative karyoplast). Stereomicroscopic picture. Bar represents 50 μ m.

Figure 26. Hoechst staining and UV illumination of the absence and presence of chromatin. UV light, inverted fluorescent microscopic picture. Bar represents 50 μ m. (a) The absence of chromatin in putative cytoplasts (b) The presence of chromatin in putative karyoplasts.

25

Figure 27. Stereomicroscopic picture of Day 7 blastocysts produced with chemically assisted handmade enucleation (CAHE). Bar represents 50 μ m.

30

Figure 28. Hoechst staining and UV illumination of blastocyst developed after chemically assisted handmade enucleation (CAHE). Bar represents 50 μ m.

35

Detailed description of the invention

In the description that follows, a number of terms used in molecular biology are utilized. In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

5 The terms 'transgenic' pig and 'genetically modified' pig are used in identical meaning herein.

The terms 'transgene' and 'gene of interest' are used herein in identical meaning herein.

The term 'recombination substrate' is herein also referred to as 'donor plasmid'.

10

The term 'DNA transposon tagged genome' refers to a genome in which a DNA transposon based DNA vector construct has been introduced. The introduced DNA transposon-based vector construct is also referred to as the integrated docking vector, for example the integrated SB docking vector (puro+, eGFP+).

15

IRES is short for internal ribosome entry site, which is a nucleotide sequence that allows for translation initiation in the middle of a messenger RNA (mRNA) sequence as part of the greater process of protein synthesis. Usually, in eukaryotes, translation can only be initiated at the 5' end of the mRNA molecule, since 5' cap recognition is
20 required for the assembly of the initiation complex. IRES mimics the 5' cap structure, and is recognized by the 40S pre-initiation complex. When an IRES segment is located between two reporter open reading frames in a eukaryotic mRNA molecule (a bicistronic mRNA), it can drive translation of the downstream protein coding region independently of the 5'-cap structure bound to the 5' end of the mRNA molecule. In
25 such a setup both proteins are produced in the cell. The first reporter protein located in the first cistron is synthesized by the cap-dependent initiation approach while translation initiation of the second protein is directed by the IRES segment located in the intercistronic spacer region between the two reporter protein coding regions.

30

Transposons are mobile genetic elements. Transposons are structurally variable, being described as simple or compound, but typically encode a transposition catalyzing enzyme, termed a transposase, flanked by DNA sequences organized in inverted orientations. For a more thorough discussion of the characteristics of transposons, one may consult Mobile Genetic Elements, D. J. Sherratt, Ed., Oxford University Press
35 (1995) and Mobile DNA, D. E. Berg and M. M. Howe, Eds., American Society for

Microbiology (1989), Washington, D.C. both of which are specifically incorporated herein by reference.

Recombination Sites

5 A key feature of the recombination reactions mediated by the above-noted recombination proteins are recognition sequences, often termed "recombination sites," on the DNA molecules participating in the recombination reactions. These recombination sites are discrete sections or segments of DNA on the participating nucleic acid molecules that are recognized and bound by the recombination proteins during recombination. For example, the recombination site for Cre recombinase is loxP 10 which is a 34 base pair sequence comprised of two 13 base pair inverted repeats (serving as the recombinase binding sites) flanking an 8 base pair core sequence. See FIG. 1 of Sauer, B., Curr. Opin. Biotech. 5:521-527 (1994). Other examples of recognition sequences include the attB and attP sequences which are recognized by 15 the recombination protein 1 Int. attB is an approximately 25 base pair sequence containing two 9 base pair core-type Int binding sites and a 7 base pair overlap region, while attP is an approximately 240 base pair sequence containing core-type Int binding sites and arm-type Int binding sites as well as sites for auxiliary proteins integration host factor (IHF), FIS and excisionase (Xis). See Landy, Curr. Opin. Biotech. 3:699-707 20 (1993).

The term "genetic determinant" is used herein to refer to a single-stranded or double-stranded "polynucleotide molecule" or "nucleic acid" comprising a structural gene of interest. The "genetic determinant" encodes a protein not ordinarily made in 25 appreciable amounts in the target cells. Thus, "genetic determinants" include nucleic acids which are not ordinarily found in the genome of the target cell. "Genetic determinants" also include nucleic acids which are ordinarily found within the genome of the target cell, but is in a form which allows for the expression of proteins which are not ordinarily expressed in the target cells in appreciable amounts. Alternatively, 30 "genetic determinants" may encode a variant or mutant form of a naturally-occurring protein.

The terms "polynucleotide" and "nucleic acid" are used interchangeably, and, when used in singular or plural, generally refers to any polyribonucleotide or 35 polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or

DNA. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term "polynucleotide" specifically includes cDNAs. The term includes DNAs (including cDNAs) and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term "polynucleotides" as defined herein. In general, the term "polynucleotide" embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells.

As used herein, a nucleotide is a base-sugar-phosphate combination. Nucleotides are monomeric units of a nucleic acid molecule (DNA and RNA). The term nucleotide includes ribonucleoside triphosphates ATP, UTP, CTG, GTP and deoxyribonucleoside triphosphates such as DATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives include, for example, [α .S]dATP, 7-deaza-dGTP and 7-deaza-dATP. The term nucleotide as used herein also refers to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives. Illustrated examples of dideoxyribonucleoside triphosphates include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP.

As used herein, a promoter is an example of a transcriptional regulatory sequence, and is specifically a DNA sequence generally described as the 5'-region of a gene located proximal to the start codon. The transcription of an adjacent DNA segment is initiated at the promoter region.

The term ' recombination site' is a recognition sequence on a nucleic acid molecule participating in an integration/recombination reaction by recombination proteins.

Recombination sites are discrete sections or segments of nucleic acid on the participating nucleic acid molecules that are recognized and bound by a site-specific recombination protein during the initial stages of integration or recombination. For example, the recombination site for Cre recombinase is loxP which is a 34 base pair sequence comprised of two 13 base pair inverted repeats (serving as the recombinase binding sites) flanking an 8 base pair core sequence. See FIG. 1 of Sauer, B., Curr. Opin. Biotech. 5:521-527(1994). Other examples of recognition sequences include the attB, attP, attL, and attR sequences described herein, and mutants, fragments, variants and derivatives thereof, which are recognized by the recombination protein 1 Int and by the auxiliary proteins integration host factor (IHF), FIS and excisionase (Xis). See Landy, Curr. Opin. Biotech. 3:699-707 (1993).

As used herein, a vector is a nucleic acid molecule (preferably DNA) that provides a useful biological or biochemical property to an Insert. Examples include plasmids, phages, autonomously replicating sequences (ARS), centromeres, and other sequences which are able to replicate or be replicated in vitro or in a host cell, or to convey a desired nucleic acid segment to a desired location within a host cell. A vector can have one or more restriction endonuclease recognition sites at which the sequences can be cut in a determinable fashion without loss of an essential biological function of the vector, and into which a nucleic acid fragment can be spliced in order to bring about its replication and cloning. Vectors can further provide primer sites, e.g., for PCR, transcriptional and/or translational initiation and/or regulation sites, recombinational signals, replicons, selectable markers (ie. selection genes).

Genetic modification

The present invention pertains to a genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

It will be appreciated that the invention does not comprise processes for modifying the genetic identity of pigs which are likely to cause them suffering without any substantial medical benefit to man or animal, or animals resulting from such processes.

The present invention also relates to modified pig embryos, blastocysts, donor cells and/or fetuses obtainable by the methods described herein.

5 The methods for producing the pig model described herein do not encompass a surgical step performed on the pig.

10 The present invention relates to a genetically modified pig, wherein the genetically modified genome comprises at least one site for integration of at least one transgene. However, the present invention also relates to porcine blastocysts, embryos, fetuses and/or cells (for example cells to be used as donor cells in nuclear transfer) derived from the genetically modified pig the genome of which comprises at least one site for integration of at least one transgene.

15 Within the scope of the present invention are also genetically modified porcine blastocysts, embryos, fetuses and/or cells, wherein the genetically modified genome comprises at least one site for integration of at least one transgene. Such genetically modified porcine blastocysts, embryos, fetuses and/or cells may be obtained by use of the recombinant target vector, and/or system of the present invention, followed by nuclear transfer as described elsewhere herein.

20 It is appreciated that the genetically modified pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) in the genome comprise more than one site for integration of at least one transgene. Thus, the genome comprises two, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 sites for integration of at least one transgene.

25 The at least one site for integration of at least one transgene is in a preferred embodiment a recombination site. The at least one site for integration is a heterologous recombination site (nucleic acids), which is not ordinarily found in the genome of the pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus).

30 The present invention takes advantage of the Cre-Lox recombination technology involving the recombination of sequences between lox P sites by the Cre recombinase protein. In another embodiment the vector comprises sequences of site directed recombination technology, namely the involving the recombination of sequences between FRT sites by the Flp (and enhanced Flp, Flpe) recombination enzyme derived from *Saccharomyces cerevisiae*. In yet another embodiment the vector of the present

35

invention takes advantage of the attB/P- Φ C31 recombination technology, wherein the vector comprises attB/P recognition sequences for the Φ C31 recombinase. Thus, the recombination technology used in the present invention may be selected from the group consisting of the Cre-LoxP, Flp-FRT, Flpe-FRT and attB/P- Φ C31 systems.

5

Accordingly, the at least one site for integration of at least one transgene present in the genome of of the pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) is a recombination site for a recombinase. Non-limiting examples of recombination sites are recombination sites for Flp, Flpe, Flpx9, Φ C32 and/or Cre
10 recombinase. Thus, in one embodiment the at least one site for integration of at least one transgene present in the genome of of the pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) is a recombination site for recombinases selected from the group consisting of Flp, Flpe, Flpx9 and Cre recombinase. In another embodiment the recombination site for recombinases is
15 selected from the group consisting of Flp, Flpe and attB/P. In preferred embodiment the recombination site is for the Flp recombinase. However, in another preferred embodiment the at least one recombination site is for Flpe or Flpx9 recombinase.

Non-limiting examples of the at least one site for integration of at least one transgene present in the genome of the pig, porcine blastocysts, embryos, fetuses and/or cells
20 (donor cells and/or cell nucleus) are FRT, attB, attP, attB/P and Lox P recombination sites. Thus, the at least one site for integration present in the genome of of the pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) is selected from the group consisting of FRT, attB/P and Lox P. It is within the scope of the present invention that the at least one site for integration is any of FRT, attB, attP,
25 attB/P or Lox P, in separate embodiments or in any combination. In a preferred embodiment the at least one site for integration is a FRT site (SEQ ID NO.: 1). In another preferred embodiment the at least one site for integration is a Lox P site for example the wtLoxP (SEQ ID NO.:2), or the core thereof (SEQ ID NO.:3), or for example the LoxP257 (SEQ ID NO.:4), or the core thereof (SEQ ID NO.:5). In yet
30 another preferred embodiment the at least one site for integration is a full length attB site (SEQ ID NO.:6, or an attB core site (SEQ ID NO.:7), or for example an attP site (SEQ ID NO.:8).

In one embodiment the genome of the genetically modified pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) comprise at least one selection gene and/or reporter gene. The selection gene is any gene conferring resistance to a drug as described elsewhere herein. In a preferred embodiment the
5 gene is a puromycin resistance gene (SEQ ID NO.:9). Alternatively, the selection gene is the eGFP gene (SEQ ID NO.:10).

In another embodiment the genome of the genetically modified pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) comprise at least one IRES element, for example the IRES element of SEQ ID NO:11.

10 Furthermore, the genome of the genetically modified pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) comprises in another embodiment promoter sequences. A number of suitable promoters are listed elsewhere herein. In one preferred embodiment the promoter is a Rous sarcoma virus (RSV) promoter (SEQ ID NO:12), simian virus 40 (SV40) promoter (SEQ ID NO:13), and/or the
15 promoter of ubiquitin (Ubi) (SEQ ID NO:14).

However, in another embodiment the genome of the genetically modified pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) comprise left inverted repeat and/or right inverted repeat originating from the SB transposon (SEQ ID NO:15).

20 The pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) of the present invention further comprise elements of the recombinant target vector as described elsewhere herein. When the recombinant target vector of the present invention is integrated into the genome of the pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) the recombinant target
25 vector is referred to as the integrated SB docking vector and the genome is referred to as the transposon-tagged genome obtained by integration of the recombinant target vector pSBT/SV40-GFIP.loxP (SEQ ID NO:16) or part thereof, transcriptional product or part thereof and/or translational product or part thereof, or the pSBT/RSV-GFIP (SEQ ID NO:17) or part thereof, transcriptional product or part thereof and/or translational
30 product or part thereof, or pSBT/SV40-GFIP (SEQ ID NO:18) or part thereof, transcriptional product or part thereof and/or translational product or part thereof, or

pSBT/SV40-GFIP.loxP (SEQ ID NO:19) or part thereof, transcriptional product or part thereof and/or translational product or part thereof.

5 In one preferred embodiment the at least one site for integration is a recombination site for site-specific transgene insertion. Transposons are sequences of DNA that can move around to different positions within the genome of a single cell and transposons are therefore often referred to as mobile genetic elements. A DNA transposon acts by cut and paste, using a transposase enzyme which binds to single-stranded DNA and incorporates it into genomic DNA. Different types of transposase work in different ways. 10 Some can bind to any part of the DNA molecule, and the target site can therefore be anywhere, while others bind to specific sequences. Transposase makes a staggered cut at the target site producing sticky ends, cuts out the transposon and ligates it into the target site. A DNA polymerase fills in the resulting gaps from the sticky ends and DNA ligase closes the sugar-phosphate backbone. This results in target site duplication and the insertion sites of DNA transposons may be identified by short direct repeats (a 15 staggered cut in the target DNA filled by DNA polymerase) followed by inverted repeats (which are important for the transposon excision by transposase). Thus, in the present context site-specific transgene insertion is characterised by the site in which the transposase has inserted the transposon. The site in which the transposon is inserted may be at a position in the genome which is partially or fully silenced due to for 20 example epigenetic modifications of the heterochromatin of the host. In a preferred embodiment of the present invention the at least one site for integration is a recombination site for site-specific transgene insertion, wherein the at least one site for integration is positioned in the genome such that the transgene is expressed.

25 The present invention also relates to genetically modified pigs porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) comprising at least one site for integration and further comprising at least one transgene. Preferably, the at least one transgene is inserted into the at least one site for integration that is into the at least one recombination site.

30 The transgene of the present invention may be any transgene. In one embodiment the transgenes are disease-causing genes and/or genes which modify genes present in the pig, embryo, blastocyst, fetus and/or cell thereof, causing the expression of the

endogenous genes to be altered. Such modifications give rise to animal models for studying a number of phenotypes of disease.

5 To identify loci that support stable ubiquitous expression and facilitate site-specific transgene insertion into such sites, a novel two-step gene insertion protocol for modification of primary porcine fibroblasts and generation of cloned transgenic pigs is presented here.

10 The insertion protocol is based on a recombinant target vector comprising a DNA transposon-based construct comprising a bicistronic gene cassette comprising (i) a recombination site and (ii) an IRES-driven selection gene.

Recombinant target vector

One aspect the present invention relates to a recombinant target vector comprising a DNA transposon based construct comprising a bicistronic gene cassette comprising (i) at least one recombination site and ii) an IRES-driven selection gene or part thereof.

15 The recombinant target vector can be integrated into the genome of a pig, embryo, blastocyst, fetus and/or cells thereof and serve as a target for the insertion of a transgene positioned on a donor plasmid.

20 The DNA transposon-based construct may be any construct in which any DNA transposon or part thereof is present. This allows the precise manipulation of an organism's DNA under controlled conditions in vivo. The DNA transposon of the present invention is selected from the group consisting of the Sleeping Beauty (SB) transposon, Frog Prince (FP) transposon, Piggybac transposon, Tol2 transposon, Himar 1 transposon. In another embodiment the DNA transposon is selected from the

25 group consisting of the SB transposon, the FP transposon and Piggybac transposon, or from the group consisting of the FP transposon, the Piggybac transposon, the Tol2 transposon and the Himar 1 transposon. However, the DNA transposon may be selected from any of the SB transposon, the FP transposon and Piggybac transposon, or from the group consisting of the FP transposon, the Piggybac transposon, the Tol2

30 transposon and the Himar 1 transposon. In the present invention in one embodiment the DNA transposon of the DNA transposon-based construct is the DNA transposon construct known as the Sleeping Beauty (SB) DNA transposon vector.

The vector of the present invention employs a site-specific recombination technology, which involves recombination sequences between binding sites for recombinases. When cells comprise site-specific integration sites (or recombination sites) for recombinases, a reciprocal recombination event occurs in the presence of a recombinase between the integration sites. The double stranded DNA is cut at both recombination sites and then subsequently ligated. The consequences of recombination depend on the orientation of the site-specific recombination sites. When two recombination sites are present on one segment of DNA (eg. on one chromosome arm), inverted recombination sites will cause an inversion, while a direct repeat of recombination sites will result in a deletion event. In the case where the two recombination sites are present on two different segments of DNA, a translocation event takes place.

In one embodiment the vector takes advantage of the Cre-Lox recombination technology involving the recombination of sequences between lox P sites by the Cre recombinase protein. In another embodiment the vector comprises sequences of site directed recombination technology, namely the involving the recombination of sequences between FRT sites by the Flp recombination enzyme derived from *Saccharomyces cerevisiae*. In yet another embodiment the vector of the present invention takes advantage of the attB/P- Φ C31 recombination technology, wherein the vector comprises attB/P recognition sequences for the Φ C31 recombinase. Thus, the recombination technology used in the present invention may be selected from the group consisting of the Cre-LoxP, Flp-FRT, Flpe-FRT and attB/P/ Φ C31 systems. Accordingly, the vector of the present invention harbors the recognition sequence selected from the group consisting of LoxP, FRT and attB/P.

However, the examples of recombination systems and recognition sequences listed above are non-limiting examples, as any recombination system functioning as disclosed herein may be used. In one preferred embodiment the vector harbors Lox P recombination sites for Cre, or even more preferred the vector harbors FRT recognition sites for Flp.

Selection and reporter genes

The selection gene present in the recombinant target vector and/or the genome of the pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) of the present invention is not limited to any particular selection gene. In the present

context the term 'selection gene' thus comprises reporter genes such as any reporter genes that can be used to evaluate whether transposition has occurred. For example the reporter gene is selected from the group consisting of the enhanced green fluorescent protein (eGFP), lac Z, dsRed, enhanced yellow fluorescent protein (eYFP), enhanced cyan fluorescent protein (eCFP), enhanced blue fluorescent protein (eBFP) and the human alpha-1-antitrypsin (hAAT).

The selection gene may be any gene suitable for selecting cells harbouring the constructs of the present invention. Typically the selection gene is a gene that confers resistance to antibiotics or drugs. Examples of such selection genes is the puromycin resistance gene (Puro), the tetracycline resistance gene, the streptomycin resistance gene, the hygromycin B resistance gene (Hygro), the zeocin resistance gene (zeo), the neomycin resistance gene (neo), and the blasticidin resistance gene (Bst). Therefore, the selection gene of the present invention is selected from the group consisting of puromycin resistance gene (Puro), the tetracycline resistance gene, the streptomycin resistance gene, the hygromycin B resistance gene (Hygro), the zeocin resistance gene (zeo), the neomycin resistance gene (neo) and the blasticidin resistance gene (Bst). In a preferred embodiment the selection gene is selected from the group consisting of puromycin resistance gene (Puro), the hygromycin B resistance gene (Hygro), the zeocin resistance gene (zeo), the neomycin resistance gene (neo) and the blasticidin resistance gene (Bst). It is appreciated that the resistance gene is selected from any of puromycin resistance gene (Puro), the tetracycline resistance gene, the streptomycin resistance gene, the hygromycin B resistance gene (Hygro), the zeocin resistance gene (zeo), the neomycin resistance gene (neo) or the blasticidin resistance gene (Bst).

The selection gene is in one embodiment driven by an IRES element.

In a preferred embodiment the IRES-driven selection gene of the recombinant target vector and/or the genome of the pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) of the present invention confers resistance to a drug, preferably puromycin.

Position of selection genes

The recombination site of the recombinant target vector and/or the genome of the pig, porcine blastocysts, embryos, fetuses and/or cells (donor cells and/or cell nucleus) of the present invention may be embedded in the coding sequence of a selection gene which allows for detecting whether a transposition has occurred. According to the

present invention the recombination site present in the vector is embedded in the coding sequence of any suitable reporter gene. The FRT, LoxP and/or attB/P recognition sites may thus be embedded in any of non-limiting examples of reporter genes listed herein..

5 For example, the FRT is embedded in the coding sequence of eGFP, lac Z, dsRed, eYFP, eCFP, eBFP or hAAT. Similarly, the LoxP is embedded in the coding sequence of eGFP, lac Z, dsRed, eYFP, eCFP, eBFP or hAAT. Moreover, the attB/P is embedded in the coding sequence of eGFP, lac Z, dsRed, eYFP, eCFP, eBFP or hAAT. In a preferred embodiment the recombination site is embedded in the coding
10 sequence of eGFP.

The recombination site may thus be embedded in a promoter driven fusion variant of the selection gene. Thus, in one embodiment the recombination site is embedded in a SV40 promoter driven fusion variant of the selection gene. In one preferred
15 embodiment the FRT site is embedded in a SV40 promoter driven fusion variant of eGFP. In another preferred embodiment wherein said FRT recombination site is embedded in a ubiquitin promoter driven fusion variant of eGFP. In yet a preferred embodiment the FRT site is embedded in a RSV promoter driven fusion variant of eGFP. However, any promoter suitable for conferring expression of a selection gene
20 may be used according to the present invention. Non-limiting examples of such promoters are the promoter of Rous sarcoma virus (RSV), promoter of cytomegalo virus (CMV), the promoter of simian virus 40 (SV40), the ubiquitin promoter (Ubi), the promoter of the human elongation factor 1 α (EF1 α), the promoter of the human phosphoglycerate kinase (PGK) or the promoter of the inducible CMV Tet On/Off.

25 Thus, the promoter is selected from the group consisting of the promoter of Rous sarcoma virus (RSV), promoter of cytomegalo virus (CMV), the promoter of simian virus 40 (SV40), the promoter of the human elongation factor 1 α (EF1 α), the promoter of the human phosphoglycerate kinase (PGK) and the promoter of the inducible CMV TetOn/Off. In one preferred embodiment the promoter is selected from the group
30 consisting of the SV40, CMV and PGK promoter.

However, according to the present invention, the promoter may be selected from any of the promoter of Rous sarcoma virus (RSV), promoter of the cytomegalo virus (CMV), the promoter of simian virus 40 (SV40), the promoter of the human elongation factor 1 α (EF1 α), the promoter of the human phosphoglycerate kinase (PGK) or the promoter of
35 the inducible CMV Tet On/Off. In a preferred embodiment the promoter is the RSV

promoter. In another preferred embodiment the promoter is the Ubi promoter. In yet another preferred embodiment the promoter is the SV40 promoter.

IRES

5 An internal ribosome entry site, abbreviated IRES, is a nucleotide sequence that allows for translation initiation in the middle of a messenger RNA (mRNA) sequence as part of the greater process of protein synthesis. Usually, in eukaryotes, translation can only be initiated at the 5' end of the mRNA molecule, since 5' cap recognition is required for the assembly of the initiation complex. IRES mimics the 5' cap structure, and is recognized
10 by the 40S pre-initiation complex. When an IRES segment is located between two reporter open reading frames in a eukaryotic mRNA molecule (a bicistronic mRNA), it can drive translation of the downstream protein coding region independently of the 5'-cap structure bound to the 5' end of the mRNA molecule. In such a setup both proteins are produced in the cell. The first reporter protein located in the first cistron is
15 synthesized by the cap-dependent initiation approach while translation initiation of the second protein is directed by the IRES segment located in the intercistronic spacer region between the two reporter protein coding regions.

The IRES of the present invention is any IRES capable of driving the expression of a selection gene independently of the 5' cap structure bound to the 5' end of the mRNA
20 molecule. Non-limiting examples of IRES elements are IRES from poliovirus, rhinovirus, encephalomyocarditis virus (EMCV), Hepatitis A virus, hepatitis C virus, Friend murine leukaemia virus, Moloney murine leukaemia virus, Rous sarcoma virus and human immunodeficiency virus. In a preferred embodiment the IRES of the present invention originates from EMCV.

25 The internal ribosome entry site, IRES, -driven selection gene is similarly not limited to any particular selection gene. In preferred embodiments the selection gene are genes conferring resistance to antibiotics or drugs, such as puromycin, tetracycline, streptomycin or hygromycin resistance genes, or the enhanced green fluorescent
30 protein (eGFP) gene, red fluorescent protein genes or the like.

The recombinant vector construct may also comprise at least one recombination site for Cre recombinase and/or Φ C31 recombinase. The at least one site for Cre recombinase may be located as disclosed in the examples herein. In a preferred

embodiment the recognition site for Cre recombinase is located between the poly A sequence and the lower inverted repeat of the vector.

5 Embodiments of the present invention are vectors such as a Sleeping Beauty DNA transposon-based vector which in its integrated form as a integrated SB docking vector serves as a target for Flp recombinase-based gene insertion, a Cre recombinase-based gene insertion or a Φ C31 recombinase-based gene insertion.

10 In a first step, the vector of the present invention is transferred by cut-and-paste transposition into the genome of a mammalian cell, for example a somatic cell and therefore is not flanked by bacteria-derived plasmid sequences. By determining the vector-derived reporter gene expression in the target cell such as a mammalian cell, embryos or animals created by for example hand-made cloning, microinjection or other cloning techniques, it is possible to characterize individual animals with a desired
15 expression profile. In a second step, target cells having desired expression profiles are propagated, and/or for example primary fibroblasts are isolated from animals as described above. The target site for the recombinase, such as for Flp, Cre and/or Φ C31 recombinase located within the integrated vector of the present invention, is subsequently utilized for site-specific gene insertion, producing a cell in which a gene
20 of interest is inserted into a location in the target cell for which the expression profile is known. Subsequently, such cells harbouring the at least one gene of interest may form the basis for propagation of a cell line. In addition, the described cell may be used for a second round of cloning, such as for the production of an animal with a desired phenotype employing said cell in a second round of hand-made cloning, microinjection
25 or other cloning techniques.

The vector of the present invention may further comprise at least one insulator element. The insulator element serves to stabilise the gene expression of the gene of interest when integrated into the genome of a target cell, and thus avoid potential
30 epigenetic silencing. In one embodiment of the present invention the at least one insulator element is 1.2 kb of the cHS4 (chicken DNase hypersensitive site 4-derived insulator element). The at least one insulator element is flanking the promoter-selection gene fusion. In one preferred embodiment two insulator elements are present in the vector.

The present invention pertains to a mammalian cell comprising a transposon tagged genome containing at least one recombination target site for site-specific gene integration of at least one gene of interest. In one preferred embodiment the at least one recombination site is the FLP recombination target site for site-specific gene insertion or integration.

In yet a further aspect the present invention relates to a mammalian cell comprising at least one gene of interest obtained by use of the bi-phased system of the present invention.

10 The mammalian cell comprises a DNA transposon tagged genome using the recombinant target vector of the present invention and/or using the bi-phased system of the present invention.

15 The mammalian cell as referred to herein is not confined to any particular cell type. The mammalian cell may thus be immune cells such as T-cells, epithelial cells, endothelial cells, fibroblast cells, cells from lung, heart, liver or neuronal cells. The mammalian cell may be of human, porcine, murine, canine or feline origin. In particular embodiments of the present invention the mammalian cell is immortal antitumorigenic cytotoxic T cells of human origin. In a preferred embodiment, the mammalian cell is a somatic cell, 20 preferably of porcine origin. In a preferred embodiment the somatic cell is a porcine fibroblast cell, for example a primary somatic cell, or a porcine neonatal fibroblast cell.

The gene of interest is prior to recombination into the integrated vector (integrated docking vector) of the present invention located on a substrate for the recombinases.

25 The substrates are characterised by the presence of a fusion between at least one recognition site and a gene of interest for example a selection gene and/or a gene conferring the establishment of a desired phenotype or genotype of the cell. In one preferred embodiment the substrate comprises a promoter driving the expression of a gene of interest followed by a polydenylation signal, at least one recombination site and 30 a selection gene without a functional ATG start codon followed by a polyadenylation sequence. One example is the FLP donor plasmid shown in figure 2. The selection gene may be selected from the group of selection genes listed above and similarly the recognition site may be selected from the recognition sites as described elsewhere herein. The fusion of the at least one recognition site and selection gene may be 35 present in a DNA construct, such as a plasmid, an in vitro-generated plasmid-derived

minicircle and/or lentiviral DNA circles. Non-limiting examples of such DNA constructs are for example plasmids containing FRT-hygro fusion cassette (SEQ ID NO:20) , or in-vitro generated plasmid-derived minicircles containing a FRT-hygro cassette, or lentiviral DNA circles containing a FRT-hygro cassette.

5

Lentiviral DNA circles are unintegrated lentiviral DNA in the form of so-called 2 LTR circles or 1 LTR circles. In the present invention the lentiviral DNA circles result from integration defective lentiviral vectors. In one embodiment of the present invention the lentiviral DNA originates from lentiviruses such as human immunodeficiency virus 1 or simian immunodeficiency virus 1.

10

The introduced gene or transgene, transcriptional and/or translational product or part thereof may originate from any species, including bacteria, pig, human, mouse, rat, yeast, invertebrates, or plants. Regulatory sequences of the transgene may drive ubiquitous or inducible or tissue- and/or time-specific expression and may also originate from any species including pig, human, mouse, rat, yeast, invertebrates, or plants.

15

Thus, a further aspect of the present invention relates to a bi-phase system for site-directed integration of genes of interest. The system comprises the recombinant target vector of the present invention and a recombination substrate. The recombination substrate comprises a fusion of at least one recognition site (recombination site) for a recombinase and a gene of interest. The recombination substrate is present in a plasmid, an in vitro generated plasmid-derived minicircle and/or a lentiviral circle as described elsewhere herein.

20

25

In a preferred embodiment for producing genetically modified pigs the mammalian cell is a porcine primary fibroblast.

Primary fibroblasts are fibroblasts derived directly from excised skin as explants.

30

It will be appreciated that the invention does not comprise processes for modifying the genetic identity of pigs which are likely to cause them suffering without any substantial medical benefit to man or animal, or animals resulting from such processes.

The present invention also relates to genetically modified pig embryos obtainable by the methods described herein.

5 The methods for producing the pig model described herein do not encompass a surgical step performed on the pig.

Sequence identity

Functional equivalents and variants are used interchangeably herein. In one preferred embodiment of the invention there is also provided variants of the genes listed herein, the recombination sites, selection genes, transposons, recombinases, promoters as
10 listed herein. When being polypeptides, variants are determined on the basis of their degree of identity or their homology with a predetermined amino acid sequence of the present invention, or, when the variant is a fragment, a fragment of any of the aforementioned amino acid sequences, respectively.

15 Accordingly, variants preferably have at least 91 % sequence identity, for example at least 91% sequence identity, such as at least 92 % sequence identity, for example at least 93 % sequence identity, such as at least 94 % sequence identity, for example at least 95 % sequence identity, such as at least 96 % sequence identity, for example at
20 least 97% sequence identity, such as at least 98 % sequence identity, for example 99% sequence identity with the predetermined sequence.

The following terms are used to describe the sequence relationships between two or more polynucleotides: "predetermined sequence", "comparison window", "sequence
25 identity", "percentage of sequence identity", and "substantial identity".

A "predetermined sequence" is a defined sequence used as a basis for a sequence comparison; a predetermined sequence may be a subset of a larger sequence, for example, as a segment of a full-length DNA or gene sequence given in a sequence
30 listing, or may comprise a complete DNA or gene sequence. Generally, a predetermined sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length.

35 Since two polynucleotides may each (1) comprise a sequence (i.e., a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides,

and (2) may further comprise a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A
5 "comparison window", as used herein, refers to a conceptual segment of at least 20 contiguous nucleotide positions wherein a polynucleotide sequence may be compared to a predetermined sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less as compared to the
10 predetermined sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.

Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:
15 482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48: 443, by the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. (U.S.A.) 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or
20 by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected.

The term "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term
25 "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and
30 multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a predetermined
35 sequence over a comparison window of at least 20 nucleotide positions, frequently

over a window of at least 25-50 nucleotides, wherein the percentage of sequence identity is calculated by comparing the predetermined sequence to the polynucleotide sequence which may include deletions or additions which total 20 percent or less of the predetermined sequence over the window of comparison. The predetermined
5 sequence may be a subset of a larger sequence, for example, as a segment of the full-length modified porcine or human Ps1 sequence, or porcine or human APP sequence polynucleotide sequence illustrated herein.

Sequence identity is determined in one embodiment by utilising fragments of peptides
10 comprising at least 25 contiguous amino acids and having an amino acid sequence which is at least 80%, such as 85%, for example 90%, such as 95%, for example 96%, such as 97%, for example 98%, such as 99% identical to the amino acid sequence of for example the products of selection genes, wherein the percent identity is determined with the algorithm GAP, BESTFIT, or FASTA in the Wisconsin Genetics Software
15 Package Release 7.0, using default gap weights.

Conservative amino acid substitutions:

Substitutions within the groups of amino acids, shown below, are considered conservative amino acid substitutions. Substitutions between the different groups of
20 amino acids are considered non-conservative amino acid substitutions.

P, A, G, S, T (neutral, weakly hydrophobic)

Q, N, E, D, B, Z (hydrophilic, acid amine)

H, K, R (hydrophilic, basic)

F, Y, W (hydrophobic, aromatic)

25 L, I, V, M (hydrophobic)

C (cross-link forming)

By the term "transcriptional or translational products" is meant herein products of gene transcription, such as a RNA transcript, for example an unspliced RNA transcript, a
30 mRNA transcript and said mRNA transcript splicing products, and products of gene translation, such as polypeptide(s) translated from any of the gene mRNA transcripts and various products of post-translational processing of said polypeptides, such as the products of post-translational proteolytic processing of the polypeptide(s) or products of various post-translational modifications of said polypeptide(s).

As used herein, the term "transcriptional product of the gene" refers to a pre-messenger RNA molecule, pre-mRNA, that contains the same sequence information (albeit that U nucleotides replace T nucleotides) as the gene, or mature messenger RNA molecule, mRNA, which was produced due to splicing of the pre-mRNA, and is a
5 template for translation of genetic information of the gene into a protein.

Pigs

The present invention relates to a genetically modified pig, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.
10 The pig of the present invention may be any pig.

In one embodiment of the present invention the pig or porcine cells originate from a wild pig. In another embodiment the pig is the domestic pig, *Sus scrofa*, such as *S. domesticus*. In yet another embodiment the invention relates to mini pigs, as well as to
15 inbred pigs. The pig can be selected e.g. from the group consisting of Landrace, Yorkshire, Hampshire, Duroc, Chinese Meishan, Berkshire and Piêtrain, such as the group consisting of Landrace, Yorkshire, Hampshire and Duroc, for example the group consisting of Landrace, Duroc and Chinese Meishan, such as the group consisting of Berkshire, Pietrain, Landrace and Chinese Meishan, for example the group consisting
20 of Landrace and Chinese Meishan. In one embodiment, the pig is not a mini-pig.

In another embodiment of the present invention the pig is a mini-pig and the mini-pig is preferably selected from the group consisting of Goettingen, Yucatan, Bama Xiang Zhu, Wuzhishan and Xi Shuang Banna. Thus, the present invention relates to any of
25 Goettingen, Yucatan, Bama Xiang Zhu, Wuzhishan and Xi Shuang Banna separately or in any combination.

Due to its size and weight of about 200 kg the domestic pig is not easily handled in a laboratory setting. A preferred alternative to the domestic pig is the Goettingen
30 (Göttingen) mini-pig that weighs about 30 kg. Therefore, a preferred embodiment the pig of the present invention is the Goettingen mini pig.

Methods for producing the mammalian cell of the present invention

The present invention also relates to a method for producing a mammalian cell comprising a SB tagged genome containing a Flp or Flpe recombination target site for site-specific gene insertion. The method for producing a mammalian cell comprises a DNA transposon tagged genome comprising a recombination target site for site-specific gene insertion comprises the steps of a) providing a mammalian cell, b) transfecting the cell of a) with a plasmid expressing a transposase and a recombinant vector comprising a DNA transposon-based construct carrying a bicistronic gene cassette comprising (i) a recombination site and ii) an IRES-driven selection gene, c) selecting DNA transposon tagged cells. The recombinant vector may comprise any DNA-transposon as described elsewhere herein. In one embodiment the recombinant target vector comprises a DNA transposon in the form of a Sleeping Beauty transposon. In one embodiment the recombinant target vector comprising a DNA transposon construct and a bicistronic gene cassette comprising (i) a FRT recombination site and ii) an IRES-driven selection gene, such as for example a puromycin resistance gene. Thus, the method comprises a) providing a mammalian cell, b) transfecting the cell of a) with a plasmid expressing a transposase and a recombinant target vector comprising a DNA transposon construct and a bicistronic gene cassette comprising (i) a FRT recombination site and ii) an IRES-driven selection gene, c) selecting SB tagged cells.

The transposon tagged cells, for example Sleeping Beauty tagged cells are selected by antibiotics or any agent allowing for the selection of transposon tagged cells. A number of selection agents are described elsewhere herein. A person skilled in the art will appreciate which antibiotic to use given that a specific antibiotic resistance gene is present in the transposon tagged cells. One example is the use of puromycin as selection agent, given that the puromycin resistance gene is present in the transposon tagged cell.

As described elsewhere herein the mammalian cell may be any cell. In one embodiment in which the mammalian cell is subsequently to be used for producing a genetically modified pig by nuclear transfer according to the hand-made protocol as described herein, the mammalian cell is preferably a porcine cell, a fibroblast and most preferred a porcine primary fibroblast or a neonatal porcine fibroblast.

It is appreciated that a desired transgene may be integrated directly into the at least one site for integration present in the genome of the cell. However, the cell in which the genome carries the at least one site for integration is in another embodiment used as a donor cell for the production of a genetically modified pig by for example microinjection of the donor cell or nucleus thereof into a oocyte or by for example somatic nuclear transfer. In a preferred embodiment the donor cell or the nucleus thereof is used for the production of a genetically modified pig by somatic nuclear transfer using the procedure as described elsewhere herein.

The transgene or gene of interest to be integrated in the targeted cells of the present invention is not limited to any particular gene. In one embodiment the gene to be integrated is a disease-causing gene which results in the formation of a genetically modified pig, embryo, blastocyst, fetus and/or donor cell displaying a phenotype of interest.

The integration of the transgene into the at least one site for integration present in the genome of the cell is employed by transfection into the cell of plasmid DNA containing the gene of interest and also a FRT sites, and a plasmid expressing the Flp-recombinase used to support integration at the FRT sites. In another preferred embodiment the integration of the transgene into the at least one site for integration present in the genome of the cell is employed by transfection into the cell of plasmid DNA containing the gene of interest and also a FRT sites, and a plasmid expressing the Flpe-recombinase used to support integration at the FRT sites.

Methods for producing the genetically modified pig of the present invention

The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell of the present invention may be produced using any technique in which modified genetic material is transferred from a donor cell to a host cell, such as an enucleated oocyte. A number of techniques exist such as introducing genetic material from a genetically modified somatic cell into an enucleated oocyte by for example microinjection or by nuclear transfer. The present invention provides improved procedures for cloning pigs by nuclear transfer which refers to the introduction of a full complement of nuclear DNA from one cell to an enucleated cell.

In cloning, the transfer of the nucleus of a somatic (body) cell or somatic cell into an egg cell (oocyte) which has had its own nucleus removed (denucleated or enucleated) is called somatic cell nuclear transfer. The new individual will develop from this reconstructed embryo and be genetically identical to the donor of the somatic cell.

5 In the present invention a genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell is obtainable by somatic cell nuclear transfer comprising the steps of a) establishing at least one oocyte having at least a part of a modified zona pellucida, b) separating the oocyte into at least two parts obtaining an oocyte and at least one cytoplasm, c) establishing a donor cell or cell nucleus having desired genetic properties, 10 d) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus, e) obtaining a reconstructed embryo f) activating the reconstructed embryo to form an embryo; culturing said embryo; and g) transferring said genetically modified embryo to a host mammal such that the embryo develops into a genetically modified fetus, wherein said genetically modified embryo obtainable by nuclear transfer 15 comprises steps a) to g) or f); wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps a) to f) or g); wherein said genetically modified fetus obtainable by nuclear transfer comprises steps a) to g.

However, the present invention also relates to a method for producing a transgenic pig, porcine embryo, blastocyst, fetus and/or donor cell comprising the steps of a) 20 establishing at least one oocyte, b) separating the oocyte into at least three parts obtaining at least two cytoplasm, c) establishing a donor cell or cell nucleus having desired genetic properties, d) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus, e) obtaining a reconstructed embryo, f) activating the reconstructed embryo to form an embryo; culturing said embryo; and g) transferring 25 said genetically modified embryo to a host mammal such that the embryo develops into a genetically modified fetus, wherein said genetically modified embryo obtainable by nuclear transfer comprises steps a) to g) or f); wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps a) to f) or g); wherein said genetically modified fetus obtainable by nuclear transfer comprises steps a) to g.

30 Furthermore, the present invention relates to a method for producing a transgenic pig, porcine embryo, blastocyst, fetus and/or donor cell comprising the steps of a) establishing at least one oocyte, b) separating the oocyte into at least three parts obtaining at least two cytoplasm, c) establishing a donor cell or cell nucleus having 35 desired genetic properties, wherein the donor cell or cell nucleus is established from a

genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell carrying in its genome at least one site for integration of at least one transgene, d) providing a transgene and integrating said transgene into the donor cell of c), d) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus, e) obtaining a
5 reconstructed embryo, f) activating the reconstructed embryo to form an embryo; culturing said embryo; and g) transferring said genetically modified embryo to a host mammal such that the embryo develops into a genetically modified fetus, wherein said genetically modified embryo obtainable by nuclear transfer comprises steps a) to g) or f); wherein said genetically modified blastocyst obtainable by nuclear transfer
10 comprises steps a) to f) or g); wherein said genetically modified fetus obtainable by nuclear transfer comprises steps a) to g).

It is appreciated that the genetic determinant in one embodiment is the at least one heterologous site for integration of at least one transgene. Preferably the heterologous site for integration is a recombination site for a recombinase as described in detail
15 elsewhere herein.

The various parameters are described in detail below.

Oocyte

The term 'oocyte' according to the present invention means an immature female
20 reproductive cell, one that has not completed the maturing process to form an ovum (gamete). In the present invention an enucleated oocyte is the recipient cell in the nuclear transfer process.

The oocytes according to the present invention are isolated from oviducts and/or
25 ovaries of a mammal. Normally, oocytes are retrieved from deceased pigs, although they may be isolated also from either oviducts and/or ovaries of live pigs. In one embodiment the oocytes are isolated by oviductal recovery procedures or transvaginal recovery methods. In a preferred embodiment the oocytes are isolated by aspiration. Oocytes are typically matured in a variety of media known to a person skilled in the art
30 prior to enucleation. The oocytes can also be isolated from the ovaries of a recently sacrificed animal or when the ovary has been frozen and/or thawed. Preferably, the oocytes are freshly isolated from the oviducts.

Oocytes or cytoplasm may also be cryopreserved before use. While it will be
35 appreciated by those skilled in the art that freshly isolated and matured oocytes are

preferred, it will also be appreciated that it is possible to cryopreserve the oocytes after harvesting or after maturation. If cryopreserved oocytes are utilised then these must be initially thawed before placing the oocytes in maturation medium. Methods of thawing cryopreserved materials such that they are active after the thawing process are well-known to those of ordinary skill in the art. However, in general, cryopreservation of oocytes and cytoplasts is a very demanding procedure, and it is especially difficult in pigs, because of the above mentioned general fragility of pig oocytes and cytoplasts, and because of the high lipid content that makes them very sensitive to chilling injury (i.e. injury that occurs between +15 and +5°C during the cooling and warming procedure).

In another embodiment, mature (metaphase II) oocytes that have been matured in vivo, may be harvested and used in the nuclear transfer methods disclosed herein. Essentially, mature metaphase II oocytes are collected surgically from either nonsuperovulated or superovulated pigs 35 to 48 hours past the onset of estrus or past the injection of human chorionic gonadotropin (hCG) or similar hormone.

Where oocytes have been cultured in vitro, cumulus cells that are surrounding the oocytes in vivo may have accumulated may be removed to provide oocytes that are at a more suitable stage of maturation for enucleation. Cumulus cells may be removed by pipetting or vortexing, for example, in the presence of in the range of 0.1 to 5 % hyaluronidase, such as in the range of 0.2 to 5% hyaluronidase , for example in the range of 0.5 to 5 % hyaluronidase, such as in the range of 0.2 to 3% hyaluronidase , for example in the range of 0.5 to 3 % hyaluronidase, such as in the range of 0.5 to 2 % hyaluronidase , for example in the range of 0.5 to 1% hyaluronidase, such as 0.5% hyaluronidase.

The first step in the preferred methods involves the isolation of a recipient oocyte from a suitable pig. In this regard, the oocyte may be obtained from any pig source and at any stage of maturation.

The stage of maturation of the oocyte at enucleation and nuclear transfer has been reported to be of significance for the success of nuclear transfer methods. Immature (prophase I) oocytes from pig ovaries are often harvested by aspiration. In order to employ techniques such as genetic engineering, nuclear transfer and cloning, such

harvested oocytes are preferably matured in vitro before the oocyte cells may be used as recipient cells for nuclear transfer.

5 Preferably, successful pig embryo cloning uses the metaphase II stage oocyte as the recipient oocyte because it is believed that at this stage of maturation the oocyte can be or is sufficiently activated to treat the introduced nucleus as if it were a fertilising sperm. However, the present invention relates to any maturation stage of the oocyte which is suitable for carrying out somatic cell nuclear transfer, embryos, blastocysts, and/or transgenic pigs obtainable by the method of somatic cell nuclear transfer of the
10 present invention.

The in vitro maturation of oocytes usually takes place in a maturation medium until the oocyte has reached the metaphase II stage or has extruded the first polar body. The time it takes for an immature oocyte to reach maturation is called the maturation period.
15

In a preferred embodiment of the present invention the oocyte is from sow or gilt, preferably from a sow.

The donor (somatic cell or nucleus of somatic cell) and recipient (cytoplasm) involved in the cell nuclear transfer method according to the present invention is a pig. Likewise, reconstructed embryos may be implanted in a pig according to the present invention. The different pigs suitable as donor, recipient or foster mother are described elsewhere herein.
20

The donor pig according to the present invention may be female, or male. The age of the pig can be any age such as an adult, or for example a fetus.
25

Embryo

According to the present invention a reconstructed embryo (i.e. single cell embryo) contains the genetic material of the donor cell. Subsequently, the reconstructed embryo divides progressively into a multi-cell embryo after the onset of mitosis. In vitro the onset of mitosis is typically induced by activation as described herein.
30

In the present invention the term 'embryo' also refers to reconstructed embryos which are embryos formed after the process of nuclear transfer after the onset of mitosis by activation. Reconstructed embryos are cultured in vitro.
35

When the embryo contains about 12-16 cells, it is called a "morula". Subsequently, the embryo divides further and many cells are formed, and a fluid-filled cystic cavity within its center, blastocoele cavity. At this stage, the embryo is called a "blastocyst". The developmental stage of the "fertilized" oocyte at the time it is ready to implant; formed from the morula and consists of an inner cell mass, an internal cavity, and an outer layer of cells called trophectodermal cells.

The blastocyst according to the present invention may be implanted into the uterus of a host mammal, in particular a pig, preferably a Goettingen minipig and continues to grow into a fetus and then an animal.

In the methods provided herein for producing genetically modified or transgenic non-human mammal, for cloning a non-human mammal, for culturing a reconstructed embryo, and /or for cryopreservation of a pig embryo, the embryo may be cultured in vitro. The embryo may for example be cultured in sequential culture. It will be appreciated that the embryo may be a normal embryo, or a reconstructed embryo as defined elsewhere herein.

The present invention thus relates to a modified porcine embryo, blastocyst and/or fetus derived from the genetically modified pig model as disclosed herein and/or the modified porcine embryo, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

Cytoplasm

An oocyte or a part of an oocyte from which the nucleus has been removed.

Donor Cell

By the term 'donor cell' of the present invention is meant somatic cell and/or cells derived from the germ line.

By the term 'somatic cell' of the present invention is meant any (body) cell from an animal at any stage of development. For example somatic cells may originate from fetal, neonatal or adult tissue. Especially preferred somatic cells are those of foetal or neonatal origin. However, cells from a germ line may also be used. According to the present invention a donor cell is a somatic cell. In another embodiment of the present invention the donor cell is a cell derived from a germ cell line.

In a preferred embodiment of the present invention the donor cell harbours desired genetic properties. However, the donor cell may harbour desired genetic properties which have been gained by genetic manipulation as described elsewhere herein. The present invention thus relates to a modified porcine donor cell (or cell nucleus), derived from the genetically modified pig model as disclosed herein and/or the modified porcine donor cell or cell nucleus, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.

Somatic cells are selected from the group consisting of epithelial cells, neural cells, epidermal cells, keratinocytes, hematopoietic cells, melanocytes, chondrocytes, lymphocytes (B and T lymphocytes), erythrocytes, macrophages, monocytes, mononuclear cells, fibroblasts, cardiac muscle cells, and other muscle cells.

These may be obtained from different organs, e. g., skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organs, bladder, kidney, urethra and other urinary organs.

The pigs from which the somatic cells may be derived are described elsewhere herein. A preferred embodiment of the invention is the use of somatic cells originating from the same species as the recipient oocyte (cytoplasm).

Preferably, the somatic cells are fibroblast cells as they can be obtained from both developing fetuses and adult animals in large quantities. Fibroblasts may furthermore be easily propagated in vitro. Most preferably, the somatic cells are in vitro cultured fibroblasts of foetal origin.

In a preferred embodiment the somatic cells are genetically modified. In yet a further preferred embodiment of the present invention the somatic cells are preferably of foetal origin, or for example from adults.

The donor cell or nucleus of the present invention harbours desired genetic properties. The donor cell or nucleus carries a SB tagged genome containing a Flp recombination target site for site specific gene insertion or integration. The SB tagged genome results from the integration of a recombinant target vector comprising a DNA transposon construct and a bicistronic gene cassette comprising (i) a FRT recombination site and (ii) an IRES-driven selection gene. The DNA transposon construct may be any

construct in which any DNA transposon is present. In the present invention the DNA transposon construct is the Sleeping Beauty (SB) DNA transposon vector. The FRT recombination site may be embedded in the coding sequence of a selection gene which allows for detecting whether a transposition has occurred. The selection gene of
5 the present invention is not limited to any particular selection gene. In preferred embodiments the selection gene are genes conferring resistance to antibiotics or drugs, such as puromycin, tetracycline, streptomycin or hygromycin resistance genes, or the enhanced green fluorescent protein (eGFP) gene, red fluorescent protein genes or the like.

10 The FRT recombination site may thus be embedded in a SV40 promoter driven fusion variant of the selection gene. However, any promoter suitable for conferring expression of a selection gene may be used according to the present invention. Non-limiting examples of such promoters are CMV (cytomegalovirus) or PGK promoter.

15 The IRES-driven selection gene is similarly not limited to any particular selection gene. In preferred embodiments the selection gene are genes conferring resistance to antibiotics or drugs, such as puromycin, tetracycline, streptomycin or hygromycin resistance genes, or the enhanced green fluorescent protein (eGFP) gene, red fluorescent protein genes or the like.

20

The recombinant vector construct may also comprise at least one site for Cre recombinase. The at least one site for Cre recombinase may be located as disclosed in the examples herein.

25 The donor cell or nucleus may also originate from a genetically modified pig comprising at least one site for integration of at least one transgene. A preferred embodiment is a donor cell or nucleus in the form of a fibroblast, such as a primary fibroblast.

Enucleation

30 The method of enucleation of an oocyte may be selected from the group of methods consisting of aspiration, physical removal, use of DNA-specific fluorochromes, exposure to ultraviolet light and/or chemically assisted enucleation. In one embodiment the present invention relates to the use of DNA-specific fluorochromes.

Enucleation may, however, be performed by exposure with ultraviolet light. In a
35 particular embodiment enucleation is chemically assisted prior to physical removal of

the nucleus. Chemically assisted enucleation using for example antineoplastic agents, such as demecolcine (N-deacetyl-N-methyl 1 colchicine), and/or for example etoposide or related agents may be performed prior to enzymatic modification of zona pellucida.

Chemically assisted enucleation comprises culturing matured COCs in maturation

5 medium as described elsewhere herein supplemented with demecolcine for a particular period of time. In the range of 0.1 $\mu\text{g/ml}$ to 10 $\mu\text{g/ml}$ demecolcine, such as 0.2 $\mu\text{g/ml}$ to 10 $\mu\text{g/ml}$, for example 0.3 $\mu\text{g/ml}$ to 10 $\mu\text{g/ml}$, such as 0.25 $\mu\text{g/ml}$ to 5 $\mu\text{g/ml}$, for example 0.3 $\mu\text{g/ml}$ to 1 $\mu\text{g/ml}$, such as 0.25 $\mu\text{g/ml}$ to 0.5 $\mu\text{g/ml}$, for example 0.4 $\mu\text{g/ml}$ demecolcin may be supplemented to the maturation medium. Similarly, maturation
10 medium may be supplemented with etoposide for example in the range of 0.1 $\mu\text{g/ml}$ to 10 $\mu\text{g/ml}$ etoposide, such as 0.2 $\mu\text{g/ml}$ to 10 $\mu\text{g/ml}$, for example 0.3 $\mu\text{g/ml}$ to 10 $\mu\text{g/ml}$, such as 0.25 $\mu\text{g/ml}$ to 5 $\mu\text{g/ml}$, for example 0.3 $\mu\text{g/ml}$ to 1 $\mu\text{g/ml}$, such as 0.25 $\mu\text{g/ml}$ to 0.5 $\mu\text{g/ml}$, for example 0.4 $\mu\text{g/ml}$ etoposide may be supplemented to the maturation medium. The time for culturing the COCs in the presence of antineoplastic agents
15 ranges from 10 min to 5 hrs, such as 30 minutes to 5 hrs, for example 10 minutes to 2 hrs, such as 30 min to 2 hrs, for example 10 min to 1.5 hrs, such as 20 min to 3 hrs, for example 10 min to 3 hrs, such as 30 min to 1.5 hrs, for example 45 min.

In a particular embodiment chemically assisted enucleation is performed using 0.45 $\mu\text{g/ml}$ demecolcine and/or etoposide added to the maturation medium for 45 min.

20

In a particular embodiment it is preferred that the enucleation is by physical removal of the nucleus. The physical removal may be by separation for example by bisection of the oocyte into two halves (two parts), one which contains the nucleus and the enucleated oocyte half, known as the cytoplasm, removing the nucleated half of the
25 oocyte and selecting the resulting cytoplasm for further procedures of the invention.

Alternatively the separation is by trisection, resulting in three parts of which two parts are cytoplasts. In another embodiment the oocyte may be separated into four parts, resulting in the production of three cytoplasts. The oocyte may even be separated into five parts by physical removal, resulting in four cytoplasts. Similarly, the oocyte may be
30 separated into six parts, for example seven parts, such as eight parts, for example nine parts, such as ten or more parts.

The physical separation of the oocyte and subsequent removal of the nucleus-bearing part of the oocyte may be achieved by the use of a microsurgical blade.

The oocytes may be screened to identify which oocytes have been successfully enucleated. Oocyte parts that harbour nuclear DNA may be identified by staining with Hoechst flouochrome, the staining procedure of which is known to a person skilled in the art. Oocyte parts harbouring nuclear DNA are discarded and the enucleated
5 oocytes (cytoplasts) are selected for further procedures.

Zona pellucida

Zona pellucida is a thick, transparent, noncellular layer or envelope of uniform thickness surrounding an oocyte
10

Generally, an intact zona pellucida is considered to be important in cell nuclear transfer due to a number of parameters. One parameter is to keep the polar body close to the metaphase plate of the oocyte in order to indicate the appropriate site for enucleation. Another parameter relates to the keeping of the donor cell close to the oocyte cytoplasm before and during fusion. The zona is also believed to confer protection for the donor
15 cell and cytoplasm during fusion. Finally, embryo development after reconstitution and activation is believed to be supported by the zona pellucida.

Modification of at least a part of the zona pellucida can be performed by a number of methods. For example physical manipulation can be used to modify the zona. But also
20 chemical treatment with agents such as acidic solutions (acidic Tyrode) can be employed. One example of chemical agents that can be employed in the present invention is acidic solutions, for example Tyrode. In a particular embodiment of the invention the zona pellucida is modified by enzymatic digestion. Such enzymatic digestion may be performed by enzymes comprising for example trypsin. Alternatively
25 a specific protease may be used, such as pronase.

In a preferred embodiment the enzymatic digestion results in at least a partial digestion of a part of zona pellucida which in a preferred embodiment of the present invention means that at least a part of the zona pellucida is being removed, or that the zona pellucida is partly removed. In the present context the zona pellucida is not completely
30 removed.

According to an especially preferred embodiment of the present invention the partially digested part of zona pellucida is characterized by the zona pellucida still being visible and by the fact that the oocyte has not become misshaped.

5 The partial digestion may be achieved by exposure to a protease. In another embodiment of the present invention the partial digestion may be accomplished by the use of a pronase. In yet another embodiment the partial digestion may be achieved by a combination of a protease and pronase.

10 In a preferred embodiment the concentration of pronase is in the range of 0.1 mg/ml to 10 mg/ml, such as 0.5 mg/ml to 10 mg/ml, for example 1 mg/ml to 10 mg/ml, such as 1.5 mg/ml to 10 mg/ml, for example 2 mg/ml to 10 mg/ml, such as 2.5 mg/ml to 10 mg/ml, for example 2.75 mg/ml to 10 mg/ml, such as 3 mg/ml to 10 mg/ml, for example 3.25 mg/ml to 10 mg/ml, such as 3.3 mg/ml to 10 mg/ml, for example 3.5 mg/ml to 10 mg/ml.

15 A preferred embodiment is a pronase concentration in the range of 2 mg/ml to 5 mg/ml, such as 2.25 mg/ml to 5 mg/ml, for example 2.5 mg/ml to 5 mg/ml, such as 2.75 mg/ml to 5 mg/ml, for example 2.8 mg/ml to 5 mg/ml, such as 2.9 mg/ml to 5 mg/ml, for example 3 mg/ml to 5 mg/ml, such as 3.1 mg/ml to 5 mg/ml, for example 3.2 mg/ml to 5 mg/ml, such as 3.3 mg/ml to 5 mg/ml.

20 A particular embodiment of the present invention is a pronase concentration in the range of 1 mg/ml to 4 mg/ml, for example 1 mg/ml to 3.9 mg/ml, such as 1 mg/ml to 3.8 mg/ml, for example 1 mg/ml to 3.7 mg/ml, such as 1 mg/ml to 3.6 mg/ml, for example 1 mg/ml to 3.5 mg/ml such as 1 mg/ml to 3.4 mg/ml, for example 1 mg/ml to 3.3 mg/ml.

25 In a preferred embodiment the pronase concentration is in the range of 2.5 mg/ml to 3.5 mg/ml, such as 2.75 mg/ml to 3.5 mg/ml, for example 3 mg/ml to 3.5 mg/ml. In a special embodiment the pronase concentration is 3.3 mg/ml.

It is clear to the skilled person that the pronase should be dissolved in an appropriate medium, one preferred medium according to the present invention is T33 (Hepes buffered TCM 199 medium containing 33% cattle serum (*as described earlier - Vajta, et al., 2003*)).

The time of incubation of the oocyte in the pronase solution is in the range of 1 second to 30 seconds, such as 2 seconds to 30 seconds, for example 3 seconds to 30 seconds, such as 4 seconds to 30 seconds, such as 5 seconds to 30 seconds.

5 In another embodiment of the present invention the incubation time is in the range of 2 seconds to 15 seconds, such as 2 seconds to 14 seconds, for example 2 seconds to 13 seconds, such as 2 seconds to 12 seconds, for example 2 seconds to 11 seconds, such as 2 seconds to 10 seconds, for example 2 seconds to 9 seconds, such as 2 seconds to 8 seconds, for example 2 seconds to 7 seconds, such as 2 seconds to 6 seconds, for example 2 seconds to 5 seconds.

10 In a particular embodiment of the present invention the incubation time is in the range of 3 seconds to 10 seconds, such as 3 seconds to 9 seconds, for example 4 seconds to 10 seconds, such as 3 seconds to 8 seconds, for example 4 seconds to 9 seconds, such as 3 seconds to 7 seconds, for example 4 seconds to 8 seconds, such as 3 seconds to 6 seconds, for example 4 seconds to 7 seconds, such as 3 seconds to 5 seconds, for example 4 seconds to 6 seconds, such as 4 seconds to 5 seconds. An especially preferred incubation time is 5 seconds.

In a preferred embodiment of the present invention the oocyte is treated for 5 seconds in a 3.3 mg/ml pronase solution at 39°C.

Reconstructed embryo

20 By the term 'reconstructed embryo' is meant the cell which is formed by insertion of the donor cell or nucleus of the donor cell into the enucleated oocyte which corresponds to a zygote (during normal fertilisation). However, the term 'reconstructed embryo' is also referred to as the 'reconstituted cell'. In the present invention the donor cell is a somatic cell. However, the donor cell may also be derived from a germ line cell.

25

Fusion

The transfer of a donor cell or a membrane surrounded nucleus from a donor cell to at least cytoplasm is according to the present invention performed by fusion. In the scenarios described below the term 'donor cell' also refers to a membrane surrounded nucleus from a donor cell. Fusion may be achieved by a number of methods.

30

Fusion may be between a donor cell and at least one cytoplasm, such as between a donor cell and at least two cytoplasts, for example between a donor cell and at least two cytoplasts, such as between a donor cell and at least three cytoplasts, such as between a donor cell and at least four cytoplasts, for example between a donor cell and at least five cytoplasts, such as between a donor cell and at least six cytoplasts, for example between a donor cell and at least seven cytoplasts, such as between a donor cell and at least eight cytoplasts.

Fusion may be performed according to the listed combinations above simultaneously or sequentially. In one embodiment of the present invention the fusion is performed simultaneously. In another embodiment fusion of the at least one cytoplasm and a donor cell is performed sequentially.

For example fusion may be achieved by chemical fusion, wherein a donor cell and the at least one cytoplasm are exposed to fusion promoting agents such as for example proteins, glycoproteins, or carbohydrates, or a combination thereof. A variety of fusion-promoting agents are known for example, polyethylene glycol (PEG), trypsin, dimethylsulfoxide (DMSO), lectins, agglutinin, viruses, and Sendai virus. Preferably phytohemagglutinin (PHA) is used. However mannitol and, or polyvinylalcohol may be used.

Alternatively, fusion may be accomplished by induction with a direct current (DC) across the fusion plane. Often an alternating current (AC) is employed to align the donor and recipient cell. Electrofusion produces a sufficiently high pulse of electricity which is transiently able to break down the membranes of the cytoplasm and the donor cell and to reform the membranes subsequently. As a result small channels will open between the donor cell and the recipient cell. In cases where the membranes of the donor cell and the recipient cell connect the small channels will gradually increase and eventually the two cells will fuse to one cell.

Alignment of the at least one cytoplasm and the donor cell may be performed using alternating current in the range of 0.06 to 0.5 KV/cm, such as 0.1 to 0.4 KV/cm, for example 0.15 to 0.3 KV/cm. In a preferred embodiment alignment of the at least one cytoplasm and the donor cell may be performed using alternating current at 0.2 KV/cm.

Fusion may be induced by the application of direct current across the fusion plane of the at least one cytoplasm and the donor cell. Direct current in the range of 0.5 to 5 KV/cm, such as 0.75 to 5 KV/cm, for example 1 to 5 KV/cm, such as 1.5 to 5 KV/cm, for example 2 to 5 KV/cm. Another preferred embodiment of the present invention is the application of direct current in the range of 0.5 to 2 KV/cm. In a further preferred embodiment the direct current may be 2 KV/cm.

The direct current may preferably be applied for in the range of 1-15 micro seconds, such as 5 to 15 micro seconds, for example 5 to 10 micro seconds. A particular embodiment may be 9 micro seconds.

In an especially preferred embodiment fusion with direct current may be using a direct current of 2 KV/cm for 9 micro seconds.

Electrofusion and chemical fusion may however be also be combined.

Typically electrofusion is performed in fusion chambers as known to the skilled person.

Fusion may be performed in at least one step, such as in two steps, for example three steps, such as in four steps, for example in five steps, such as six steps, for example seven steps, such as in eight steps.

Fusion may be performed in for example a first step wherein the at least one cytoplasm is fused to the donor cell. A second step of fusion may comprise fusion of the fused pair (cytoplasm-donor cell, reconstructed embryo) with at least one cytoplasm, such as at least two cytoplasts, for example three cytoplasts, such as four cytoplasts, for example five cytoplasts, such as six cytoplasts, for example seven cytoplasts, such as eight cytoplasts. The second step of fusion with fusion of at least one cytoplasm and the fused pair may be performed sequentially or simultaneously. In one embodiment the at least two cytoplasts are fused to the fused pair simultaneously. In another embodiment the at least two cytoplasts are fused to the fused pair sequentially.

In one embodiment of the invention the second step of fusion may also be an activation step wherein the reconstructed embryo is activated to enter mitosis. As described elsewhere herein.

Activation

In a preferred embodiment the reconstructed embryo may be allowed to rest prior to activation for a period of time in order to allow for the nucleus of the donor cell to reset its genome and gain totipotency in the novel surroundings of the enucleated cytoplasm.

5 The reconstructed embryo may for example rest for one hour prior to activation.

Preferably, the reconstructed embryo may be activated in order to induce mitosis.

Methods for activation may preferably be selected from the group of consisting of electric pulse, chemically induced shock, increasing intracellular levels of divalent
10 cations or reducing phosphorylation. A combination of methods may be preferred for activation.

In one particular embodiment of the invention the activation and the second step of fusion may be performed simultaneously. However, the activation of the reconstituted
15 embryo and the at least one additional step of fusion between the reconstructed embryo and the at least one cytoplasm may be performed sequentially.

Reducing the phosphorylation of cellular proteins in the reconstructed embryo by known methods such as for example by the addition of kinase inhibitors may activate
20 the reconstituted embryo. A preferred embodiment may involve the use of agents that inhibit protein synthesis, for example cycloheximide. A further preferred embodiment may be using agents that inhibit spindle body formation, for example cytochalasin B.

In one embodiment of the invention the intracellular levels of divalent cations may be increased. Divalent cations such as for example calcium may be comprised in the
25 activation medium. Preferably, the cations may enter the reconstructed embryo, particularly upon subjecting the reconstructed embryo to an electric pulse. In a preferred embodiment the electric pulse may cause entering of calcium into the reconstructed embryo.

30

The application of an electrical pulse using direct current may be an activation step. However, in a preferred embodiment the electrical pulse applied for activation may also serve as an additional fusion step.

Prior to applying an electrical pulse using direct current the at least one cytoplasm and the at least one reconstructed embryo may be aligned by the application of alternating current. The alternating current may be in the range of the range of 0.06 to 0.5 KV/cm, such as 0.1 to 0.4 KV/cm, for example 0.15 to 0.3 KV/cm. In a preferred embodiment alignment of the at least one cytoplasm and the donor cell may be performed using alternating current at 0.2 KV/cm.

Activation may be induced by the application of direct current across the fusion plane of the at least one cytoplasm and the donor cell. Direct current in the range of 0.2 to 5 KV/cm, such as 0.4 to 5 KV/cm, for example 0.5 to 5 KV/cm.. Another preferred embodiment of the present invention is the application of direct current in the range of 0.5 to 2 KV/cm. In a further preferred embodiment the direct current may be 0.7 KV/cm.

The direct current may preferably be applied for in the range of 10 to 200 micro seconds, such as 25 to 150 micro seconds, for example 50 to 100 micro seconds. A particular embodiment may be 80 micro seconds.

In an especially preferred embodiment fusion with direct current may be using a direct current of 0.7 KV/cm for 80 micro seconds.

An especially preferred embodiment of activation according to the present invention may be use of an electrical pulse in combination with subjecting the reconstructed embryo to agents that inhibit protein synthesis, spindle body formation, and divalent cations.

Activation may be performed by any combination of the methods described above.

In vitro culture of embryos

One aspect of the invention relates to a method of in vitro culturing embryos, whereby the blastocyst rate increased to 25.3%. Thus, a method of culturing a reconstructed embryo is within the scope of the present invention, comprising the steps of a) establishing at least one oocyte having at least a part of zona pellucida, b) separating the oocyte into at least two parts obtaining an oocyte having a nucleus and at least one cytoplasm, c) establishing a donor cell or cell nucleus having desired genetic properties, d) fusing at least one cytoplasm with the donor cell or membrane surrounded cell

nucleus, e) obtaining the reconstructed embryo, f) activating the reconstructed embryo to form an embryo, and e) culturing said embryo.

5 Another aspect of the invention relates to a method of cell nuclear transfer in which a step of culturing the embryo is included.

10 In a preferred embodiment in relation to the methods described herein embryos are cultured in a sequential set of media. Preferably the blastocysts are grown in traditional medium such as for example NCSU37 or equivalent medium as known to a person skilled in the art, wherein glucose is removed and substituted by other agents. One agent may be pyruvate. Another agent may be lactate. The agents may also be combined and replace glucose in the traditional medium.

15 The embryos may be cultured in the substituted media as described above from Day 0 to Day 3, such as from Day 0 to Day 2.

20 The pyruvate concentration may range from 0.05 to 1 mM, such as 0.1 to 1 mM, for example 0.125 to 1 mM, such as 0.15 to 1 mM. However the concentration of sodium pyruvate may also range from 0.05 mM to 0.9 mM , such as 0.05 to 0.8 mM, for example 0.05 to 0.7 mM, such as 0.05 to 0.6 mM , for example 0.05 to 0.5 mM, such as 0.05 to 0.4 mM, for example 0.05 to 0.3 mM, such as 0.05 to 0.2 mM. Preferably the concentration ranges between 0.05 to 0.17 mM. A preferred concentration of sodium pyruvate is 0.17 mM.

25 The lactate concentration may range from 0.5 to 10 mM, such as 0.75 to 10 mM, for example 1 to 10 mM, such as 1.5 to 10 mM, such as 1.75 to 10 mM, for example 2 to 10 mM, such as 2.5 to 10 mM. However the concentration of sodium lactate may also range from 0.5 mM to 9 mM , such as 0.5 to 8 mM, for example 0.5 to 7 mM, such as 0.5 to 6 mM , for example 0.5 to 5 mM, such as 0.5 to 4 mM, for example 0.5 to 0.3 mM. Preferably the concentration ranges between 1 to 5 mM, such as 2 to 4 mM, for example 2 to 3 mM. A preferred concentration of sodium lactate is 2.73 mM.

35 After the initial glucose-free incubation medium glucose is again replacing the pyruvate and lactate. The embryos may be cultured in the glucose containing medium from Day 4 to Day 3, preferably from Day 3 to Day 7. The glucose concentration may range from

1 to 10 mM, such as 2 to 10 mM, for example 3 to 10 mM, such as 4 to 10 mM, for example 5 to 10 mM. However, the glucose concentration may also range from 1 to 9 mM, such as 2 to 8 mM, for example 3 to 7 mM, such as 4-6 mM. A preferred concentration of glucose according to the present invention is 5.5 mM of glucose.

5

Organ or tissue donation

In one embodiment, the animals of the invention may be used as a source for organ or tissue donation for humans or other animals, either animals of the same species or animal of other species. Transfer between species is usually termed
10 xenotransplantation. Entire organs that may be transplanted include the heart, kidney, liver, pancreas or lung. Alternatively, parts of organs, such as specific organ tissues may be transplanted or transferred to humans or other animals. In a yet further embodiment, an individual cell or a population of individual cells from an animal of the invention may be transferred to a human being or another animal for therapeutic
15 purposes.

Cryopreservation

The term 'cryopreserving' as used herein can refer to vitrification of an oocyte, cytoplasm, a cell, embryo, or pig of the invention. The temperatures employed for
20 cryopreservation is preferably lower than -80 degree C, and more preferably at temperatures lower than -196 degree C. Oocytes, cells and embryos of the invention can be cryopreserved for an indefinite amount of time. It is known that biological materials can be cryopreserved for more than fifty years.

It is within the scope of the present invention that embryos may be cryopreserved prior
25 to transfer to a host pig when employing methods for producing a genetically engineered or transgenic non-human mammal. Such cryopreservation prior to transfer may be at the blastocyst stage of embryo development. Vitrification is a form of cryopreservation where living cells are rapidly cooled so that the fluid of the cell does not form into ice. Thus, vitrification relates to the process of cooling where cells or
30 whole tissues are preserved by cooling to low sub-zero temperatures, such as (typically) -80 C or -196 C

In particular the invention relates to the vitrification of an oocyte, however, the invention also relates to the vitrification of embryos, preferably embryos at the blastocyst stage. In one embodiment, the embryo is cultured to blastocyst stage prior to vitrification.

Especially pig embryos are covered by the present invention. Also vitrified cytoplasts are covered by the present invention, as are cells.

Yet another aspect of the invention relates to the cryopreservation of a pig embryo
5 derived by a method for cell nuclear transfer as described herein comprising a step of
vitrifying a pig embryo. A further aspect of the invention relates to pig embryos
obtained, or obtainable by the methods provided herein.

Mitochondria

10 Cells of the tissue of the genetically modified non-human mammals and/or non-human
embryos obtainable by the present invention may harbour mitochondria of different
maternal sources. In a preferred embodiment the non-human mammals and/or non-
human embryos may harbour mitochondria from only one maternal source. However,
15 in another preferred embodiment the non-human mammals and/or non-human
embryos may harbour mitochondria from at least two maternal sources, such as three
maternal sources, for example four maternal sources, such as five maternal sources,
for example six maternal sources, such as seven maternal sources, for example eight
maternal sources, such as nine maternal sources, for example ten maternal sources.
The probability of having a specific number of maternal sources can be calculated
20 based on the observed types of mitochondria.

Examples

Based on the well-described mechanisms of SB transposition (4-8) and Flp
recombination (9, 10), the present invention discloses a new target vector for site-
25 specific integration into the genome. This vector carries within the context of a SB
transposon vector a bicistronic gene cassette containing (i) the FRT recombination site
embedded in the coding sequence of eGFP and (ii) an IRES-driven puromycin
resistance gene. We demonstrate efficient selective plasmid insertion into SB-tagged
genomic loci. In an attempt to further improve the performance of these vectors, we
30 have analyzed the effect of insulator elements, believed to protect inserted foreign
genes against transcriptional silencing, within the context of SB vectors. Our
investigations indicate that insulators flanking the FRT gene expression cassette may
serve to maintain and stabilize gene expression of Flp-inserted transgenes.

Two nonviral integration technologies are employed in the present invention, the SB transposon system and the Fip recombinase, in a combined effort to achieve active locus detection, mediated by SB, and site-directed insertion at an attractive site, mediated by Fip. A bi-phased technology is disclosed in which an integrating SB vector, carrying a reporter gene and a selective marker gene, may first serve as a reporter for continuous gene expression and hence as a target for gene insertion (Fig. 1). By using an actively integrated vector as opposed to plasmid DNA that is randomly recombined into the genome we certify (i) that only a single copy, and not concatemers, of the vector are inserted and, moreover, (ii) that the reporter cassette is not flanked by sequences derived from the bacterial plasmid backbone which may have a detrimental effect on the locus activity over time. In a second modification step this vector may serve as a target for insertion of one or more gene expression cassettes in a well-characterized locus.

DNA transposon-based genomic insertion of recombinase recognition sites

Epigenetic modifications leading to transcriptional silencing of inserted foreign DNA are major challenges in strategies for genetic manipulation of cell lines and transgenic animals. Hence, both the identification of active genomic loci which support continuous, undisturbed gene expression and development of genetic tools to insert genes of interest site-specifically at these preferred loci are key aims in genetic engineering. We use in this study two nonviral integration technologies, the SB transposon system and the Fip recombinase, in a combined effort to achieve active locus detection, mediated by SB, and site-directed insertion at an attractive site, mediated by Fip. We describe a bi-phased technology in which an integrating SB vector, carrying a reporter gene and a selective marker gene, may first serve as a reporter for continuous gene expression and hence as a target for gene insertion (Fig. 1). By using an actively integrated vector as opposed to plasmid DNA that is randomly recombined into the genome we certify (i) that only a single copy, and not concatemers, of the vector are inserted and, moreover, (ii) that the reporter cassette is not flanked by sequences derived from the bacterial plasmid backbone which may have a detrimental effect on the locus activity over time. In a second modification step this vector may serve as a target for insertion of one or more gene expression cassettes in a well-characterized locus (Fig. 1B).

The transgenic model system

To circumvent the problems existing for random transgenesis in terms of copy numbers and variable insertion position we examined the possibility to perform controlled transgenesis for the future generation of cloned transgenic pigs by SCNT. The strategy was to insert a model gene-cassette into the porcine genome by use of a SB transposon-derived vector and subsequently use the Flp recombinase recognition site within the cassette to introduce a transgene and selection marker through a specific recombination event.

A transposon, pSBT/SV40-FGIP, was constructed for the use in porcine transgenesis.

For a schematic description of the construct see Fig. 2A. The enhanced green fluorescent protein (eGFP) gene was linked to a puromycin resistance gene through an internal ribosome entry site (IRES). This bicistronic gene cassette was placed under control of the SV40 promoter. The original start codon of the eGFP gene was replaced by a start codon located upstream of an inserted FRT site. We have previously shown that this fusion variant of the eGFP gene encodes fluorescent protein [28]. The FRT site is positioned immediately after the SV40 promoter and should enable Flp-mediated recombination. If such a recombination event is successful the eGFP and puromycin resistance genes will be removed from the promoter context and rendered inactive.

The plasmid DNA inserted at the FRT site thus can be constructed such that the expression of a novel selection marker, the hygromycin B resistance gene (hygro^R), is dependent of the ATG start codon already present upstream from the FRT site located in the transposon (Fig. 2B). This selection marker exchange will allow selecting for only correct and site-directed recombination events. By including a gene of interest, here the DsRed marker gene under control of the cytomegalovirus (CMV) promoter, as a new transgenic unit on the plasmid carrying the FRT-hygro fusion gene, a colour shift from green to red can be monitored as a result of successful recombination.

The pSBT/RSV-GFIP vector was constructed as follows:

The pSBT/RSV-GFIP vector contains the terminal inverted of the SB DNA transposon flanking a FRT-GFP.IRES.puro bicistronic gene cassette driven by a promoter derived from Rous sarcoma virus (RSV). The eGFP sequence was amplified from peGFP.N1 (Clontech) using a forward primer containing the 48-bp FRT sequence. To analyze FRT-GFP functionality, the FRT-eGFP fusion was inserted into an expression vector containing the SV40 promoter. The PCR-fragment containing FRT-tagged eGFP fusion gene was digested with MluI and XmaI and inserted into MluI/XmaI-digested pSBT/RSV-hAAT (pT/hAAT in ref. (8), obtained from Mark Kay, Stanford University,

USA), generating a transposon vector with RSV-driven eGFP expression (pSBT/RSV-eGFP). An IRES-puro cassette was PCR-amplified from pectoenv-IRES-puro (provided by Finn Skou Pedersen, University of Aarhus, Denmark), digested with XmaI, and inserted into XmaI-digested pSBT/RSV-eGFP, generating pSBT/RSV-GFIP (see
5 sequence listing). Alternative versions of this vector containing the SV40 promoter (pSBT/SV40-GFIP) and the promoter derived from the human ubiquitin gene (pSBT/Ubi-GFIP), were generated. In addition, by inserting a Cre recombination target site (loxP) into the MluI site located between the left inverted repeat of the transposon and the SV40 promoter of pSBT/SV40-GFIP, the vector pSBT/SV40-GFIP.loxP was
10 created. The donor plasmid pcDNA5/FRT, containing a FRT-hygro fusion gene without a start codon, was obtained from Invitrogen. The Flp-encoding plasmid, pCMV-Flp was obtained from A. Francis Stewart, University of California San Francisco, USA). This plasmid encodes the enhanced Flp variant designated Flp_{x9} (11). A SB-vector containing two copies of the 1.2-kb chicken DNase hypersensitive site 4 (cHS4)-
15 derived insulator element (12, 13) was generated by inserting PCR-amplified cHS4 sequences and an intervening linker into NotI/Spel-digested pSBT/PGK-puro (obtained from Mark Kay, Stanford University, USA). The PGK-puro cassette was cloned back into construct by using restriction sites located in the linker, generating pSBT/cHS4.PGK-puro.cHS4. All self-inactivating (SIN) lentiviral vector constructs were
20 derived from pCCL.WPS.PGK-eGFP.WHV obtained from Dr. Aebischer, Swiss Federal Institute of Technology, EPFL, Lausanne, Switzerland. The puromycin resistance gene was amplified by PCR and inserted in pCCL.WPS.PGK-eGFP.WHV downstream from the promoter, generating pCCL.WPS.PGK-puro.WHV. The FRT-hygro fusion gene was PCR-amplified from pcDNA5/FRT and inserted into the HpaI site (located between Ψ
25 and cPPT cis elements) of pCCL.WPS.PGK-puro.WHV, generating pLV/FRT-hygro.PGK-puro. To generate pLV/PGK-Flp the Flp gene was PCR-amplified from pCMV-Flp, digested with BamHI/XhoI, and inserted into BamHI/XhoI-digested pCCL.WPS.PGK-puro.WHV.

30 Transposition of FRT-tagged SB vectors

To be able to easily follow the activity of SB-tagged loci in modified cells, we constructed SB transposon vectors (pSBT/SV40-GFIP, pSBT/SV40-GFIP.loxP, pSBT/RSV-GFIP) containing a bicistronic gene expression cassette encoding eGFP and the puromycin resistance gene. We inserted the 48-bp Flp recombination target
35 sequence (FRT) immediately downstream from the eGFP start codon, generating a

fusion gene encoding FRT-tagged eGFP. Transient expression studies demonstrated comparable levels of activity of the eGFP and FRT-eGFP proteins (data not shown). We tested first the transposition efficiency of pSBT/RSV-GFIP by co-transfecting with pCMV-SB and pCMV-mSB, respectively, in HEK-293 cells. As expected the GFIP
5 transposon was efficiently transposed into the genomic DNA thereby conferring resistance to puromycin (Fig.3). As an alternative strategy, optimized for use in hard-to-transfect cell lines, we generated a helper-independent transposon-transposase (HITT) vector (the concept first demonstrated by Mikkelsen et al. in (6)) in which the GFIP-containing transposon and the SB expression cassette were located on a single
10 plasmid. Transposition assays using this HITT configuration showed high levels of transposition in HeLa cells (data not shown). By analysis of puromycin-resistant colonies generated with two-plasmid transfections, stable eGFP expression was verified by fluorescence microscopy (Fig. 3, insert), demonstrating functionality of both vector genes. Three puromycin-resistant clones, HEK-GFIP1, HEK-GFIP2, and HEK-
15 GFIP3, obtained by insertion of SBT/SV40-GFIP.loxP, SBT/SV40-GFIP, and SBT/RSV-GFIP transposons, respectively, were isolated and expanded for further analysis.

The target transposon SBT/RSV-GFIP was inserted into the genome of HEK-293 cells by co-transfecting (using Fugene-6 from Roche) 1.5 µg pSBT/RSV-GFIP with 1.5 µg
20 pCMV-SB (or 1.5 µg pCMV-mSB as a negative control). pCMV-SB, obtained from Perry Hackett, University of Minnesota, Minnesota, USA, encodes the Sleeping Beauty transposase reconstructed from fossil DNA transposable elements of salmoid fish. SB-tagged cell clones were generated by selecting transfected cells with puromycin (1 µg/ml). Clones were isolated and expanded and utilized as target clones for Flp-mediated gene insertion. To demonstrate site-specific insertion of transfected plasmid
25 DNA 12 µg pCMV-Flp was co-transfected (by CaPO₄) with either (i) 3 µg pcDNA5/FRT or (ii) 3 µg pLV/FRT-hygro.PGK-puro into SBT/RSV-GFIP-tagged HEK-293 cells. To select for site-specific insertions cells were grown in medium containing hygromycin B (200 µg/ml).

30 Cloning of constructs

Vectors expressing different variants of the SB transposase were generated by inserting PCR-amplified transposase sequences into the pcDNA3.1D/V5.His.Topo vector (Invitrogen, Carlsbad, CA). SB sequences utilized to generate pCMV-
35 mSB.Topo, pCMV- SB.Topo or the pCMV-HSB3.Topo mSB, SB10, and HSB3

sequences were derived from pCMV-mSB (Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000, 25(1):35-41), pCMV-SB (Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000, 25(1):35-41), and pCMV-HSB3 (Yant SR, Park J, Huang Y, Mikkelsen JG, Kay MA: Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol 2004, 24(20):9239-9247), respectively.

The SB-based docking vector, pSBT/SV40-FGIP, was generated from pSBT/RSV-FGIP (Moldt B, Staunstrup NH, Jakobsen M, Yanez-Munoz RJ, Mikkelsen JG: Site-directed genomic insertion of lentiviral DNA circles, Submitted for publication) by replacing the RSV promoter with a PCR-amplified SV40 promoter. pSBT/PGK puro has been described previously (Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000, 25(1):35-41). To generate the transgene donor plasmid, designated pFRT/hygro.CMV-DsRed, the red fluorescence protein gene (RFP) was derived from pDS-red-N1 by cleavage with HindIII and NotI restriction enzymes. The RFP gene was inserted into the pcDNA5/FRT vector (Invitrogen, Carlsbad, CA).

Transposition assays and Flp recombination

2.6×10^4 NPFs, HEK293 cells, or NIH3T3 cells, seeded in 6-well dishes, were co-transfected with 0.5 μ g plasmid DNA carrying the transposon (SBT/PGK-puro or SBT/SV40-FGIP) and 0.5 μ g of pCMV-mSB.Topo, pCMV-wt-SB.Topo, or pCMV-HSB3.Topo. Transfections were performed with Fugene-6 (Roche, Basel, Switzerland) according to the manufacturer's instructions. Transgenic NPF colonies harboring SBT/SV40-FGIP were harvested after 9 days of puromycin selection. Solitary colonies were scraped off with a glass pasteur pipette and transferred to 96-well dishes. The cells were expanded and used for studies of Flp recombination or handmade cloning. All transposition experiments were carried out in triplicates and cell colonies were counted after staining the colonies in methylene blue after 9 days of puromycin selection. Flp recombination was carried out as follows: for neonatal pig fibroblasts (NPFs), pools of clones containing the SBT/SV40-FGIP transposon were co-

transfected with 5.5 ug of the FLP recombinase expression vector (pOG44; Invitrogen, Carlsbad, CA) and 0.5 ug donor plasmid using Fugene-6 as transfection reagent. On the following the day, cells were washed with PBS and starting from day two after transfection the cells were grown in medium containing 400 ug/ μ l hygromycin B for 11 days. Selection was carried out for 11 days prior to harvesting of the cells and DNA purification. PCR using genomic DNA from pooled NPFs as template was performed to verify Flp recombination. A forward primer located downstream from LIR and a reverse primer located at the beginning of the *hygro^R* gene was used to amplify the fragment of interest. The presence of a precise junction between the SV40 promoter and the *hygro^R* gene was confirmed by sequencing of the PCR fragment. For studies in HEK293 and NIH3T3 cells, 8×10^5 cells seeded in 10-cm dishes were co-transfected with 1 ug of donor plasmid and 9 ug of pOG44 by treating the cells with calcium phosphate. The transfection mixture was left on the cells overnight and 1×10^5 cells were subsequently seeded in 70 cm² bottles and subjected to hygromycin B (200 ug/ μ l) selection for 11 days. Cell colonies were stained with methylene blue prior to counting of the colonies.

Sleeping Beauty (SB) transposition in neonatal porcine fibroblasts (NPFs)

The applicability of SB transposition in pig fibroblasts was tested in NPFs derived from a skin biopsy from a male Göttingen minipig (Ellegaard Göttingen Minipigs ApS) using a 2-kb long SB transposon designated SBT/PGK-puro (Fig. 4A). In pSBT/PGK-puro, the SB inverted repeats (IRs) flank an expression cassette consisting of the puromycin resistance gene driven by the phosphoglycerate kinase (PGK) promoter. pSBT/PGK-puro was co-transfected into NPFs with plasmid encoding either of three different SB transposase variants including a mutated inactive form (mSB), the original SB10, and the hyperactive version HSB3 encoded by pCMV-mSB.Topo, pCMV-SB10.Topo, and pCMV-HSB3.Topo, respectively. After 9 days of puromycin selection fibroblast colonies were stained with methylene blue. The formation of colonies was highly enhanced by co-transfection with a functional transposase (Fig. 4B), and the hyperactive transposase generated two-fold more colonies than SB10 (Fig. 4B). We therefore conclude that SB mobilization and transposase-dependent transgenesis is highly efficient in NPFs.

SB transposition is strongly influenced by the transposon length (Izsvak Z, Ivics Z, Plasterk RH: Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000, 302(1):93-102). To test if the 3.3 kb long

SBT/SV40-FGIP transposon (Fig. 2A) was efficiently inserted into the genome of NPFs primary cells were co-transfected with pSBT/SV40-FGIP and plasmid DNA encoding mSB, SB10, and HSB3, respectively. In this experiment we also included the murine fibroblast cell line NIH3T3 and the human kidney cell line HEK-293, as these two cell lines represent well-described cell types in which transposase-dependent gene insertion already has been described. Moreover, as NPFs are primary cells and have a short division potential, analyses that require long term growth in culture are not possible. The colony formation assay in HEK-293 cells showed a transposase-dependent increase in the number of puromycin-resistant colonies. The colony number was further increased by the hyperactive transposase (Fig. 5A). Similar results were obtained in NIH3T3 cells (Fig. 5B). Fluorescence microscopy analyses confirmed that colonies resulting from SBT/SV40-FGIP transposition expressed eGFP (Fig. 5, right panels and data not shown).

In NPFs, we again observed transposase-dependent formation of colonies. Compared to the shorter pSBT/PGK-Puro transposon, we consistently measured a decrease in colony forming efficiency for pSBT/SV40-FGIP (Fig. 4B versus Fig. 5C). This result is in accordance with previous findings showing that the efficiency of transposase-mediated transgenesis depends on the length of the insert between the IRTs. Fluorescence microscopy of puromycin-resistant NPF colonies confirmed that all cells expressed eGFP (Fig. 5C, right). By comparing the extent of colony formation in the presence of active versus inactive transposase, our data suggest that the transposition efficiency in NPFs is comparable to the efficiencies measured in the NIH3T3 and HEK293 cell lines. We therefore conclude that the pSBT/SV40-FGIP vector is suitable for gene transfer in pig primary cells.

Transgene substitution by Flp recombination

Next, we wanted to examine the possibility of using the FRT site to substitute transgenes within porcine cells. For this purpose cells from clones containing the pSBT/SV40-FGIP transposon were re-transfected with an expression vector for Flp recombinase and the donor vector, pFRT/hygro.CMV-DsRed, which carries a new set of transgenes including the gene encoding DsRed driven by a CMV promoter and a promoter-less hygromycin gene lacking a start codon and flanked upstream by an FRT site (Fig. 1B). Flp-mediated recombination is expected to activate the expression of the hygromycin B resistance gene by inserting the ATG-less *hygro* gene downstream from

the SV40 promoter and the ATG-FRT cassette located in the SBT/SV40-FGIP transposon (Fig. 2B).

At first, we examined for the occurrence of hygromycin B-resistant clones after selection for recombination. To test the functionality of the recombination system we addressed the recombination in NIH3T3 and HEK293 cells which are well-
5 characterized for Flp-mediated recombination. Cells derived from three different NIH3T3 clones containing the SBT/SV40-FGIP transposon were analyzed. For all three cell lines a Flp-dependent occurrence of hygromycin B-resistant colonies was observed, indicating that the correct recombination event was possible in the context of the inserted transposon (Fig. 6A). A similar experiment in HEK293 cells also showed a
10 Flp-dependent appearance of hygromycin B-resistant colonies (Fig. 6B). Thus, recombinase-mediated insertion of the hygromycin B resistance gene is possible in the context of the vectors used. Coupled to insertion of the hygro^R gene is the removal of the puromycin resistance gene from the promoter sequence and the flanking ATG-start
15 codon. Thus, Flp-mediated recombination should result in sensitivity towards puromycin selection of the cells. Indeed, in HEK-293 cells we observed that the cells became sensitive to puromycin after Flp-mediated recombination (data not shown). To substantiate the data concerning Flp recombination we identified the transposon insertion site in one of clones by ligation-mediated PCR. Using primers flanking the
20 borders of the inserted FRT/hygro plasmid, we could verify precise insertion into the FRT site of the inserted SB transposon (data not shown).

In NPFs, we were unable to detect the formation of hygromycin B-resistant colonies in a colony-forming assay. However, we note that this cannot be attributed to the lack of the correct recombination but is a consequence of the lack of sufficient cell passage
25 potential of these primary cells, which already had been through one round of selection. As an alternative approach, we performed a PCR analysis on genomic DNA of transfected NPFs to screen for the presence of insertions at an early stage before colony formation. The PCR analysis was performed on isolated genomic NPF DNA with a forward primer within the left IR of the SBT/SV40-FGIP transposon and a
30 reverse primer in the hygro^R gene. This primer combination should amplify a 700-bp fragment only if the recombination event has happened. Indeed such a fragment could be amplified from transgenic NPF cells co-transfected with the donor plasmid and the vector expressing Flp (Fig. 6C). In cells which were transfected with FRT-donor plasmid only, we could not detect 700-bp band, indicating that this band is indeed a
35 result of the specific Flp-directed recombination event. Sequencing of this fragment

confirmed that precise insertions mediated by Flp in NPFs had occurred with the expected sequence specificity within the FRT site. Thus, we conclude that NPFs can support Flp-mediated recombination with resulting alterations in transgene expression profiles.

5 In addition to selection marker exchange a Flp recombination event within the docking vector should result in a shift of expression from eGFP to DsRed. To monitor the presence of such a colour exchange, we examined a HEK-293-derived cell clone (clone 4) by epifluorescence analysis. Prior to transfection with the DsRed-encoding donor plasmid and the Flp expression vector, HEK-293 cells containing the integrated
10 SBT/SV40-FGIP transposon showed a clear green fluorescent signal (Fig. 6D). Two days after transfection the cells expressed both DsRed and eGFP as a result of transient presence of the DsRed expression vector after transfection. Cells were grown under hygromycin B selection and at 6 and 11 days after transfection the eGFP signal had disappeared and only DsRed expression could be monitored, supporting the notion
15 that expression of the eGFP and DsRed transgenes had been shifted within the integrated transposon of clone 4 (Fig. 6D, panel 1 through 5). Similarly, stable DsRed expression could be monitored in transfected transposon-tagged NPFs only when Flp had been present (Fig. 6E), although these cells could not form hygromycin B-resistant colonies due to their limited passaging potential.

20

Transgenic NPFs give rise to viable porcine blastocysts

Due to the limited lifespan of the NPF cells, the porcine master cell line transgenic for the SBT/SV40-FGIP transposon could not be used for insertion of other transgenes in a second round of selection, and thus prevented us from demonstrating transgene
25 insertion at a defined position in the NPF genome. Formal proof would therefore require generation of cloned 'master pigs' carrying the SBT/SV40-FGIP insertion and studies of gene insertion in primary cells derived from these pigs. We therefore examined the possibility of generating SBT/SV40-FGIP-transgenic animals from which cells with regained growth potential can be derived and used for Flp-mediated
30 recombination and a subsequent second round of cloning. To this end we here addressed the question if transgenic NPFs have potential to generate transgenic blastocysts by the use of HMC-directed SCNT. After SB transposition using the pSBT/SV40-FGIP vector and selecting with puromycin for 9 days, NPF clones were isolated, expanded to about 1×10^5 cells and stored at -135°C . All clones expressed
35 eGFP (Fig. 7A). Batches of cells were thawed and used for handmade cloning. Viable

blastocysts were obtained. Fluorescent analysis showed that the blastocysts expressed eGFP in all cells (Fig 7B). Thus, SBT/SV40-FGIP-transgenic NPFs are applicable for cloning by SCNT and expression of the transgene is maintained in both the inner cell mass and the trophoblast layer at the blastocyst stage of development.

5

Handmade cloning (HMC) and establishment of pregnancies

Handmade cloning was performed as described herein. Briefly, oocytes with partially digested zona pellucida were enucleated by oriented bisection according to the position of the polar body. The part of the oocytes without chromatin, i.e. the cytoplasts, was collected and electrofused with transgenic NPFs. Another cytoplast was electrofused with each cytoplast-fibroblast pair during a second round of fusion which also activated the reconstructed embryos and transgenic blastocysts developed after 7 days of in vitro culture.

15 For the cloning and delivery of transgenic piglets, transgenic donor cells as described herein were used in HMC. Except where otherwise indicated all chemicals were obtained from Sigma Chemical Co. (St Louis, MO, USA).

Oocyte collection and in vitro maturation (IVM)

20 Cumulus-oocyte complexes (COCs) are aspirated from 2 to 6 mm follicles from slaughterhouse-derived sow ovaries and matured in groups of 50 in 400 µl IVM medium consisting of bicarbonate-buffered TCM-199 (GIBCO BRL) supplemented with 10% (v/v) cattle serum (CS), 10% (v/v) pig follicular fluid, 10 IU/ml eCG, 5 IU/ml hCG (Suigonan Vet; Skovlunde, Denmark) at 38.5 °C in 5% CO₂ in humidified air in the Submarine Incubation System (SIS; Vajta et al., 1997) for 41–44 h.

25 HMC is performed by a procedure based on partial digestion of the zona pellucida, as described earlier (Du et al., 2005 and 2007). Matured COCs was freed from cumulum cells in 1 mg/ml hyaluronidase in Hepes-buffered TCM-199. From this point (except where otherwise indicated) all manipulations are performed on a heated stage adjusted to 39 °C, and all drops used for handling oocytes were of 20 µl covered with mineral oil. Zonae pellucidae of are partially digested with 3.3 mg/ml pronase solution dissolved in T33 (T for Hepes-buffered TCM 199 medium; the number means percentage (v:v) of CS supplement, here 33%) for 20 s, then oocytes are washed quickly in T2 and T20 drops. Oocytes with distended and softened zonae pellucidae are lined up in T20 drops
35 supplemented with 2.5 µg/ml cytochalasin B. With a finely drawn glass pipette, oocytes

are rotated to locate the polar body on the surface. By oriented bisection with an Ultra Sharp Splitting Blade (AB Technology, Pullman, WA, USA) less than half of the cytoplasm close to the polar body is removed manually from the remaining putative cytoplasm.

5

Transgenic donor fibroblasts grown to a confluent monolayer in DMEM supplemented with 10% FCS are trypsinized and kept in T20 (Kragh et al., 2004). Fusion is performed in two steps. For the first step, 50% of the available cytoplasts were transferred into 1 mg/ml of phytohemagglutinin (PHA; ICN Pharmaceuticals, Australia) dissolved in T0 for 3 s, then each one is quickly dropped over a single APPsw transgenic fibroblast. After attachment, cytoplasm-fibroblast cell pairs are equilibrated in fusion medium (0.3 M mannitol and 0.01% PVA) for 10 s and transferred to the fusion chamber (BTX microslide 0.5 mm fusion chamber, model 450; BTX, San Diego, CA, USA). Using an alternating current (AC) of 0.6 kV/cm and 700 kHz, pairs are aligned to the wire of a fusion chamber with the somatic cells farthest from the wire, then is fused with a direct current of 2.0 kV/cm for 9 μ s. After the electrical pulse, cell pairs are incubated in T10 drops to observe whether fusion has occurred.

10

15

Approximately 1 h after the first fusion, each pair is fused with another cytoplasm and activated simultaneously in activation medium (0.3 M mannitol, 0.1 mM MgSO_4 , 0.1 mM CaCl_2 and 0.01% PVA). By using an AC of 0.6 kV/cm and 700 kHz, one fused pair and one cytoplasm is aligned to one wire of the fusion chamber, with fused pairs contacting the wire, followed by a single DC pulse of 0.85 kV/cm for 80 μ s. When fusion is observed in T10 drops, reconstructed embryos are transferred into porcine zygote medium 3 (PZM-3; Yoshioka et al., 2002) supplemented with 5 μ g/ml cytochalasin B and 10 μ g/ml cycloheximide. After a 4 h incubation at 38.5 °C in 5% CO_2 , 5% O_2 and 90% N_2 with maximum humidity, embryos are washed three times in PZM-3 medium before culture

20

25

Embryo culture and transfer

30

Embryos are cultured at 38.5 °C in 5% CO_2 , 5% O_2 and 90% N_2 with maximum humidity in PZM-3 medium in the well of well system (WOWs; Vajta et al., 2000). Day 5 and 6 blastocysts with clearly visible inner cell mass are surgically transferred to Danish landrace sows on day 4 or 5 after weaning. Pregnancies are diagnosed by ultrasonography on day 21 and confirmed every second week. Piglets are delivered by Caesarean section on day 114, 24 h after treatment with prostaglandin F2.

35

Flp-based plasmid insertion into integrated SB vectors

To facilitate Flp-based gene insertion into integrated SB vectors HEK-GFIP1, HEK-GFIP2, and HEK-GFIP3 were co-transfected with pcDNA/FRT (containing the FRT-hygro fusion gene) and pCMV-Flpx9. Upon subsequent hygromycin B selection, 312, 53, and 1800 drug-resistant colonies appeared in the three cell lines. (Fig. 8). Notably, for each of the three cell lines co-transfection with pUC19 instead of pCMV-Flpx9 did not result in colony formation, indicating that there was no background of false positives in the system. Subsequent PCR and sequence analysis confirmed correct Flp-based gene insertion (data not shown). We are currently investigating whether the variable number of hygromycin B-resistant colonies obtained is a result of different properties of the transposons used or perhaps variable SB copy numbers in the three cell lines.

Vector construction and procedure: The target transposon SBT/RSV-GFIP was inserted into the genome of HEK-293 cells by co-transfecting (using Fugene-6 from Roche) 1.5 µg pSBT/RSV-GFIP with 1.5 µg pCMV-SB (or 1.5 µg pCMV-mSB as a negative control). pCMV-SB, obtained from Perry Hackett, University of Minnesota, Minnesota, USA, encodes the Sleeping Beauty transposase reconstructed from fossil DNA transposable elements of salmoid fish. SB-tagged cell clones were generated by selecting transfected cells with puromycin (1 µg/ml). Clones were isolated and expanded and utilized as target clones for Flp-mediated gene insertion. To demonstrate site-specific insertion of transfected plasmid DNA 12 µg pCMV-Flp was co-transfected (by CaPO₄) with either (i) 3 µg pcDNA5/FRT or (ii) 3 µg pLV/FRT-hygro.PGK-puro into SBT/RSV-GFIP-tagged HEK-293 cells. To select for site-specific insertions cells were grown in medium containing hygromycin B (200 µg/ml).

Gene-flanking insulators stabilize gene expression from integrated transposons.

In ongoing work we have demonstrated that expression from integrated SB-vectors, depending on the site of integration, can be transcriptionally silenced over time. Such silenced vectors can be re-activated by treating vector-containing cells with 5-azacytidine or trichostatin A indicating that epigenetic changes at the targeted locus are responsible for silencing. Based on these findings we flanked the gene expression cassette of these vectors with cHS4 insulators and monitored the effect on gene expression stability. Interestingly, we found in transposition assays, carried out in F9 embryonal carcinomal cells, that insulation of the PGK-puro cassette inside these

transposons resulted in a dramatic 5-fold increase in the number of puromycin-resistant colonies compared to numbers achieved with un-insulated vectors (data not shown). These data strongly indicate that insulators stabilize gene expression from transposed SB vectors and therefore insulators are included in a novel generations of FRT-tagged SBT/GFIP vectors.

Strategies for Flp-based insertion of circular virus-derived substrates. As long as genetically engineered cells are easy to transfect supercoiled plasmid DNA is an efficient substrate for Flp-based gene insertion into the genome. To facilitate site-specific gene insertion in hard-to-transfect cell lines or tissues that are not easily transfected *in vivo* we wanted to explore alternative substrates for site-specific recombination. We focused on circular DNA intermediates that are generated during lentivirus infection and which are often considered dead-end reverse-transcribed products of infection. 2-LTR DNA circles are generated by DNA repair and ligation of the full-length linear viral DNA (Fig. 9, left), whereas 1-LTR DNA circles are generated by homologous recombination between the two LTRs of the episomal and linear viral DNA (Fig. 4, right). We hypothesized that these circles, generated during lentiviral vector transduction, may support Flp-based recombination, allowing site-specific integration of DNA circles devoid of bacterial sequences (Fig. 9, bottom).

1- and 2-LTR lentiviral DNA circles are efficient substrates for site-specific gene insertion. To maximize circle formation and accumulation we generated integration-defective lentiviral vectors (ID-LVs) which contained a mutated inactive integrase protein. We generated a lentiviral vector, pLV/FRT-hygro.PGK-puro, that contains the FRT-hygro recombination sequence and found in transduction titer assays that this vector was only slightly less efficiently transferred in comparison to the original vector (Fig. 10). We then transfected HEK-GFIP3 cells with pCMV-Flpx9 and on the following day transduced transfected cells with ID-LV/FRT-hygro.PGK-puro at a MOI~100. Based on transfection and transduction of about 10^7 cells, we obtained in triplicate assays on average approximately 20 hygromycin B-resistant colonies (Fig. 11A). Background activity was not registered in cells transfected with pUC19 prior to ID-LV/FRT-hygro.PGK-puro-transduction. PCR amplifications using as template genomic DNA from 10 of the hygromycin B-resistant colonies verified that DNA circles had been inserted site-specifically into SB-tagged loci (Fig. 11B). PCR across the FRT integration site resulted in band sizes

indicative of specific gene insertion, whereas primers that amplified sequences containing the LTR region(s) of the integrated circles resulted in amplicons with either one or two LTRs (Fig. 11B). Hence, 1-LTR and 2-LTR integrations each were detected in 5 separate clones. We conclude that lentiviral DNA circles can act as substrates for Fip-based site-specific recombination.

ID-LV-encoded Fip supports Fip-based gene insertion. Based on this finding we set out to test whether Fip likewise could be delivered by ID-LVs. We therefore generated a lentiviral vector, pLV/PGK-Fip containing a PGK-driven Fip gene and transduced HEK-GFIP3 cells with ID-LV/PGK-puro at a MOI~100. Twenty four hours post-transduction cells were transfected with a FRT-tagged plasmid substrate (pcDNA5/FRT) and then treated with hygromycin B. Again, we detected in triplicate experiments about 20 drug-resistant colonies (Fig. 12). In comparison, transfection with pCMV-Fipx9 resulted in about 100 colonies, whereas transduction with a Fip-less vector, ID-LV/PGK-eGFP, did not result in colony formation. Fip-dependent colony formation in this assay indicates that Fip, generated from ID-LVs, is sufficient to confer substrate recombination and site-specific gene insertion.

ID-LV co-transduction results in site-specific lentiviral DNA circle insertion.

We finally combined the actions of ID-LV/FRT-hygro and ID-LV/PGK-Fipx9 vectors in one experiment by co-transducing HEK-GFIP3 cells and selecting transduced cells for hygromycin B resistance. In this setup we obtained on average 8 colonies per transduction (Fig. 13), demonstrating that Fip encoded by an integrating-defective vector facilitates insertion of lentiviral DNA circles carrying the Fip recognition sequence. This finding demonstrates for the first time site-specific insertion of lentiviral vectors and confirm that DNA circles generated during lentiviral transduction may serve as substrate for genomic integration. By integrating viral circles rather than plasmid DNA, we obtain insertions that are not potentially harnessed by bacterial sequences derived from the plasmid backbone and, moreover, pave the way for Fip-based gene insertions in hard-to-transfect cell lines or tissues.

Transduction of cells with integration-proficient and –deficient lentiviral vectors.

VSV-G-pseudotyped lentiviral vectors were generated by co-transduction of 293T cells with 13 µg pMDGpLg/RRE, 3 µg pRSV-Rev, 3.75 µg pMD2G, and 13 µg lentiviral vector plasmid. Vector production plasmid were obtained from Dr. Aebersch, Swiss

Federal Institute of Technology, EPFL, Lausanne, Switzerland. Integration-defective lentiviral vectors (ID-LV) were generated by replacing pMDGpLg/RRE with pMDLg/pRREintD64V (obtained from Rafael Yáñez-Muñoz, University College London, UK) in the transfection mixture. pMDLg/pRREintD64V contains a point mutation in the integrase coding sequence rendering the encoded integrase inactive (14).

Transduction titers of integration-proficient lentiviral vectors carrying the PGK-puro cassette were determined by transferring serially diluted supernatant from transfected 293T cells to HEK-293 target cells prior to puromycin selection. Maximal levels of lentiviral DNA circles were obtained by transducing SB-tagged target clones with ID-LVs at estimated MOIs of 100-500. In experiments involving transfected pCMV-Flp the cells were transfected one day prior to transduction with ID-LV/FRT-hygro.PGK-puro to ensure the presence of Flp at the time of circle formation. In the reciprocal experiment in which Flp was provided by lentiviral circles and plasmid DNA served as a substrate for recombination the cells were transduced with ID-LV/PGK-Flp one day prior to transfection. In ID-LV/FRT-hygro.PGK-puro + ID-LV/PGK-Flp co-transduction experiments the cells were simultaneously transduced with ID-LV/PGK-Flp and ID-LV/FRT-hygro.PGK-puro. After transfection/transduction of SBT/RSV-GFIP-tagged clones, cells were grown in medium containing hygromycin B. In selected experiments hygromycin B-resistant colonies were counted, isolated, expanded, and analyzed by insert-specific PCRs. PCRs included (i) selective amplification of sequences at the integration site and (ii) amplification of inserted 1- and 2-LTR sequences generated during lentiviral DNA circularization.

Construction of alternative vector and transfer to porcine fibroblasts

The SB transposon-based vector used in this study was derived from the pSBT/SV40-GFIP.loxP vector. This vector contains, within the context of a SB transposon, a bicistronic FRTeGFP-IRES-puro (GFIP) cassette flanked upstream by an ATG start codon and downstream by a poly A sequence. Moreover, the vector contains a recognition site for the Cre recombinase (loxP) located between the upper inverted repeat of the vector and the SV40 promoter driving expression of the FRTeGFP-IRES-puro cassette.

Construction of pSBT/SV40-GFIP.loxP vector

The pSBT/RSV-GFIP vector contains the terminal inverted of the SB DNA transposon flanking a FRT-GFP.IRES.puro bicistronic gene cassette driven by a promoter derived

from Rous sarcoma virus (RSV). The eGFP sequence was amplified from peGFP.N1 (Clontech) using a forward primer containing the 48-bp FRT sequence. To analyze FRT-GFP functionality, the FRT-eGFP fusion was inserted into an expression vector containing the SV40 promoter. The PCR-fragment containing FRT-tagged eGFP fusion gene was digested with MluI and XmaI and inserted into MluI/XmaI-digested pSBT/RSV-hAAT (pT/hAAT in ref. (8), obtained from Mark Kay, Stanford University, USA), generating a transposon vector with RSV-driven eGFP expression (pSBT/RSV-eGFP). An IRES-puro cassette was PCR-amplified from pcoenv-IRES-puro (provided by Finn Skou Pedersen, University of Aarhus, Denmark), digested with XmaI, and inserted into XmaI-digested pSBT/RSV-eGFP, generating pSBT/RSV-GFIP (see Fig 14). Alternative versions of this vector containing the SV40 promoter (pSBT/SV40-GFIP) and the promoter derived from the human ubiquitin gene (pSBT/Ubi-GFIP), were generated. In addition, by inserting a Cre recombination target site (loxP) into the MluI site located between the left inverted repeat of the transposon and the SV40 promoter of pSBT/SV40-GFIP, the vector pSBT/SV40-GFIP.loxP was created. The donor plasmid pcDNA5/FRT, containing a FRT-hygro fusion gene without a start codon, was obtained from Invitrogen. The Flp-encoding plasmid, pCMV-Flp was obtained from A. Francis Stewart, University of California San Francisco, USA). This plasmid encodes the enhanced Flp variant designated Flp_{x9} (11). A SB-vector containing two copies of the 1.2-kb chicken DNase hypersensitive site 4 (cHS4)-derived insulator element (12, 13) was generated by inserting PCR-amplified cHS4 sequences and an intervening linker into NotI/SpeI-digested pSBT/PGK-puro (obtained from Mark Kay, Stanford University, USA). The PGK-puro cassette was cloned back into construct by using restriction sites located in the linker, generating pSBT/cHS4.PGK-puro.cHS4

25

For further use in pigs an alternative Cre recognition site (loxP-257) was inserted into a unique AscI site that was created by mutagenesis at a position located between the poly A sequence and the lower inverted repeat of the vector. This vector was designated pSBT/loxP.SV40-GFIP.loxP257. The presence of two Cre recombination sites allows Cre recombinase-mediated cassette exchange after Flp-based plasmid insertion, thereby facilitating, if needed, removal of plasmid sequences and selection genes.

30

SB transposition in primary pig fibroblasts

The SB transposon vectors, either SBT/PGK-puro or the target transposon SBT/loxP.RSV-GFIP.loxP257, were inserted into the genome of pig fibroblast by co-transfecting (using Eugene-6 from Roche) 1.5 µg pSBT/lox.RSV-GFIP.loxP257 (or pSBT/PGK-puro) with 1.5 µg pCMV-SB (or 1.5 µg pCMV-mSB as a negative control).
5 pCMV-SB (rights held by Perry Hackett, University of Minnesota, Minnesota, USA) encodes the Sleeping Beauty transposase reconstructed from fossil DNA transposable elements of salmoid fish. pCMV-SB, pCMV-mSB, and the hyperactive variant pCMV-HSB3 were obtained from Mark Kay, Stanford University, USA. SB-tagged cell clones appeared as a result of selecting transfected cells with puromycin (0.5 µg/ml). Colonies
10 were fixed and stained in methylene blue in methanol and subsequently counted.

Solid SB transposition in primary pig fibroblasts

SB transposes efficiently in most mammal cells but with higher efficacy in human cells than in murine cells. Transposition of SB vectors has never been analyzed in porcine
15 cells, and we therefore initially tested activity in primary pig fibroblasts. We utilized a standard transposon encoding a puromycin resistance gene (SBT/PGK-puro) and found decent levels of transposition, resulting in about 75 drug-resistant colonies in cultures of fibroblasts co-transfected with pSBT/PGK-puro and pCMV-SB (Fig. 15). Less than 3 colonies appeared after transfection with pSBT/PGK-puro and pCMV-
20 mSB, the latter which encodes an inactive version of the transposase. Interestingly, a mean of almost 140 colonies was obtained using the hyperactive transposase variant HSB3, indicating that HSB3 also in porcine cells mediates higher levels of transposition compared to the original SB transposase.

Efficient insertion of a FRT-tagged SB vector in pig fibroblasts

To generate SB-tagged cell clones containing a Flp recombination target site for site-specific gene insertion, we co-transfected the pSBT/loxP.SV40-loxP257 plasmid with pCMV-mSB, pCMV-SB, and pCMV-HSB3, respectively. HSB3 again showed the
highest activity, resulting in about 30 drug-resistant colonies after transfection of 3 H
30 10^4 fibroblasts (Fig. 16).

Puromycin-resistant colonies were isolated and expanded. Clone analysis by fluorescence microscopy demonstrated efficient FRTeGFP expression (Fig. 17), demonstrating vector functionality and easy FRTeGFP detection in pig fibroblasts. These fluorescent cell clones carrying the Flp FRT recombination sequence are
35 currently being used for creation of cloned transgenic animals by hand-made cloning.

Verification of SBT/loxP.SV40-GFIP.loxP257 as target for Flp recombination

Due to limitations of long-term growth of primary pig fibroblasts in tissue culture we were not able to demonstrate Flp-based gene insertion into FRT-tagged SB vectors in pig fibroblasts. We therefore chose to test functionality of the FRT-containing vector by a standard set of recombination experiments carried out in HEK-293 cells. We generated clones of HEK-293 cells containing the transposed SBT/loxP.SV40-GFIP.loxP257 vector. By co-transfection of such clones with (i) a pcDNA5/FRT-derived substrate plasmid containing a FRT-hygro fusion gene and a red fluorescent protein (RFP) expression cassette and (ii) a plasmid encoding the Flp recombinase (pCMV-Flpx9), we subsequently identified hygromycin B resistant colonies. By fluorescence microscopy we observed that site-specifically engineered clones, as expected, turned-off eGFP expression and turned-on RFP expression (data not shown). This 'green-to-red' phenotypic change indicates that the integrated SB-derived target vector serves as acceptor site for Flp-based recombination.

Controlled integration of transgenes by gene-shifting

A gene shift with the help of the Sleeping Beauty (SB) DNA transposon technology and Flpe recombination is presented in this example. We inserted into HEK 293 cells a SB transposon containing an eGFP gene and an frt site. The frt site enables gene shifting with a donor plasmid containing the RFP gene as well as an frt site (see fig. 18). Cells which underwent complete gene shifting, changed colour from green to red fluorescence and also changed antibiotic resistance, as the eGFP is linked to a puromycin resistance gene, and the RFP to a hygromycine B resistance gene. One clone with such characteristics was examined by LM-PCR and the location of the transposon, including the eGFP and frt site was found on chromosome 10. The insertion site showed typical signs of SB integration in the form of TA duplication flanked by distinctive consensus sequences. The transposon was sequenced before and after gene shifting, which confirmed that the transposon was intact, initially without the RFP gene, and with RFP after gene shifting (fig 19 and 20).

These findings imply that gene shifting can be controlled at a precise place in the genome. The potential of SB and the transposon was investigated in minipig cells. The results showed that primary pig fibroblasts also support SB insertion thus creating a platform for gene shifting in pig cells (see fig 21). We prepared minipig cells for SB-

mediated gene shifting, and by hand made cloning (HMC) we show that such cells give rise to viable blastocysts expressing the transgene (see fig 22).

5 In conclusion, the Sleeping Beauty DNA transposon-based vector of the present invention serves in its integrated form as a target for recombinase-based gene insertion. The SB vector is efficiently transferred by cut-and-paste transposition into the genome of primary porcine fibroblasts and therefore is not flanked by plasmid-derived bacterial sequences. Use of these genetically engineered primary cells in for example microinjection and hand-made cloning allows subsequent detailed analyses of SB
10 vector-derived eGFP expression in cloned pigs and identification of animals with attractive expression profiles (e.g. ubiquitous, tissue-specific). Primary fibroblasts from such 'master pigs' is further modified by Flp-based recombination, allowing site-directed gene insertion in a SB vector-tagged locus which is not silenced in the tissue of interest. Cloned pigs harboring a site-specifically inserted disease gene of interest or
15 a shRNA expression cassette for downregulation of endogenous genes can be generated by a second round of animal cloning.

Except where otherwise indicated all chemicals for the nuclear transfer procedure were obtained from Sigma Chemical Co. (St Louis, MO, USA).

20

Oocyte Collection and in vitro maturation (IVM)

Cumulus-oocyte complexes (COCs) were aspirated from 2-6 mm follicles from slaughterhouse-derived sow or gilt ovaries. COCs were matured in groups of 50 in 400 μ l bicarbonate-buffered TCM-199 (GIBCO BRL) supplemented with 10% (v/v) cattle
25 serum (CS), 10% (v/v) pig follicular fluid, 10 IU/ml eCG, 5 IU/ml hCG (Suigonan Vet; Skovlunde, Denmark) at 38.5°C in the "Submarine Incubation System" (SIS; Vajta, et al. 1997) in 5% CO₂ in humidified air for 41-44 hours.

In vitro fertilization (IVF)

30 IVF experiments were performed with *in vitro* matured oocytes in 3 identical replicates. After maturation, COCs were washed twice with mTBM containing 2mM caffeine (mTBM_{fert}) and transferred in groups of 50 to 400 μ l mTBM_{fert}. Freshly ejaculated semen was treated as described previously (Booth, et al., in press). After 2 h capacitation at 38.5°C and in 5% CO₂ in humidified air, sperm was added to the
35 oocytes with the adjusted final concentration of 1×10^5 sperm/ml. Fertilization was

performed at 38.5°C and in 5% CO₂ in humidified air in the SIS for 3 h. After the insemination, the presumptive zygotes were vortexed in mTBM_{fert} to remove cumulus cells before washing in IVC medium and placing in culture dishes (see *Embryo culture and evaluation*).

5

Handmade cloning (HMC)

The applied HMC method was based on our previous work in cattle and pig (Kragh, et al., 2004; Peura and Vajta, 2003; Vajta, et al., 2003), but with significant modifications. Briefly, at 41 h after the start of maturation, the cumulus investment of the COCs was removed by repeated pipetting in 1mg/ml hyaluronidase in Hepes-buffered TCM199. From this point (except where otherwise indicated), all manipulations were performed on a heated stage adjusted to 39°C, and all drops used for handling oocytes were of 20 µl volume covered with mineral oil. Oocytes were briefly incubated in 3.3mg/ml pronase dissolved in T33 (T for Hepes-buffered TCM 199 medium; the number means percentage (v/v) of CS supplement, here 33%) for 5 s. Before the oocytes started to become misshaped in pronase solution, they were picked out and washed quickly in T2 and T20 drops. Oocytes with partially digested but still visible zona were lined up in drops of T2 supplemented with 3 mg/ml polyvinyl alcohol (TPVA) and 2.5 µg/ml cytochalasin B. Trisection instead of bisection was performed manually under stereomicroscopic control with Ultra Sharp Splitting Blades (AB Technology, Pullman, WA, USA; Fig. 23a). Fragments of trisected oocytes were collected and stained with 5 µg/ml Hoechst 33342 fluorochrome in TPVA drops for 5 min, then placed into 1 µl drops of the TPVA medium on the bottom of a 60 mm Falcon Petri dish covered with oil (3-4 fragments per drop). Using an inverted microscope and UV light, positions of fragments without chromatin staining (cytoplasts) were registered and later collected under a stereomicroscope in T10 drops until the start of the fusion.

Fetal fibroblast cells were prepared as described previously (Kragh, et al., *in press*). Fusion was performed in two steps where the second one included the initiation of activation, as well. For the first step, one third of the selected cytoplasts (preferably the smaller parts) were used. With a finely drawn and fire-polished glass pipette, 10 cytoplasts were transferred as a group to 1 mg/ml of phytohaemagglutinin (PHA; ICN Pharmaceuticals, Australia) for 3 s, then quickly dropped onto one of the few fibroblast cells individually that were sedimented in a T2 drop. After attachment, 10 cytoplast-fibroblast cell pairs were equilibrated in fusion medium (0.3 M mannitol and 0.01%

35

PVA) for 10 s. Using an alternative current (AC) of 0.6KV/cm and 700 KHz, cell pairs were aligned to the wire of a fusion chamber (BTX microslide 0.5 mm fusion chamber, model 450; BTX, SanDiego, CA, USA) with the donor cells farthest from the wire (Fig. 23b), then fused with a direct current (DC) of 2.0 KV/cm for 9 μ s. After the electrical pulse, cell pairs were removed carefully from the wire, transferred to T10 drops and incubated to observe whether fusion had occurred.

Approximately 1 hour after the first fusion, fused pairs together with the remaining two thirds of cytoplasts were equilibrated in activation medium drops separately (0.3 M mannitol, 0.1 mM MgSO_4 , 0.1 mM CaCl_2 and 0.01% polyvinylalcohol (PVA)). Under a 0.6KV/cm AC, cytoplast - fused pair - cytoplast triplets were aligned sequentially to the wire in groups of 10, with fused pairs located in the middle (Fig. 23c). A single DC pulse of 0.7 KV/cm for 80 μ s was used for the second fusion and initiation of activation. The triplets were then removed from the wire and transferred carefully to T10 drops to check the fusion (Fig.23d). Reconstructed embryos were incubated in culture medium (see *Embryo culture and evaluation*) supplemented with 5 μ g/ml cytochalasin B and 10 μ g/ml cycloheximide for 4 h at 38.5°C in 5% CO_2 , 5% O_2 and 90% N_2 with maximum humidity, then washed thoroughly for 3 times in IVC medium before culture.

Parthenogenetic activation (PA)

Parthenogenetically activated oocytes were produced either separately or in parallel with HMC. Oocytes were denuded in the same way as above except that a longer incubation in pronase was used to get the zona pellucida completely removed. Zona free (ZF) oocytes were then equilibrated for 10 s in activation medium (0.3 M mannitol, 0.1 mM MgSO_4 , 0.1 mM CaCl_2 and 0.01% PVA) and transferred to the fusion chamber (BTX microslide 0.5 mm fusion chamber, model 450; BTX, SanDiego, CA, USA). A single DC pulse of 0.85 KV/cm for 80 μ s was generated with a BLS CF-150/B cell fusion machine (BLS, Budapest, Hungary) and applied to ZF oocytes. For zona intact (ZI) oocytes, a single DC pulse of 1.25 KV/cm for 80 μ s was used (according to our unpublished preliminary experiments, these parameters resulted in the highest activation and subsequent in vitro development for ZI and ZF oocytes, respectively). The procedure after the electrical pulse was the same as for HMC reconstructed embryos.

Embryo culture and evaluation

All porcine embryos produced by the above treatments were cultured in a modified NCSU37 medium (Kikuchi, et al., 2002) containing 4 mg/ml BSA at 38.5°C in 5% O₂, 5% CO₂ and 90% N₂ with maximum humidity. The culture medium was supplied with 0.17 mm sodium pyruvate and 2.73 mm sodium lactate from Day 0 (the day for fertilization and activation) to Day 2, then sodium lactate and sodium pyruvate was replaced with 5.5mm glucose from Day 2 to Day 7. All ZF embryos were cultured in the WOW system (Vajta, et al., 2000) in the same culture medium and gas mixture as used above, with careful medium change on Day 2 without removing the embryos from the WOWs. The blastocyst rate was registered on Day 7. To determine total cell numbers, blastocysts were fixed and mounted to a glass microscopic slide in glycerol containing 20 µg/ µl Hoechst 33342 fluorochrome. After staining for 24 h, embryos were observed under a Diaphot 200 inverted microscope with epifluorescent attachment and UV-2A filter (Nikon, Tokyo, Japan).

Example 1

Differences in developmental competence between sow (2.5 years, 170Kg in weight) derived oocytes and gilt (5.5~6 months, 75Kg in weight) derived oocytes were investigated through ZF and ZI PA after 44 h in vitro maturation. Four combined groups were investigated in 3 identical replicates: (1) ZF oocytes from sows (2) ZI oocytes from sows (3) ZF oocytes from gilts (4) ZI oocytes from gilts. For ZF activation, a single DC pulse of 0.85 KV/cm for 80 µs was applied, while a single 1.25 KV/cm pulse was used to activate ZI oocytes. Following 7 days culture as described above, the percentage of blastocysts per activated embryo was determined.

The *in vitro* developmental competence of parthenogenetically activated oocytes derived from either sows or gilts was investigated. As shown in Table 1, the blastocyst rates of parthenogenetically activated oocytes from sows were significantly higher than those from gilts, either after ZF or ZI PA.

Table 1.

Blastocyst development of Day 7 parthenogenetically activated sow and gilt oocytes

<i>Zona Free</i>		<i>Zona Intact</i>	
<i>No. of activated oocytes</i>	<i>No. of blastocysts (%)</i> *	<i>No. of activated oocytes</i>	<i>No. of blastocysts (%)</i> *

sow	103	43(42±4) ^a	110	61(55±6) ^c
gilt	85	17(20±2) ^b	137	36(26±5) ^d

^{a,b} Different superscripts mean significant differences ($p < 0.05$).

^{c,d} Different superscripts mean significant differences ($p < 0.05$).

* Percentage (Mean $\pm$ S.E.M) of embryos developed to blastocysts.

- 5 The difference in oocytes developmental competence between sows and gilts has been examined in in vitro production (IVP) and somatic cell nuclear transfer (SCNT) embryos separately, resulting in a similar conclusion as in the earlier publication of other research groups (Sherrer, et al., 2004; Hyun, et al., 2003), i.e. that embryos from sow-derived oocytes are superior to those from gilt-derived oocytes in supporting
- 10 blastocyst development. Although gilts used in our study were at the borderline of maturity, the difference between Day 7 blastocyst rates after PA was significant, proving the superior developmental competence of sow oocytes.

Example 2

- 15 The feasibility of modified porcine HMC was investigated in 6 identical replicates, with IVF and in parallel ZF PA as controls. The more competent sow oocytes (according to Example 1) were used in Example 2. Seven days after reconstruction and/or activation, the number of blastocysts per reconstructed embryo and total cell numbers of randomly selected blastocysts were determined.
- 20 More than 90% of oocyte fragments derived from morphologically intact oocytes could be recovered for HMC after the trisection. In average, 37 embryos could be reconstructed out of 100 matured oocytes. The developmental competence of all sources of porcine embryos is shown in Table 2. On Day 7, the development of reconstructed embryos to the blastocyst stage was 17±4% with mean cell number of
- 25 46±5, while the blastocyst rates for IVF, and ZF PA were 30±6% and 47±4% (n=243, 170, 97) respectively.

Table 2.

In vitro development of embryos produced by HMC, IVF and ZF PA

30

<i>Embryo origins</i>	<i>No. of embryos/oocytes in culture</i>	<i>No. of blastocysts</i>	<i>blastocyst rates (Mean $\pm$ S.E.M).</i>	<i>Mean cell number of blastocysts</i>
-----------------------	--	---------------------------	--	--

HMC	243	41	17±4 ^a	46±5 ^d
IVF	170	52	30±6 ^b	74±6 ^e
ZF PA	97	46	47±4 ^c	53±7 ^d

^{a,b,c} Different superscripts mean significant differences ($p < 0.05$).

^{d,e} Different superscripts mean significant differences ($p < 0.05$).

Although the theoretical maximum efficiency was still not approached, the integration of zona partial digestion and oocyte trisection almost doubled the number of reconstructed embryos compared to our earlier system (Kragh, et al., 2004 Reprod. Fertil. Dev 16, 315-318). This increase in reconstruction efficiency may have special benefits in porcine cloning since oocyte recovery after aspiration is more demanding and time-consuming than in cattle. An even more important point is the high embryo number required for establishment of pregnancies following porcine nuclear transfer. IVC in pigs is also regarded as a demanding and inefficient procedure (Reed, et al., 1992 Theriogeneology 37, 95-109). A disadvantage of ZF systems is that the embryos have to reach at least the compacted morula or early blastocyst stage *in vitro* to avoid disintegration in the oviduct without the protective layer of the zona pellucida. On the other hand, once in the blastocyst stage, zona free embryos can be transferred successfully as proved by calves born after either embryonic or somatic cell nuclear transfer (Peura et al., 1998; Tecirlioglu et al., 2004; Oback et al., 2003; Vajta, et al., 2004) and also by the piglets born after zona-free IVP of oocytes (Wu, et al., 2004). NCSU37 medium has been the most widely and successfully used medium for the culture of pig embryos. However, despite the improved embryo development compared with other media, the viability of IVP porcine embryos is still compromised after IVC. Some reports suggested that glucose is not metabolized readily by early porcine embryos before the eight-cell stage but used in higher amounts in embryos between the compacted morula and blastocysts stages (Flood, et al., 1988). The replacement of glucose with pyruvate and lactate in NCSU37 for the first 2 days culture resulted in a blastocyst rate of 25.3% for IVP porcine embryos in Kikuchi's study (Kukuchi, et al., 2002), which was further corroborated by our present studies with an IVP blastocysts rate of 30% in average. Moreover, the first evaluation of this sequential culture system on porcine HMC and ZF PA embryos has resulted in blastocyst rates of 17% and 47% respectively. Sometimes, the blastocyst rate of ZI PA could even reach levels as high as 90% (Du, unpublished)

Statistical analysis

ANOVA analysis was performed using SPSS 11.0. A probability of $P < 0.05$ was considered to be statistically significant.

5

Example 3

Vitrification of hand-made cloned porcine blastocysts produced from delipated in vitro matured oocytes.

10 Recently a noninvasive procedure was published for delipation of porcine embryos with centrifugation but without subsequent micromanipulation (Esaki *et al.* 2004 Biol Reprod. 71, 432-6).

Cryopreservation of embryos/blastocysts was carried out by vitrification using Cryotop (Kitazato Supply Co, Fujinomiya Japan) as described previously (Kuwayama *et al.* 15 2005a; 2005b). At the time of vitrification, embryos/blastocysts were transferred into equilibration solution (ES) consisting of 7.5% (V/V) ethylene glycol (EG) and 7.5% dimethylsulfoxide (DMSO) in TCM199 supplemented with 20% synthetic serum substitute (SSS) at 39°C for 5 to 15 min. After an initial shrinkage, embryos regained their original volume. 4~6 embryos/blastocysts were transferred into 20 ul drop of 20 vitrification solution (VS) consisting of 15% (V/V) EG and 15% (DMSO) and 0.5M sucrose dissolved in TCM199 supplemented with 20% SSS. After incubation for 20 s, embryos were loaded on Cryotop and plunged into liquid nitrogen. The process from exposure in VS to plunging was completed with 1 min.

25 Embryos/blastocysts were thawed by immersing Cryotop directly into thawing solution (TS) consisting of 1.0M sucrose in TCM199 plus 20% SSS for 1min, then transferred to dilution solution (DS) consisting of 0.5 M sucrose in TCM199 plus 20% SSS for 3 min. To remove cryoprotectant, embryos/blastocysts were kept twice in a washing solution (WS; TCM199 plus 20% SSS), 5 min for each time. Survival of vitrified blastocysts was 30 determined according to reexpansion rates after 24 h recovery in culture medium supplemented with 10% calf serum (CS).

The non-invasive delipation method was applied to in vitro matured porcine oocytes and further development of delipated oocytes after parthenogenetic activation was

investigated in 4 identical replicates. Oocytes were randomly separated into delipation and control groups.

For delipation, oocytes were digested with 1mg/ml pronase in the presence of 50% cattle serum (CS) for 3 min, and washed in Hepes-buffered TCM-199 medium

5 supplemented with 20% CS which results in partial zona pellucida digestion (Fig. 24a).

Subsequently 40-50 oocytes were centrifuged ($12000 \times g$, 20 min) at room temperature in Hepes-buffered TCM-199 medium supplemented with 2% CS, 3 mg/ml PVA and 7.5 $\mu\text{g/ml}$ cytochalasin B (CB) (Fig. 24b). Zonae pellucida of both centrifuged and intact oocytes were removed completely with further digestion in 2mg/ml pronase solution.

10 For activation, a single direct current of 85Kv/cm for 80us was applied to both groups, followed by 4 h treatment with 5 $\mu\text{g/ml}$ CB and 10 $\mu\text{g/ml}$ cycloheximide (CHX). All embryos were then cultured in the modified NCSU37 medium. Day 7 blastocysts were vitrified and warmed by using the Cryotop technique (Kuwayama et al., RBM Online, in press) at 38.5°C. Survival of vitrified blastocysts was determined according to

15 reexpansion rates after 24 h recovery in culture medium supplemented with 10% CS. Cell numbers of reexpanded blastocysts from both groups were determined after Hoechst staining. Results were compared by ANOVA analysis. Partial zona digestion and centrifugation resulted in successful delipation in 173/192 (90%) of oocytes. The development to blastocysts was not different between delipated and intact oocytes (28 $\pm$ 7% vs. 28 $\pm$ 5% respectively; $P>0.05$). However, survival rates of blastocysts derived from delipated oocytes were significantly higher than those developed from intact oocytes (85 $\pm$ 6% vs. 32 $\pm$ 7% respectively; $P<0.01$). There is no difference in average cell number of reexpanded blastocysts derived from either delipated or intact oocytes (36 $\pm$ 7 vs. 38 $\pm$ 9, respectively; $P>0.05$). The results demonstrate that the simple delipation

20 technique does not hamper the in vitro development competence of activated porcine oocytes, and improves the cryosurvival of the derived blastocysts without significant loss in cell number.

After delipation, zona pellucida of oocytes from both groups was removed completely.

30 The same parameters as described above for electrical activation were applied to both groups. Seven days after activation, blastocyst rates and blastocyst cell numbers were determined.

The feasibility of applying a non-invasive delipation technique to in vitro matured

35 porcine oocytes was investigated. 90% (173/192) oocytes can be delipated

successfully. As shown in table 3, the development to blastocysts was not different between delipated and intact oocytes ($28\pm 7\%$ vs. $28\pm 5\%$ respectively; $P>0.05$). However, survival rates of blastocysts derived from delipated oocytes were significantly higher than those developed from intact oocytes ($85\pm 6\%$ vs. $32\pm 7\%$ respectively; $P<0.01$). There is no difference in average cell number of reexpanded blastocysts derived from either delipated or intact oocytes (36 ± 7 vs. 38 ± 9 , respectively; $P>0.05$).

Table 3. Developmental competence and cryosurvival of vitrified-thawed embryos from delipated and intact activated oocytes.

Oocyte treatment	Activated oocyte	Blastocyst rate (%)	Reexpanded blastocyst after warming (%)	Mean cell number of reexpanded blastocysts
Delipated	173	28 ± 7	85 ± 6	36 ± 7
Intact	156	28 ± 5	32 ± 7	39 ± 9

Handmade Cloning of delipated oocytes

Delipated oocytes were used for HMC in 5 replicates. Four identical replicates of non-delipated oocytes for HMC were used as a control system. Seven days after reconstruction, blastocysts produced from both groups were vitrified with Cryotop. Survival rates and cell numbers of re-expanded blastocysts were determined as described for the blastocysts produced by PA.

20

Except where otherwise indicated, all manipulations were performed on a heated stage adjusted to 39°C , and all drops used for handling oocytes were of 20 μl volume covered with mineral oil. For somatic cell nuclear transfer, the handmade cloning (HMC) described in our previous work (Du, et al., 2005) was applied with a single modification: for enucleation of both delipated and control oocytes, bisection instead of trisection was applied.

25

Briefly, after the removal of cumulus investment, control oocytes were incubated in 3.3mg/ml pronase dissolved in T33 for 10 s. Before the oocytes started to become misshaped in pronase solution, they were picked out and washed quickly in T2 and

T20 drops. Delipated oocytes after centrifugation were digested in the 3.3mg/ml pronase solution for an additional 5 s.

Both control and delipated oocytes with partially digested, distended and softened zona pellucidae were lined up in T2 drops supplemented with 2.5 µg/ml cytochalasin B. Bisection was performed manually under stereomicroscopic control (Fig 24c) with Ultra Sharp Splitting Blades (AB Technology, Pullman, WA, USA). Halves were collected and stained with 5 µg/ml Hoechst 33342 fluorochrome in T2 drops for 5 min, and then placed into 1 µl drops of T2 medium on the bottom of a 60 mm Falcon Petri dish covered with oil (3-4 halves per drop). Using an inverted microscope and UV light, positions of halves without chromatin staining (cytoplasts) were registered. Cytoplasts were later collected under a stereomicroscope and stored in T10 drops.

Porcine foetal fibroblast cells were prepared with trypsin digestion from monolayers as described previously (Kragh, et al., 2005). Fusion was performed in two steps where the second one included the initiation of activation, as well. For the first step, 50% of the available cytoplasts were transferred into 1 mg/ml of phytohaemagglutinin (PHA; ICN Pharmaceuticals, Australia) dissolved in T0 for 3 s, then quickly dropped over single fibroblast cells. After attachment, cytoplast-fibroblast cell pairs were equilibrated in fusion medium (0.3 M mannitol and 0.01% PVA) for 10 s and transferred to the fusion chamber. Using an alternating current (AC) of 0.6KV/cm and 700 KHz, pairs were aligned to the wire of a fusion chamber with the somatic cells farthest from the wire (Fig 24d), then fused with a direct current of 2.0 KV/cm for 9 µs. After the electrical pulse, cell pairs were removed carefully from the wire, transferred to T10 drops and incubated to observe whether fusion had occurred.

Approximately 1 hour after the first fusion, each pair was fused with another cytoplast in activation medium. AC current and a single DC pulse of 0.7 KV/cm for 80 µs were applied as described above. Fusion was detected in T10 drops, then reconstructed embryos were transferred into IVC0-2 medium (see *Embryo culture and evaluation*) supplemented with 5 µg/ml cytochalasin B and 10 µg/ml cycloheximide. After a 4 h incubation at 38.5°C in 5% CO₂, 5% O₂ and 90% N₂ with maximum humidity, embryos were washed 3 times in IVC0-2 medium before culture.

Table 4. Developmental competence and cryosurvival of vitrified-thawed embryos of SCNT porcine embryos derived from delipated and intact oocytes.

HMC group	No. of reconstructed embryos	Blastocyst rate (%) [*]	Reexpanded blastocyst after warming (%) [*]	Mean cell number of reexpanded blastocysts [*]
Delipated	240	21±6 ^a	79±6 ^b	41±7 ^d
Intact	150	23±6 ^a	32±8 ^c	39±5 ^d

Different superscripts mean significant differences ($p < 0.05$).

*: mean±S.E.M.

- 5 In vitro developmental competence was observed in HMC with delipated oocytes when Day 7 blastocyst rates were compared with control HMC group (21±6% vs. 23±6% respectively; $P > 0.05$; Table 4). Cryosurvival rate after vitrification of cloned blastocysts derived from delipated oocytes was significantly higher than those developed from intact oocytes (79±6% vs. 32±8, respectively; $P < 0.01$).

10

Example 4

Chemically assisted handmade enucleation (CAHE) and comparison to existing methods

- 15 After 41-42 h maturation *in vitro*, COCs were further cultured for 45 min in the same solution supplemented by 0.4 µg/ml demecolcine. Cumulus cells were then removed by pipetting in 1 mg/ml hyaluronidase dissolved in Hepes-buffered TCM-199. From this point (except where otherwise indicated), all manipulations were performed on a heated stage adjusted to 39°C. All drops used for handling oocytes were of 20 µl in volume, and were covered with mineral oil.

20

Basic steps of the HMC procedure have been described elsewhere herein. Briefly, oocytes without cumulus cells were incubated in 3.3 mg/ml pronase dissolved in T33 (T for Hepes-buffered TCM 199 medium; the number means percentage [v/v] of CS supplement, here 33%) for 20 s. When partial lyses of zonae pellucidae and slight deformation of oocytes occurred, they were picked up and washed quickly in T2 and T20 drops. Nine oocytes were lined up in one T2 drop supplemented with 2.5 µg/ml cytochalasin B (CB). By using a finely drawn and fire-polished glass pipette, oocytes were rotated to find a light extrusion cone and/or strongly attached polar body on the surface, and oriented bisection was performed manually under stereomicroscopic

25

control with a microblade (AB Technology, Pullman, WA, USA). Less than half of the cytoplasm (close to the extrusion or PB) was separated from the remaining part (Fig. 25). After bisection of all 9 oocytes in the drop, larger parts and smaller parts (with the extrusion or attached PB) were collected and placed into separate drops of T2, respectively.

Oriented handmade enucleation without demecolcine treatment (OHE)

All steps were similar to the previously described procedure, but demecolcine preincubation was not applied.

Random handmade bisection for enucleation (RHE)

Demecolcine preincubation was omitted from the pretreatment of this group, as well. After removal of cumulus cells, zonae pellucidae were partially digested by pronase as described above. Random handmade equal bisection was applied in drops of T2 supplemented with 2.5 µg /ml CB. All demi-oocytes were selected and stained with 10 µg /ml Hoechst 33342 in T2 drops for 10 min, then placed into 1 µl drops of T2 medium covered with mineral oil (three demi-oocytes into each drop). Using an inverted microscope and UV light, the positions of chromatin free demi-oocytes, i.e. cytoplasts were registered. These cytoplasts were later collected under a stereomicroscope and stored in T2 drops before further manipulations.

Fusion and initiation of activation

Porcine fetal fibroblast cells were prepared as described previously (Kragh, et al., 2005, Du, et al., 2005). Fusion was performed in two steps, where the second one included the initiation of activation as well. For the first step, with a finely drawn and fire-polished glass pipette, approximately 100 somatic cells were placed into a T2 drop, and 20-30 cytoplasts were placed into a T10 drop. After a short equilibration, groups of 3 cytoplasts were transferred to 1 mg/ml of phytohaemagglutinin (PHA) for 2-3 sec, then each was quickly dropped over a single somatic cell. Following attachment, cytoplast-somatic cell pairs were picked up again and transferred to a fusion medium (0.3 M mannitol supplemented with 0.01% [w/v] PVA). By using an alternative current (AC) of 0.6 KV/cm and 700 KHz, equilibrated pairs were aligned to one wire of a fusion chamber (BTX microslide 0.5 mm fusion chamber, model 450; BTX, San Diego, CA) with the somatic cells farthest from the wire, then fused with a single direct current (DC)

impulse of 2.0 KV/cm for 9 μ sec. Pairs were then removed carefully from the wire to a T10 drop, and incubated further to observe whether fusion had occurred.

Approximately 1 h after the fusion, fused pairs and the remaining cytoplasts were separately equilibrated in activation medium (0.3 M mannitol, 0.1 mM MgSO_4 , 0.1 mM CaCl_2 , supplemented with 0.01% [w/v] PVA). By using a 0.6 KV/cm AC, one pair and one cytoplast was aligned to one wire of the fusion chamber, with fused pairs contacting the wire. A single DC pulse of 0.86 KV/cm for 80 μ sec was used for the second fusion and initiation of activation. Fusion was checked in after incubation in T10 drops.

Traditional Cloning (TC)

Micromanipulation was conducted with a Diaphot 200 inverted microscope (Nikon, Tokyo, Japan), as described before (Chen et al., 1999; Zhang et al., 2005). Briefly, after 42-44 h *in vitro* maturation, the cumulus cells were removed as described above. All manipulations were performed on a heated stage adjusted to 39°C. A single 50 μ L micromanipulation solution drop was made in the central area on a lid of 60 mm culture dish and covered with mineral oil. Groups of 20-30 oocytes and fetal fibroblast cells were placed in the same drop. After incubation for 15-30 min, the oocyte was secured with a holding pipette (inner diameter = 25-35 μ m and outer diameter = 80-100 μ m). After being placed at the position of 5-6 o'clock, the first polar body and the adjacent cytoplasm (approx. 10% of the total volume of the oocyte) presumptively containing metaphase plate were aspirated and removed with a beveled injection pipette (inner diameter = 20 μ m). A fetal fibroblast cell was then injected into the space through the same slit. After nuclear transfer (NT), reconstructed couplets were transferred into drops of media covered with mineral oil for recovery for 1 - 1.5 h until fusion and activation was conducted. The recovery medium was NCSU-23 supplemented with 4 mg/mL BSA and 7.5 μ g/mL CB. Reconstructed couplets were incubated in fusion medium for 4 min. Couplets were aligned manually using a finely pulled and polished glass capillary to make the contact plane parallel to electrodes. A single, 30 μ sec, direct current pulse of 2.0 kV/cm was then applied. After culture in drops of IVC0-2 (specified in "Embryo culture and evaluation") supplemented with 7.5 μ g/mL CB for 30-60 min, fusion results were examined under a stereomicroscope. Fused couplets were subjected to a second pulse in activation solution. After 30 min incubation in T10 they were transferred to IVC0-2 to evaluate *in vitro* development.

Further steps of activation

After the activation impulse, all reconstructed embryos were incubated in IVC0-2 supplemented with 5 µg/ml CB and 10 µg/ml cycloheximide at 38.5°C in 5% CO₂, 5% O₂, and 90% N₂, with maximum humidity.

Embryo culture and evaluation

4 h later, all reconstructed and activated embryos were washed and cultured in Nunc four-well dishes in 400 µl IVC0-2 covered by mineral oil at 38.5°C in 5% CO₂, 5% O₂, and 90% N₂, with maximum humidity. IVC0-2 was a modified NCSU37 medium (Kikuchi, et al., 1999), containing 4 mg/ml BSA, 0.17 mM sodium pyruvate, and 2.73 mM sodium lactate from Day 0 (the day for activation) to Day 2. Sodium pyruvate and sodium lactate were replaced with 5.5 mM glucose from Day 2 to Day 7 (IVC2-7). All zona free embryos were cultured in the Well of the Well (WOW) system (Vajta et al., 2000) in the same culture medium and gas mixture as used above, with careful medium change on Day 2 without removing the embryos from the WOWs. TC embryos were cultured in groups of 15 to 30 in wells of four-well dishes by using the same medium amount and composition. Cleavage and blastocyst rates were registered on Day 2 and Day 7, respectively. To determine total cell numbers, blastocysts were fixed and mounted to a glass microscope slide in a small amount (<2 µl) of glycerol containing 10 µg/ml Hoechst 33342. After staining for several hours at room temperature, embryos were observed under a Diaphot 200 inverted microscope with epifluorescent attachment and UV-2A filter (Nikon, Tokyo, Japan).

Comparison of efficiency of CAHE vs. OHE

The efficiency and reliability of CAHE was tested in 12 identical replicates by using a total of 620 oocytes. After 41-42 h maturation, oocytes were subjected to demecolcine incubation. Oriented bisection was performed in oocytes where an extrusion cone and/or a strongly attached PB was detected after partial pronase digestion. Percentages of bisected vs. total oocytes and surviving vs. bisected oocytes were registered. Subsequently both putative cytoplasts and karyoplasts were collected separately and stained with Hoechst 33342 (10 µg/ml in T2 for 10 min). The presence or absence of chromatin was detected under an inverted fluorescent microscope (Fig. 26).

The efficiency and reliability of OHE was investigated in 9 identical replicates using a total of 414 oocytes. After 42-43 h in vitro maturation, oriented bisection was performed in matured oocytes where an extrusion cone and/or a PB was detected after partial pronase digestion. Results were evaluated as described in the previous paragraph.

5

The results are shown in Table 5.

Table 5: The efficiency of chemically assisted handmade enucleation (CAHE) and oriented handmade enucleation (OHE)

Groups	No. of treated oocytes	Bisected/total oocytes (%) [*]	Cytoplasm/bisection (%) [*]	Cytoplasm/total oocyte (%) [*]
CAHE	620	96±1 ^a	94±2 ^b	90±3 ^c
OHE	414	92±2 ^a	88±3 ^b	81±4 ^d

10

*: mean ± A.D. (absolute deviations)

Different superscripts mean difference (P<0.05)

15

No differences between groups regarding extrusion cones and/or attached polar bodies allowing oriented bisection or in the lysis rates were detected, and the successful enucleation per bisected oocyte ratio was also similar. However the overall efficiency of the procedure measured by the cytoplasm per total oocyte number was higher in the CAHE than in the OHE group.

20

Comparison of in vitro development of embryos produced with CAHE, RHE and TC

25

In 8 replicates, a total of 468 in vitro matured oocytes were randomly distributed and subjected to three of the enucleation procedures described above. Fusion rates between cytoplasm and donor fibroblasts were registered. Reconstructed embryos were activated and cultured as described earlier. Cleavage and blastocyst rates were determined on Day 2 and Day 7, respectively. Stereomicroscopic characteristics of the developed blastocysts were compared between groups.

30

Table 6: Developmental competence of embryos derived from chemically assisted handmade enucleation (CAHE), random handmade enucleation (RHE) and traditional, micromanipulator based cloning (TC).

Groups	No. of reconstructed embryos	Fusion rate (%)*	Cleavage rate (%)*	Blastocyst rate (%)*	Cell no. of blastocysts (Day 7)
CAHE	150	87±7 ^a	97±6 ^b	28±9 ^d	57±6 ^e
RHE	86	81±4 ^a	87±8 ^b	21±9 ^d	49±7 ^e
TC	178	81±10 ^a	69±9 ^c	21±6 ^d	53±6 ^e

*: mean ± A.D. (absolute deviations)

Different superscripts mean difference (P<0.05).

Fusion rates after enucleation were similar between CAHE, RHE and TC, respectively.

- 5 The second fusion and activation resulted in negligible (<1%) losses in the first two groups. Although TC resulted in lower cleavage per reconstructed embryo rates than the other two groups, this difference was not present in the blastocyst per reconstructed embryo rates.
- 10 Stereomicroscopic characteristics (size; estimated proportion and outlines of the inner cell mass) did not differ between groups. Cell numbers (57±6 vs. 49±7 vs. 53±6) of the produced blastocysts from CAHE, RHE and TC are shown in Table 6, Fig. 27 and Fig. 28.
- 15 Statistical analysis
AVEDEV was performed by Microsoft XP Excel software and ANOVA was performed by SAS system. A probability of P<0.05 was considered to be statistically significant.
- 20 Example 5
Production of piglets
- 25 *Handmade cloning (HMC)*
Forty one hrs after the start of *in vitro* maturation, the cumulus investment of the COCs was removed by repeated pipetting in 1mg/ml hyaluronidase in Hepes-buffered TCM199. From this point (except where otherwise indicated) all manipulations were performed on a heated stage adjusted to 39°C, and all drops used for handling oocytes were of 20 µl volume covered with mineral oil. Oocytes were briefly incubated in 3.3mg/ml pronase dissolved in T33 (T for Hepes-buffered TCM 199 medium; the number means percentage (v/v) of calf serum (CS) supplement, here 33%) for 20 sec

and then quickly washed in T2 and T20 drops. Oocytes with partially digested but still visible zona were lined up in drops of T2 supplemented with 2.5 µg/ml cytochalasin B (CB). With a finely drawn and fire-polished glass pipette, oocytes were rotated to find the polar body (PB) on the surface, and oriented bisection was performed manually under stereomicroscopic control with a microblade (AB Technology, Pullman, WA, USA). Thus, less than half of the oocyte cytoplasm (close to the extrusion or PB) was removed from the remaining putative cytoplasm. Cytoplasts were washed twice in T2 drops and collected in a T10 drop.

Fetal fibroblast cells were prepared as described previously (Kragh, P.M. *et al. Theriogenology* 64, 1536-1545 (2005)).

Fusion was performed in two steps where the second one included the initiation of activation, as well. For the first step, halves of putative cytoplasts were used. With a finely drawn and fire-polished glass pipette, 10 cytoplasts were transferred as a group to 1 mg/ml of phytohaemagglutinin (PHA; ICN Pharmaceuticals, Australia) for 3 sec, then quickly dropped individually onto one of the few fibroblast cells that were sedimented in a T2 drop. After attachment, 10 cytoplast-fibroblast cell pairs were equilibrated in fusion medium (0.3 M mannitol and 0.01% PVA) for 10 sec. Using an alternative current (AC) of 0.6KV/cm and 700 KHz, cell pairs were aligned to the wire of a fusion chamber (BTX microslide 0.5 mm fusion chamber, model 450; BTX, SanDiego, CA, USA) with the somatic cells farthest from the wire, then fused with a direct current (DC) of 2.0 KV/cm for 9 µsec. After the electrical pulse, cell pairs were removed carefully from the wire, transferred to T10 drops and incubated to observe whether fusion had occurred.

Approximately 1 hr after the first fusion, fused pairs together with the remaining cytoplasts were equilibrated in activation medium drops separately (0.3 M mannitol, 0.1 mM MgSO₄, 0.1 mM CaCl₂ and 0.01% PVA). Under a 0.6KV/cm AC, cytoplast - fused pair were aligned sequentially to the wire in groups of 10, with fused pairs far from the wire. A single DC pulse of 0.7 KV/cm for 80 µsec was used for the second fusion and initiation of activation. The pairs were then removed from the wire and transferred carefully to T10 drops to check the fusion. Reconstructed embryos were incubated in PZM-3 medium supplemented with 5 µg/ml CB and 10 µg/ml cycloheximide for 4 hr at 38.5 °C in 5% CO₂, 5% O₂ and 90% N₂ with maximum humidity, then washed thoroughly before culture.

Traditional Cloning (TC)

Micromanipulation was conducted with a Diaphot 200 inverted microscope (Nikon, Tokyo, Japan). Cumulus cells were removed as described above after 42 to 44 hr maturation. All manipulations were performed on a heated stage adjusted to 39°C. A single 50 µL drop of micromanipulation solution (NCSU-23 supplemented with 4 mg/mL BSA and 7.5 µg/mL CB) was made in the central area on a lid of 60 mm culture dish and covered with mineral oil. Groups of 20 to 30 oocytes and fetal fibroblast cells were placed in the same drop. After incubation for 15 to 30 min, one oocyte was secured with a holding pipette (inner diameter = 25-35 µm and outer diameter = 80-100 µm). After being placed at the position of 5-6 o'clock, the first polar body and the adjacent cytoplasm (approx. 10% of the total volume of the oocyte) presumptively containing metaphase plate were aspirated and removed with a beveled injection pipette (inner diameter = 20 µm). A fetal fibroblast cell was then injected into the space through the same slot. After nuclear transfer (NT), reconstructed couplets were transferred into drops of media covered with mineral oil for recovery for 1 to 1.5 hrs until fusion and activation was conducted. Reconstructed couplets were incubated in fusion medium for 4 min. Couplets were aligned manually using a finely pulled and polished glass capillary to make the contact plane parallel to electrodes. A single, 30 µsec, direct current pulse of 2.0 kV/cm was then applied. After culture in drops of PZM-3 medium supplemented with 7.5 µg/mL CB for 30-60 min, fusion results were examined under a stereomicroscope. Fused couplets were subjected to a second pulse in activation solution. After 30 min incubation in T10 they were transferred to PZM-3 medium to evaluate *in vitro* development.

Embryo Culture and Transfer

Reconstructed embryos were cultured in PZM-3 medium (Dobrinisky, J.T. et al. *Biol Reprod* 55, 1069-1074 (1996) supplemented with 4 mg/ml BSA. Zona-free embryos produced from HMC were cultured in the modified WOWs system (Feltrin, C. Et al. *Reprod Fertil Dev* 18, 126 (2006). Two different cell lines (LW1-2 for HMC, LW2 for TC) were used as nuclear donor cells for HMC and TC to allow the identification of the offspring from the two procedures. LW1-2 and LW2 originate from fetuses from a cross (with Duroc) and pure Danish landrace, respectively.

The average blastocyst per reconstructed embryo rate after *in vitro* culture for 7 days was 50.1±2.8 % (mean±S.E.M), which is significantly higher ($p<0.01$) for HMC than that

of TC performed in parallel in our laboratory (Table 7) and also the highest one that has ever been reported in pig cloning.

Table 7

5 *In vitro* development of embryos produced from handmade cloning and traditional cloning

Group	Somatic cell donor	No. of reconstructed embryos	Cleavage rate (%)	Blastocyst rate (%)
HMC	LW1-2	643	83.7±4.90 ^a	50.06±2.80 ^a
TC	LW2	831	74.86±13.16 ^b	28.98±2.84 ^b

a, b, Values of different superscripts within columns are significantly different ($p < 0.05$).

*: mean±S.E.M.

10

Mixed blastocysts produced from both HMC and TC were surgically transferred to 11 naturally synchronized sows on Day 4 or 5 of estrous cycle. Six (55%) recipients were diagnosed pregnant by ultrasonography, 2 aborted and by the time of writing 2 have delivered 3 and 10 piglets, respectively. A litter size of 10 cloned piglets is, according to our knowledge, the largest litter size so far achieved in pig cloning. All of them are healthy and behave normally except one showed rigid flexure of distal joint of one foreleg. %).

15

Preliminary results suggest that when embryos of similar stages were transferred, recipients on Day 4 of the estrous cycle supported pregnancy establishment better than those of Day 5 (Table 8).

20

Table 8. *In vivo* development of cloned porcine embryos

Recipient number	Embryos transferred		Embryo stage (Day)	Recipient cycle (Day)	Pregnancy status	No. of piglets born		Gestation length (Day)
	HMC embryo	TC embryo				piglets from HMC	No. piglets from TC	
1327	22	10	D5,6,7	4	Y	2	1	116
1539	36	10	D7	4	Y	8	2	115
1309	30	28	D5,6	4	Y			
1553	45	44	D5,6	4	Y			
1668	48	18	D5,6	5	Y, aborted			
1428	78	22	D5,6	5	Y, aborted			

1725	44	4	D5,6,7	5	N	-	-	-
1643	22	11	D5,6,7	4	N	-	-	-
1520	30	26	D5,6	4	N	-	-	-
1363	37	7	D6,7	5	N	-	-	-
1560	99	42	D5,6,7	5	N	-	-	-

Microsatellite Analysis

Parental analysis using 10 different porcine microsatellite markers confirmed the identical genotype of cloned piglets and donor cells used for nuclear transfer.

- 5 Identification was done by microsatellite analysis of genomic DNA from each of the newborn piglets, the surrogate sow, and the donor skin fibroblasts LW1-2 and LW2 originating from two fetuses that represent Danish landrace and Duroc, respectively. Ten polymorphic microsatellite loci (SW886, SW58, SW2116, SW1989, SW152, SW378, KS139, SO167, SW1987, SW957) located on different porcine chromosomes
- 10 were amplified by 3-color multiplex PCR and the products analyzed on the Genetic Analyzer 3130 X1 (Applied Biosystems) using the program Gene Mapper 3.7.

For the second recipient, the offspring per embryo rate (22%) was the highest one ever reported so far in pig cloning (Walker, S.C. *et al. Cloning Stem Cells* 7, 105-112 (2005);

15 Hoshino, Y. *et al. Cloning Stem Cells* 7, 17-26 (2005)). Comparable live birth/transferred embryo efficiencies were obtained in HMC (17%) and TC (15%).

Statistical Analysis

- Differences between the experimental groups were evaluated using independent-
- 20 samples t-test by SPSS 11.5. $P < 0.05$ was considered significant.

References

1. S. O'Gorman, D. T. Fox, G. M. Wahl, *Science* **251**, 1351 (Mar 15, 1991).
2. J. R. Broach, J. B. Hicks, *Cell* **21**, 501 (Sep, 1980).
- 5 3. B. Thyagarajan, E. C. Olivares, R. P. Hollis, D. S. Ginsburg, M. P. Calos, *Mol Cell Biol* **21**, 3926 (Jun, 2001).
4. A. M. Geurts *et al.*, *Nucleic Acids Res* **34**, 2803 (2006).
5. Z. Ivics, P. B. Hackett, R. H. Plasterk, Z. Izsvak, *Cell* **91**, 501 (Nov 14, 1997).
6. J. G. Mikkelsen *et al.*, *Mol Ther* **8**, 654 (Oct, 2003).
- 10 7. T. J. Vigdal, C. D. Kaufman, Z. Izsvak, D. F. Voytas, Z. Ivics, *J Mol Biol* **323**, 441 (Oct 25, 2002).
8. S. R. Yant *et al.*, *Nat Genet* **25**, 35 (May, 2000).
9. C. S. Branda, S. M. Dymecki, *Dev Cell* **6**, 7 (Jan, 2004).
10. A. L. Garcia-Otin, F. Guillou, *Front Biosci* **11**, 1108 (2006).
- 15 11. F. Buchholz, P. O. Angrand, A. F. Stewart, *Nat Biotechnol* **16**, 657 (Jul, 1998).
12. J. H. Chung, M. Whiteley, G. Felsenfeld, *Cell* **74**, 505 (Aug 13, 1993).
13. T. M. Yusufzai, G. Felsenfeld, *Proc Natl Acad Sci U S A* **101**, 8620 (Jun 8, 2004).
14. R. J. Yanez-Munoz *et al.*, *Nat Med* **12**, 348 (Mar, 2006).
- 20
8. Onishi A, Iwamoto M, Akita T, Mikawa S, Takeda K, Awata T, Hanada H, Perry AC: Pig cloning by microinjection of fetal fibroblast nuclei. *Science (New York, NY)* 2000, 289(5482):1188-1190.
9. Polejaeva IA, Chen SH, Vaught TD, Page RL, Mullins J, Ball S, Dai Y, Boone J, Walker S, Ayares DL *et al*: Cloned pigs produced by nuclear transfer from adult somatic cells. *Nature* 2000, 407(6800):86-90.
- 25 10. Kragh PM, Vajta G, Corydon TJ, Purup S, Bolund L, Callesen H: Production of transgenic porcine blastocysts by hand-made cloning. *Reprod Fertil Dev* 2004, 16(3):315-318.
11. Kragh PM, Du Y, Corydon TJ, Purup S, Bolund L, Vajta G: Efficient in vitro
- 30 production of porcine blastocysts by handmade cloning with a combined electrical and chemical activation. *Theriogenology* 2005, 64(7):1536-1545.
12. Du Y, Kragh PM, Zhang Y, Li J, Schmidt M, Bogh IB, Zhang X, Purup S, Jorgensen AL, Pedersen AM *et al*: Piglets born from handmade cloning, an innovative cloning method without micromanipulation. *Theriogenology* 2007, 68(8):1104-1110.
- 35 13. Dorer DR, Henikoff S: Expansions of transgene repeats cause heterochromatin formation and gene silencing in *Drosophila*. *Cell* 1994, 77(7):993-1002.
14. Garrick D, Fiering S, Martin DI, Whitelaw E: Repeat-induced gene silencing in mammals. *Nature genetics* 1998, 18(1):56-59.

15. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z: Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. *Cell* 1997, 91(4):501-510.
- 5 16. Yant SR, Wu X, Huang Y, Garrison B, Burgess SM, Kay MA: High-resolution genome-wide mapping of transposon integration in mammals. *Mol Cell Biol* 2005, 25(6):2085-2094.
17. Liu G, Geurts AM, Yae K, Srinivasan AR, Fahrenkrug SC, Largaespada DA, Takeda J, Horie K, Olson WK, Hackett PB: Target-site preferences of Sleeping Beauty transposons. *J Mol Biol* 2005, 346(1):161-173.
- 10 18. Dupuy AJ, Clark K, Carlson CM, Fritz S, Davidson AE, Markley KM, Finley K, Fletcher CF, Ekker SC, Hackett PB *et al*: Mammalian germ-line transgenesis by transposition. *Proc Natl Acad Sci U S A* 2002, 99(7):4495-4499.
19. Fischer SE, Wienholds E, Plasterk RH: Regulated transposition of a fish transposon in the mouse germ line. *Proc Natl Acad Sci U S A* 2001, 98(12):6759-6764.
- 15 20. Horie K, Kuroiwa A, Ikawa M, Okabe M, Kondoh G, Matsuda Y, Takeda J: Efficient chromosomal transposition of a Tc1/mariner-like transposon Sleeping Beauty in mice. *Proc Natl Acad Sci U S A* 2001, 98(16):9191-9196.
21. Luo G, Ivics Z, Izsvak Z, Bradley A: Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. *Proc Natl Acad Sci U S A* 1998, 95(18):10769-10773.
- 20 22. Wilber A, Linehan JL, Tian X, Woll PS, Morris JK, Belur LR, McIvor RS, Kaufman DS: Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. *Stem Cells* 2007, 25(11):2919-2927.
23. Mikkelsen JG, Yant SR, Meuse L, Huang Z, Xu H, Kay MA: Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. *Mol Ther* 2003, 8(4):654-665.
- 25 24. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. *Nat Genet* 2000, 25(1):35-41.
- 30 25. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA: Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. *Nature* 2005, 436(7048):272-276.
26. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA: Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. *Nature* 2005, 436(7048):221-226.
- 35 27. Clark KJ, Carlson DF, Foster LK, Kong BW, Foster DN, Fahrenkrug SC: Enzymatic engineering of the porcine genome with transposons and recombinases. *BMC Biotechnol* 2007, 7:42.

28. Moldt B, Staunstrup NH, Jakobsen M, Yanez-Munoz RJ, Mikkelsen JG: Site-directed genomic insertion of lentiviral DNA circles. Submitted for publication.
29. Izsvak Z, Ivics Z, Plasterk RH: Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. *J Mol Biol* 2000, 302(1):93-102.
- 5 30. Manuelidis L: Heterochromatic features of an 11-megabase transgene in brain cells. *Proceedings of the National Academy of Sciences of the United States of America* 1991, 88(3):1049-1053.
31. Henikoff S: Conspiracy of silence among repeated transgenes. *Bioessays* 1998, 20(7):532-535.
- 10 32. Robertson G, Garrick D, Wilson M, Martin DI, Whitelaw E: Age-dependent silencing of globin transgenes in the mouse. *Nucleic acids research* 1996, 24(8):1465-1471.
33. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1 integration in the human genome favors active genes and local hotspots. *Cell* 2002, 110(4):521-529.
- 15 34. Wu X, Li Y, Crise B, Burgess SM: Transcription start regions in the human genome are favored targets for MLV integration. *Science (New York, NY)* 2003, 300(5626):1749-1751.
35. Wilson MH, Coates CJ, George AL, Jr.: PiggyBac Transposon-mediated Gene Transfer in Human Cells. *Mol Ther* 2007, 15(1):139-145.
- 20 36. Ivics Z, Katzer A, Stuwe EE, Fiedler D, Knepel S, Izsvak Z: Targeted Sleeping Beauty transposition in human cells. *Mol Ther* 2007, 15(6):1137-1144.
37. Yant SR, Huang Y, Akache B, Kay MA: Site-directed transposon integration in human cells. *Nucleic Acids Res* 2007, 35(7):e50.
38. Yant SR, Park J, Huang Y, Mikkelsen JG, Kay MA: Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. *Mol Cell Biol* 2004, 24(20):9239-9247.
- 25 39. Chen ZY, He CY, Ehrhardt A, Kay MA: Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. *Mol Ther* 2003, 8(3):495-500.
- 30 40. Riu E, Chen ZY, Xu H, He CY, Kay MA: Histone Modifications are Associated with the Persistence or Silencing of Vector-mediated Transgene Expression In Vivo. *Mol Ther* 2007, 15(7):1348-1355.
41. Chen ZY, He CY, Kay MA: Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. *Hum Gene Ther* 2005, 16(1):126-131.
- 35

Sequences

SEQ ID NO: 1

FRT site (recombination ie. recognition sequence)

Gaagtactattccgaagttcctattctctagaaagtataggaacttc

5

SEQ ID NO: 2

Wt loxP

ggaaagtccccaggctccccaggcaggcagaagtatgcaaagcatcgaggatgtacgggccagatatacgcgataa

cttcgtataatgtatgtatacgaagttatacgcgtagggtttaccgcatcaccgaaacgcgcgaggcagctgtggaat

10

gtgtgtcagttagggtgtggaaagtccccaggctccccagca

SEQ ID NO: 3

Wt loxP core

Ataacttcgtataatgtatgtatacgaagttat

15

SEQ ID NO:4

LoxP 257

ttctattctgggggtgggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgtctggggatg

20

cggtaggctctatggaaccagctggggcgcgcattaaacttcgtataaagtctcctatacgaagttatattctagttgtggtt

gtccaaactcatcaatgtatcttatcatgtctggatccc

SEQ ID NO: 5

LoxP 257 core

attaacttcgtataaagtctcctatacgaagttatatt

25

SEQ ID NO: 6

attB full-length

gtcgacatgcccccggtgaccgtcgagaacccgctgacgctgccccggtatccgcacccgcccgcgacgcccgtcgacgt

30

cccgtgctcaccgtgaccaccgcgcccagcggttcgagggcgagggctcccgggtgcgccgcgcttcgcccggatc

aactaccgccacctcgaccggtcatcatgatggaccagatgggtgaggtggagtacgcgcccggggagcccaaggg

cacgccctggcaccgcaccgcggttcgagaccgtgacctacatcgtcgacggtacctg

35

SEQ ID NO: 7

attB core

gtgccagggcggtgccctgggctccccgggcgcg

40

SEQ ID NO: 8

attP core

ccccaaactgagagaactcaaaggttaccacagttgggg

SEQ ID NO: 9

puromycin resistance gene

atgaccgagtacaagcccacggtgcgcctcgccaccgcgacgacgtccccggggccgtacgcaccctcgccgccg

45

cgttcgccgactaccccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaaga

actcttctcacgcgcgtcgggctcgacatcggaaggtgtgggtcgcgacgacggcgccgcggtggcggtctggac

cacgccggagagcgtcgaagcggggcggtgttcgcccagatcgggccgcgcatggccgagttgagcgggtcccg

50

ctggccgcgacgaacagatggaaggcctctggcgccgcaccggcccaaggagcccgcgtggttctggccaccgt

cggcgctcgcggaccaccagggaagggctcgggcagcgccgtcgtgctccccggagtggaggcggccgagcgc

gccgggggtgcccgccttctggagacctccgcgccccgcaacctccccttctacgagcggtcgggttcaccgtcaccg
ccgacgtcgaggtgcccgaaggaccgcgcacctggtgcatgaccgcaagccgggtgcctga

SEQ ID NO: 10

5 eGFP gene, coding sequence

gtgagcaagggcgaggagctgttcaccgggggtggtgcccacctcgtggtcagctggacggcgacgtaaacggccacaa
gttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgacctgaagttcatctgcaccaccggcaa
gctgcccgtgcccggcccaccctcgtgaccacctgacctacggcgtgcagtgttcagccgtaccccgaccacatg
aagcagcacgacttctcaagtccgcatgcccgaaggctacgtccaggagcgcaccatcttctcaaggacgacggc
10 aactacaagaccgcgcccagggtgaagttcgagggcgacacctggtgaaccgcacgcagctgaagggcatcgactt
caaggaggacggcaacatctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgac
aagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcggcgac
cactaccagcagaacaccccccatcggcgacggccccgtgctgctgcccgaaccactacctgagcaccagtcgcg
cctgagcaaagacccaacgagaagcgcgcatcacatggtcctgctggagttcgtgaccgcgcgggatcacctcgcg
15 catggacgagctgtacaagtaa

SEQ ID NO: 11

Sequence of IRES from ECMV

ccccctaacgttactggccgaagccgcttgaataaggccgggtgtgcgtttgtctatatgttatttccaccatattgccgtcttt
20 tggcaatgtgagggcccgaaacctggccctgtcttctgacgagcattcctaggggtctttccctctcgccaaaggaat
gcaaggctcgttgaatgtcgtgaaggaagcagttcctctggaagcttctgaagacaaacaacgtctgtagcgacctttg
caggcagcgggaacccccacctggcgacaggtgcctctcgcgccaaaagccacgtgtataagatacacctgcaaag
gcggcacaaccccagtgccacgttgtgagttggatagttgtgaaagagtcaaatggctctcctcaagcgtattcaacaa
ggggctgaaggatgccagaaggtagcccatgtatgggatctgacgtggggcctcggtgcacatgcttcatgtgttttag
25 tcgagggttaaaaaacgtctaggccccccgaaccacggggacgtggttttctttgaaaaacacgat

SEQ ID NO: 12

RSV promoter

ggatgtacgggcccagatatacgcgtatctgaggggactaggggtgtgttaggcgaaaagcggggcttcgggtgtacgcg
30 gttaggagtccctcaggatatagtagtttcgcttttgcatagggagggggaaatgtagtcttatgcaatacactgtagtctt
gcaacatggaacgatgagttagcaacatgccttacaaggagagaaaaagcaccgtgcatgccgattggtggaagta
aggtggtacgatcgtgccttattaggaaggcaacagacaggtctgacatggattggacgaaccactgaattccgcattgc
agagataattgtatttaagtgcttagctcgatacaataaacgccatttgaccattcaccacattggtgtgcacctcc

35 SEQ ID NO: 13

SV40 promoter

Cagctgtggaatgtgtcagttagggtgtggaagtccccaggctccccagcaggcagaagtatgcaaagcatgcat
ctcaattagtcagcaaccaggtgtggaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaatt
agtcagcaaccatagtcgcccccctaactccgcccatactccgcccagttccgcccattctccgcccata
40 ggctgactaatttttttatttatgcagaggccgaggccgctcggcctctgagctattccagaagtagtgaggaggctttttg
gaggc

SEQ ID NO: 14

Sequence of ubiquitin promoter

45 tctgccgagtcattgtccttgtcccgcggccccgggagccccccgcgaccggcctgggagggtcaggaggttgaagg
gggctgagcaaaggaagccccgtcattacctcaaatgtgacccaaaaataaagaccggtccatctcgaggggtgggc
cagggcggggtcaggagggaggggagggagaccccgactctgcagaaggcgctcgtgctgccccacgtccgcgcg
aacgcgggggttcgcgaccgaggggacgcggggggtgaggggaggggcccgcggagccgcggtaaggaacgc
50 gggccgcccaccgctccgggtgcagcgccctccgcgcccgggttttggcgccctcccgcgggcgccccctcctcacgg
cgagcgctgccacgtcagacgaagggcgagcgagcgctcctgatccttccgcccggacgctcaggacagcggccccg
ctgctcataagactcggccttagaaccacagtatcagcagaaggacattttaggacgggactgggtgactctagggcac

5 tggttttcttccagagagcggaacaggcgaggaaaaagtagtcccttctcggcgattctcgggagggatcctcggtggggc
 ggtgaacgccgatgattatataaggacgcgcgggtgtggcacagctagtccgtcgcagccgggatttgggtcgcgggt
 ctgttttggtatcgctgtatcgctacttggtagtagcgggctgctgggctggccggggcttctgtggccgcccgggcccgt
 cgggtgggacggaagcgtgtggagagaccgccaagggctgtagctgggtccgcgagcaagggtgccctgaactgggg
 gttggggggagcgcagcaaaatggcggctgttcccgagcttgaatggaagacgctgtgaggcgggctgtgaggtcgt
 10 tgaacaagggtggggggcatggtgggcggcaagaacccaaggctttaggccttcgctaatacggggaaagctcttattc
 gggtagatgggctggggcaccatctggggaccctgacgtgaagttgtcactgactggagaactcgggttgcgtcgtgtg
 cgggggcccagttatggcgtgccgttggcagtgacccgtaccttgggagcgcgcgccctcgtcgtcgtgacgt
 caccgttctgttggcttataatgcagggtggggccaccctgccgttaggtgtgcggtaggcttttccgctgcaggacgca
 15 ggggtcgggcctagggtaggctctcctgaatcgacaggcgccggaccctcgtgtgaggggagggataagtgaggcgtca
 gtttcttggctgggtttatgtacctatcttctaagtagctgaagctccgggtttgaactatgcgctcggggttggcgagtggtt
 gtgaagtttttaggcacctttgaaatgtaatcatttgggtcaatatgtaatttcagtgtagactagtaaattgtccgctaaatt
 ctggccgttttggctttttagtagacg

15

SEQ ID NO: 15

SB inverted repeats

Tacagtgaagtcggaagttacatacacttaagttggagtcattaaaactcgttttcaactactccacaaatttctgttaac
 aaacaatagtttggcaagtcagttaggacatctacttgtgcatgacacaagtcattttccaacaattgtttacagacagatt
 20 attcacttataattcactgtatcacaattccagtgggtcagaagttacatacact

AND

Gtatgttaacttctgaccactgggaatgtatgaaagaaataaaagctgaaatgaatcattctctactattattctgatat
 ttcacattcttaaaataaagtggtgatcctaactgaccttaagacaggggaatctttactcggattaaatgicaggaattgtga
 25 aaaagtgagtttaaagtatttggctaagggtgatgtaaactccgacttcaactgta

25

SEQ ID NO: 16

pSBT/SV40-GFIP.lxp, sequence

30 SB inverted repeats

SV40 promoter

Start codon

FRT site

eGFP

35 Puro

tcgcgcgtttcggtagtacggtgaaaacctctgacacatgcagctcccggagacgggtcacagctgtctgtaagcggat
 gccgggagcagacaagcccgtcagggcgctcagcgggtgttggcgggtgtcgggctggcttaactatgcggcatca
 40 gagcagattgtactgagagtgaccatagcgggtgtgaaataccgcacagatgcgtaaggagaaaataccgcatcagg
 cgccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctattacgccagctggcgaa
 agggggatgtgctgcaaggcgattaagttgggtaacgccagggttttccagtcacgacgttgtaaaacgacggccagt
 gaattcgagctcggtagcctacagttgaagtcggaagttacatacacttaagttggagtcattaaaactcgttttcaactac
 tccacaaatttctgttaacaaacaatagtttggcaagtcagttaggacatctacttgtgcatgacacaagtcattttccaa
 45 caattgttacagacagattattcacttataattcactgtatcacaattccagtgggtcagaagttacatacactaagttgact
 gtgcctttaaacagcttggaaaattccagaaaatgatgtcatggctttagaagcttctgtagactaattgacatcatttgagt
 caattggagggtgtacctgtggatgtattcaagggaaattctgtggaatgtgtgcagttagggtgtggaagccccaggctc
 cccaggcaggcagaagtatgcaaagcatcgaggatgtacgggcccagatatacgcgataaactcgtataatgtatgctat
 acgaagttatcgctgagggtttaccgctatcacggaaacgcgcgaggcagctgtggaatgtgtgcagttagggtgtgg
 50 aaagtcgccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcgcccccctaactcc
 cccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcgcccccctaactcc
 gcccatccccgccctaactccgccagttccgcccattctccgcccattggctgactaattttttattatgcagaggccga
 ggccgcctcggcctctgagctattccagaagtagtgaggaggctttttggaggctaccatggagaagttactattccgaa

gttcctattctctagaaagtataggaactcaagcttggcactgggtagcaagggcgaggagctgttcaccgggggtgtgc
ccatcctggctcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgaggcgaggcgatgccac
ctacggcaagctgacctgaagttcatctgcaccaccggcaagctgccgtgccctggcccaccctcgtgaccacctg
acctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcagcacttctcaagtcgcccatgccgaag
5 gctacgtccaggagcgaccatcttctcaaggacgacggcaactacaagaccgcgcgaggtgaagttcgagggc
gacaccctggtaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctgg
agtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatc
cgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggcccc
gtgtgtgtcccgacaaccactacctgagcaccacgtccgcctgagcaaagaccccaacgagaagcgcgatcacat
10 ggtcctgtctggagttcgtgaccgcccgggatcactctcggcatggacgagctgtacaagtaaacggccgcccga
attggggccaccggtgctagccccctaacgttactggccgaagccgcttgaataaggccggtgtgcgtttgtctatgtat
ttccaccatattgccgtcttttgcaatgtgagggcccgaaacctggccctgtcttctgacgagcattctaggggtcttcc
ccctctcgccaaaggaatgcaaggtctgtgaatgtcgtgaaggaagcagttcctctggaagcttctgaagacaaacaa
cgctctgtagcgaccttgcaggcagcggaaacccccacctggcgacaggtgccctctcgggccaaaagccacgtgtat
15 aagatacacctgcaaaggcggcacaacccccagtgccacgtgtgagttggatagttgtggaagagtc aaatggctctc
ctcaagcgtattcaacaaggggctgaaggatgccagaaggtacccattgtatgggatctgactgtgggctcggtgc
acatgctttacatgtgttagtcgaggttaaaaaacgtctagggcccccgaaaccacggggacgtggttttcttgaaaaac
acgataataccatgaccgagtacaagcccacggtgcgcctcgccaccgcgacgacgtccccggggcgtacgcac
cctcgccgcccgttcgcccactaccccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccg
20 agctgcaagaactcttctcacgcgcgtcgggctcgacatcggcaagggtgtgggtcgcgacgacggcgccgcggtg
gcggtctggaccacgcccggagagcgtcgaagcggggcggtgttcgcccagatcgccccgcgatggccgagttga
gcggttcccggtggccgcgacgaacagatggaaggcctcctggcgccgcaccggcccaaggagcccgcgtggtt
cctggccaccgtcggcgtctcgcccgaccaccaggggcaagggtctgggcagcgcgctcgtgctccccggagtgagg
cggccgagcgcgcccgggtgcccgccttcttgagacctccgcgccccgcaacctcccccttctacgagcggctcggctt
25 caccgtcacccgacgtcgaggtgcccgaaggaccgcgcacctgggtgcagcccgcaagcccgggtcctgacgc
ccgcccacaagaccgcagcggccgacggaaaggagcgcacgaccccatgcatcgaatcgatatcgccggccgcga
ctctagatcataatcagcccgggggtgatcagcctcgactgtgccttctagtgtccagccatcgtgtttgcccctccccgt
gccttcttgacctggaagggtccactcccactgtccttcttaataaaatgaggaaatgcatcgcatgtctgagtaggt
gtcattctattctgggggtgggggtggggcaggacagcaaggggaggattgggaagacaatagcaggcatgctggg
30 gatcggtgggctctatggaaccagctggggctcgacattctagtgtgtgttgcctaaactcatcaatgtatcttatctatgct
ggatcccatcacaaagcttgacctcaatctatagaaaggaggaatgagccaaaattcacccaacttattgtgggaag
ctgtggaaggctactcgaaatgtttgacccaagttaaacaatttaaaaggcaatgctaccaaatactaattgagtgtatgta
acttctgaccactgggaatgtgatgaaagaaataaaagctgaaatgaatcattctctactattattctgatatttcacattc
ttaaataaaagtgtgatcctaactgaccttaagacagggaaatcttactcggattaatgtcaggaattgtgaaaaagtga
35 gtttaaatgtatttgctaagggtgatgtaaactccgacttcaactgtagggatcctctagagtcgacctgcaggcatgcaa
gcttggcgtaatcatgtgcatagctgttctgtgtgaaatgttatccgctcacaattccacacaacatacagacgggaagc
ataaagtgtaaagcctgggggtgcctaagtagtgagctaaactacattaattgcgttgcgctcactgccgcttccagtcgg
gaaacctgtcgtgccagctgcattaatgaatcgcccaacgcgcccgggagaggcggttgcgtattggggcgctcttccgctt
cctcgctcactgactcgtcgcgtcggctcgttcggctcgcggcagcggtatcagctcactcaaaggcggtataacggttat
40 ccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaaggccagcaaaaaggccaggaaccgtaaaaa
ggccgctgtgtgctggttttccataggtcggccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggc
gaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgtctcctgttccgacctgccc
cttaccggataacctgtccgccttctccctcgggaagcgtggcgcttctcaatgctcagcgtgtaggtatctcagttcgggt
aggtcgttctccaagctgggctgtgtgcacgaacccccgttcagcccgaccgctgcgccttaccggtaactatcgct
45 tgagccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgt
aggcgggtgtacagagttctgaagtggtggcctaactacggctacactagaaggacagtatttggtatcgcgtcgtcgt
aagccagttaccttcggaaaaaagagttggtagctctgatccggcaacaaaccaccgctggtagcgttgggtttttgttg
caagcagcagattacgcgcagaaaaaaggatcgaagaagatcctttgatcttttctacggggtcgtacgctcagtgga
acgaaaaactcacgttaagggtatttggcatgagattatcaaaaaggatcttcacctagatccttttaataaaaaatgaagt
50 tttaaatcaatctaaagtatatatgagtaaaactggctcgtacagttaccaatgcttaatcagtgaggcacctatctcagcgatc
tgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggaggggcttaccatctggccccagt
gctgcaatgataccgcgagaccacgcctaccggctccagattatcagcaataaaccagccagccggaagggccga

gcgcagaagtggctcctgcaactttatccgcctccatccagctctattaattgttgcgggaagctagagtaagtagttcgcca
gttaatagtttgcgcaacggtgttgcattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccgg
tcccaacgatcaaggcgagttacatgatccccatgttgtgcaaaaaagcggttagctcctcggctcctccgatcgttgtc
agaagtaagtggccgcagtggtatcactcatggttatggcagcactgcataattctctactgtcatgccatccgtaagatg
5 ctttctgtgactggtagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcggcggtcaat
acgggataataccgcgccacatagcagaactttaaagtgtcatcattggaaaacggttctcggggcgaaaactctca
aggatcttaccgctgttgagatccagttcgtatgaaccactcgtgcacccaactgatcttcagcatctttactttcaccagc
gtttcgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggcgacacggaaatgttgaatac
tcatactcttctttcaatattattgaagcattatcagggttattgtctcatgagcggatacatattgaatgtatttagaaaaat
10 aaacaaataggggttccgcgcacatttccccgaaaagtgccacctgacgtctaagaaaccattattatcatgacattaac
ctataaaaataggcgtatcacgagggccctttcgtc

SEQ ID NO: 17
15 pSBT/RSV-GFIP, sequence

SB inverted repeats
RSV promoter
Start codon
20 FRT site
eGFP
Puro

tcgcgcgtttcgggtgatgacggtgaaaacctctgacacatgcagctccccggagacgggtcacagcttgtctgtaagcggat
25 gccgggagcagacaagcccgtcagggcgcgctcagcgggtgttggcgggtgtcggggctggcttaactatgcggcatca
gagcagattgtactgagagtgcacatatgcgggtgtgaaataccgcacagatgcgtaaggagaaaaataccgcacagg
cgccattcgccattcaggctgcgcaactgttgggaaggcgatcgggtgcgggcctctcgtctattacgccagctggcgaa
agggggatgtgtgcaaggcgattaagtgggtaacgccaggggtttccagtcacgacgttgtaaaacgacggccagt
gaattcgagctcggtagccctacagttgaagtgggaagttacatacacttaagttggagtcattaaaactcgttttcaactac
30 tccacaaaattcttgttaacaaacaatagtttggcaagtcagttaggacatctactttgtcatgacacaagtcattttccaa
caattgtttacagacagattatttcacttataattcactgtatcacaattccagttgggtcagaagttacatacactaagttgact
gtgcctttaaacagcttggaataatccagaaaatgatgtcatggctttagaagctctgtagactaattgacatcatttgagt
caattggagggtgtacctgtggatgtattcaagggaaattctgtggaatgtgtgtcagttaggggtgtggaagccccagggtc
cccaggcaggcagaagtatgcaaacatcgaggatgtacgggccagatatacgcgtatctgaggggactaggggtgtgt
35 ttaggcgaaaagcggggcttcgggtgtacgcggtaggagtcacctcaggatatagtagtttgcgttttgcatagggaggg
ggaaatgtagtcttatgcaatacactgtagtcttgaacatggtaacgatgagttagcaacatgccttacaaggagagaa
aaagcaccgtgatgccgattgggtggaagtaagggtggtagcatcgtgccttattaggaaggcaacagacaggtctgaca
tggattggacgaaccactgaattccgcattgcagagataattgtatttaagtgcctagctcgatacaataaacgccattga
ccattcaccacattgggtgtgacactccaaagcttgatactaccatggagaagttactattccgaagttcctattcttagaaa
40 gtataggaacttcaagcttggcactgtgtgagcaagggcgaggagctgttcaccgggggtgtgccatcctggtcgagct
ggacggcgacgtaaacggccacaagttcagcgtgtccggcgaggcgaggcgatgccacctacggcaagctgac
cctgaagttactgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcag
tgcitcagccgtacccccgaccacatgaagcagcagcacttctcaagtccgcatgccgaaggctacgtccaggagc
gcaccatcttctcaaggacgacggcaactacaagaccgcgccgaggtagaagttcagggcgacaccctgggtgaac
45 cgcacgcagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaaca
gccacaacgtctatatcatgcccagacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgag
gacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgtgcccgcaca
accactacctgagcaccagtcgcccttgagcaaaagaccccaacgagaagcgcgatcacatggctctgtggagttc
gtgaccgcccggggtacactctcggtatggacgagctgtacaagtaagcatagcggccgtaaattccgccctctct
50 ccctccccccccctaactgtactggccgaagccgcttgaataaggccgggtgtgcgttctgtatgttatttccaccata
ttgccgtcttttggcaatgtgagggcccgaaacctggccctgtctcttgacgagcattcctaggggtcttccccctcgcgc
aaaggaatgcaaggctgttgaatgtcgtgaaggaagcagttcctctggaagcttctgaagacaacaacgtctgtagc

gaccctttgcaggcagcggaacccccacctggcgacaggtgcctctgcgggccaaaagccacgtgtataagatacac
ctgcaaaggcggcacaaacccagtgccacgtgtgagttggatagttgtgaaagagtc aaatggctctcctaagcgt
attcaacaaggggctgaaggatgccagaaggtagcccatgtatgggatctgatctggggcctcggtgcacatgcttta
catgtgttagtcgagggttaaaaaacgtctaggccccccgaaccacggggacgtggtttccttgaaaaacacgatgata
5 agcttgccacaacctgaccgagtagaagccacggtgcgcctcgccaccgcgacgacgtccccgggcccgtacg
caccctcgccgcccgttcgcccactaccccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggtca
ccgagctgcaagaactcttctcagcgcgctcgggctcgacatcggaagggtgtgggtcgcggaagcagcgccgcg
gtggcggctctggaccacgccggagagcgtcgaagcggggggcggtgttcgcccagatcgccccgcgcatggccgagtt
gagcgggtcccggttgccgcgcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccgcgtg
10 gttcctggccaccgtcggtctcgcgccgaccaccagggcaagggtctgggcagcgccgtcgctccccggagtgga
ggcgccgagcgcgcgggggtccccgccttctggagacctccgcgccccgcaacctcccccttctacgagcggctcgg
cttaccgtcacccgcgacgtcgagggtcccgaaggaccgcgcacctgggtgatgaccgcaagcccgggtgcctgaa
gatcccccgggggatcagcctcgactgtgccttctagtggcagccatctgtgttggccctcccccgctccttctgaccc
tggaagggtgccactcccactgtccttcttaataaaatgaggaaattgcacgcattgtctgagtaggtgtcattctattctgg
15 ggggtgggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctgggtagcggtgggt
ctatggaaccagctggggtcgacattctagtgtggtttgccaactcatcaatgtatcttcatgcttgatcccatcaca
aagctcgacctcaatcctatagaaaggaggaatgagccaaaattcacccaacttattgtgggaagctgtggaaggcta
ctcgaaatgtttgaccaagttaaacaatttaaaggcaatgtaccaaataactaattgagtgtagttaacttctgacctact
gggaatgtgatgaagaataaaagctgaaatgaatcattctctactattattctgatatttcacattcttaaaataaagtg
20 gtgatcctaactgaccttaagacagggaaatcttactcggattaaatgtcaggaattgtgaaaaagtgagtttaaatgtattg
gctaagggtgatgtaaacttccgacttcaactgtagggtacctctagagtcgacctgcaggcatgcaagcttggcgtaatc
atggcatagctgttctgtgtgaaattgttatccgctcacaattccacacaacatacagacccggaagcataaagtgtaaa
gcctgggtgacctaatgagtgagtaactcacaitaattgcgttgcgctcactgcccgttccagtcgggaaacctgtcgt
gccagctgcattaatgaatcgccaacgcgcggggagaggcggttgcgtattggcgctcttccgcttctcgcctcactg
25 actcgtcgcctcgggtcgttcgggtgcggcgagcgggtatcagctcactcaaaggcggtaatccggtatccacagaatca
ggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccggttgc
ggcgttttccataggctccgccccctgacgagcatcacaataatcgacgtcaagttagaggtggcgaaacccgac
aggactataaagataaccaggcggttccccctggaagctccctcgtgcgctcctgttccgacctgcccgttaccggatac
ctgtccgccttctccttccgggaagcgtggcgcttctcaatgtcagcgtgtaggtatctcaggtcgggtgtaggtcgtc
30 caagctgggtcgtgtgcacgaacccccgttcagccgaccgctgcgccttatccggtaactatcgttctgagtcacaacc
ggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcgggtgtac
agagttctgaagtgggtggcctaactacgggtacactagaaggacagtagtttggtatctgcgctcgtctgaagccagttacc
ttcgaaaaaagagttggtagctcttgatccggcaaaacaaaccaccgctggttagcggtgggtttttgttgcaagcagcaga
ttacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaaactca
35 cgtaagggtatttggtcatgagattatcaaaaaggatcttcacctagatccttttaataaaaaatgaagtttaaatcaatct
aaagtatatatgagtaaacttggtctgacagttaccaatgttaatcagtgaggcacctatctcagcgatctgtctatttcgttc
atccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgat
accgcgagaccacgctcaccggctccagatttatcagcaataaaccagccagccggaaggggccgagcgcagaagt
ggctctgcaactttatccgctccatccagcttattaattgttgccgggaagctagagtaagtagttcgccagttaatagttgc
40 gcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatgggttcattcagctccggttcccaacgat
caaggcgagttacatgatcccccattgtgtgcaaaaaagcgggttagctccttcggctcctccgatcgttgcagaagtaagtt
ggccgcagtggtatcactcatgggtatggcagcactgcataattctctactgtcatgccatccgtaagatgctttctgtgactg
gtgagtactcaaccaagtcattctgagaatagtgatgcggcgaccgagttgctcttgcggcgctcaatccgggataata
ccgcgccacatagcagaactttaaagtgctcatcattggaaaacgttctcggggcgaaaactctcaaggatcttaccg
45 ctgttgagatccagttcgatgaacccactcgtgcacccaactgatcttcagcatctttactttaccagcgtttctgggtgag
caaaaacaggaaggcaaaatgccgcaaaaaagggaataaggcgacacggaaatgtgaatactcatactcttctt
ttcaatattatgaagcatttatcagggtattgtctcatgagcggatacatattgaatgtattgaaaaataaacaataagg
gggtccgcgcacattccccgaaaagtgccacctgacgtctaagaaaccattattatcatgacattaacctataaaaaatag
50 gcgtatcacgaggcccttctgc

SEQ ID NO: 18
pSBT/SV40-GFIP, sequence

SB inverted repeats
5 SV40 promoter
Start codon
FRT site
eGFP
Puro

10

15

20

25

30

35

40

45

50

tcgcgcgtttcgggtgatgacggtgaaaacctctgacacatgcagctcccggagacggtcacagctgtctgtaagcggat
gccccggagcagacaagccccgcagggcgctcagcgggtgttgccgggtgtcggggctggcttaactatgccccatca
gagcagattgtactgagagtgaccatatgcgggtgaaataccgcacagatgcgtaaggagaaaataccgcatcagg
cgccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggctcttcgctattacgccagctggcgaa
agggggatgtgtcgaaggcgattaagttgggtaacgccaggggtttccagtcacgacgtgtgaaaacgacggccagt
gaattcgagctcggtagcctacagttgaagtcggaagttacatacacttaagttggagtcataaaactcgttttcaactac
tccacaaatttctgttaacaaacaatagtttggcaagtcagttaggacatctactttgtcatgacacaagtcattttccaa
caattgtttacagacagattattcacttataattcactgtatcacaattccagtgggtcagaagttacatacactaagttgact
gtgcctttaaacagcttggaaaattccagaaaatgatgtcatggctttagaagcttctgatagactaattgacatcattgagt
caattggagggtgtacctgtggatgtattcaagggaattctgtggaatgtgtgtcagttagggtgtggaaagtcacgggtc
cccaggcaggcagaagtatgcaaagcatcgaggatgtacgggcccagatatacgctgagggtttcaccgtatcaccg
aaacgcgcgaggcagctgtggaatgtgtgtcagttagggtgtggaaagtcacgggtccccagcaggcagaagtatg
caaagcatgcaictcaattagtcagcaaccaggtgtggaaagtcacgggtccccagcaggcagaagtatgcaaag
catgcatctcaattagtcagcaaccatagtcacggcccttaactccgcccacccgcccctaactccgcccagttccgccc
attctccgccccatggctgactaattttttattatgcagaggccgaggccgctcggcctctgagctattccagaagtagt
gaggaggctttttggagggtacctaggaagttactattccgaagttcctattcttagaaagtataggaacttcaagctt
ggcactgtgtgagcaagggcgaggagctgttcacgggggtgtgtccatcctgtgtcagctggacggcgacgtaaacg
gccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgacctgaagttcatctgcacca
ccggcaagctgcccgtgccctggcccacctcgtgaccacctgacctacggcgtgcagtgcttcagccgctacccga
ccacatgaagcagcacgacttctcaagtcgccatgccgaaggctacgtccaggagcgaccatcttctcaaggac
gacggcaactacaagacccgcgcccagggtgaagttcaggggagacacctgggtgaaccgcacgcagctgaagggc
atcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatg
gccgacaagcagaagaacggcatcaagggtgaactcaagatccgccacaacatcgaggacggcagcgtgcagctc
gccgaccactaccagcagaacacccccatcggcgacggccccgtgtgtgtcccgacaaccactacctgagcacc
agtccgcccctgagcaaagaccccaacgagaagcgcatcacatggtcctgtgtgaggttcgtgaccgcccggggtc
actctcggcatggacgagctgtacaagtaaagcgccgcccgaattgggcccaggggtgtagccccctaactgtactg
gccgaagccgcttgaataaggccggtgtgcgtttgtctatgttattttccaccatattgccgtctttggcaatgtgagggc
ccggaaaccttgccctgtctcttgacgagcattcctaggggtcttccctctcgccaaaggaatgaagggtctgttgaat
gtcgtgaaggaagcagttcctctggaagcttctgaagacaaacacgtctgtagcgacctttgcaggcagcgggaacc
ccccacctggcgacagggtgctctgcggccaaaagccacgtgtataagatacactgcaaaggcgccacaacccca
gtgccacgttgtgagttggatagttgtgaaagagtc aaatggctctcctcaagcgtattcaacaaggggctgaaggatg
cccagaaggtagcccatgtatgggatctgacttggggcctcggtgcacatgctttacatgtgttagtcgaggttaaaaa
cgtctaggccccccgaaccacggggacgtggttttcttgaaaaacacgataatacatgaccgagtacaagcccacg
gtgcgctcgccaccgcgacgacgtccccggggcgtacgcacctcgccgcccgttcgcccactaccccgccac
gcgccacaccgtcgatccgacggccacatcgagcgggtcaccgagctgcaagaactcttctcagcgcgctggggct
cgacatcggaagggtgtgggtcgcgacgacggcgccggttgccggtctggaccacggcgagagcgtcgaagc
gggggcccgtgttcgagatcgcccgcgcatgcccaggttgagcgggttcccggtggccgcgagcaacagatgg
aaggcctcctggcgccgacccggcccaaggagcccgcgtgttcttgccacgctcggcgtctcgccgaccaccag
ggcaagggtctgggcagcgcgctgtctccccggagtgaggcgccgagcgcgcccgggtgcccgccttcttga
gacctccgccccgcaacctccccctctacgagcgggtcgggttaccgtcaccgcccagctcgagggtcccgaagg
accgcgacacctgggtgatgacctgcaagcccggtgcctgacgcccggccacaagacccgcagcggccgaccgaaa
ggagcgcacgaccccatgcatcgaatcgatatcgcgccgagcgtctagatcataatcagccgggggtgatcagcct

cgactgtgccttctagttgccagccatctgtgtttgccccctccccgtgccttcttgaccctggaagggtgccactcccactgt
 cctttctaataaaatgaggaaattgcatcgcatgtctgagtaggtgtcattctattctgggggtgggggtggggcaggac
 agcaagggggaggattggaagacaatagcaggcatgtggggatgcggtgggctctatggaaccagctggggctc
 gacattctagttgtgtttgtccaaactcatcaatgtatcttatcatgtctggatcccatcacaagctctgacctcaatcctata
 5 gaaaggaggaaatgagccaaaattcacccaacttattgtgggaagctgtggaaggctactcgaatgtttgacccaagtt
 aaacaatttaaaggcaatgctaccaataactaattgagtgatgttaacttctgacctactgggaatgtgatgaaagaaat
 aaaagctgaaatgaatcattctctactattattctgatattcacattcttaaaataaagtgggtatcctaactgaccttaaga
 caggaatctttactcggattaatgtcaggaatgtgaaaaagtgaattaaatgtatttgctaagggtgatgtaaactcc
 gacttcaactgtagggatcctctagagtcgacctgcaggcatgcaagcttggcgtaaatcatggcatagctgtttcctgtgtg
 10 aaattgttatccgtcacaaatccacacaacatacgagccggaagcataaagtgtaaagcctgggggtgctaatagtgtg
 agctaactcacattaattgcgttgcgctcactgcccgccttccagtcgggaaccctgtcgtgccagctgcattaatgaatcg
 gccaacgcgcggggagaggcggttgcgtattgggcgctcttccgcttctcgtcactgactcgctgcgctcggttcg
 gctgcggcgagcggtatcagtcactcaaaggcggttaatacgggtatccacagaatcaggggataacgcaggaaaga
 acatgtgagcaaaaaggccagcaaaaaggccaggaaccgtaaaaaggccgctgtgctggcgttttccataggctccgcc
 15 cccctgacgagcatcacaaaaatcgacgctcaagtcagagggtggcgaaacccgacaggactataaagataccaggc
 gtttccccctggaagctccctcgtgcgctctcctgttccgacctgcccgttaccggatacctgtccgcctttctccctcggga
 agcgtggcgcttttcaatgctcacgctgtaggtatctcagttcggtgttaggtcgttcgctccaagctgggctgtgtgcacga
 accccccgttcagcccagccgctgcgccttatccggttaactatcgtcttgagtccaacccggtaagacacgacttatcgcc
 actggcagcagccactggtaacaggattagcagagcgaggatgtaggcggtgctacagagtcttgaagtgggtggcct
 20 aactacggctacactagaaggacagttattgtatctgcgctcgtgaagccagttaccttcggaaaaagagtggtagc
 tcttgaaccggcaaaaccaccgctggtagcggtgtttttgtttgcaagcagcagattacgcgcagaaaaaaagg
 atcacaagaagatccttgaatcttttaccggggtcgtacgctcagtggaacgaaaaactcacgttaagggattttggtcatga
 gattatcaaaaaggatcttcacctagatccttttaattaaaaatgaagtttaaatcaatctaaagtatatatagtaaacttg
 gctgcagagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactcccc
 25 gtcgtgtagataactacgatacgggagggcctaccatctggccccagtgctgcaatgataccgcgagacccacgctcac
 cggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggctcgtcaactttatccgcctc
 catccagcttattaattgttgcgggaagctagagtaagtagttcgccagttaatagtttgcgcaacggtgttgccattgctac
 aggcacgtggtgtcacgctcgtcgtttggtatggcttattcagctccggttcccaacgatcaaggcgagttacatgatccc
 ccatgttgtgcaaaaaagcggttagctccttcggctccgatcgtgtgcagaagtaagttggccgcagtggtatcactcatg
 30 gttatggcagcactgcataattctctactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcatt
 ctgagaatagtgatgcggcgaccgagttgctcttggccggcgctcaatacgggataataccgcgccacatagcagaactt
 taaaagtgtcatcatgtgaaaacggttcttcggggcgaaaaactctcaaggatcttaccgctgttgagatccagttcgatgta
 acccactcgtgcacccaactgatcttcagcatcttttactttaccagcggttctgggtgagcaaaaaacaggaaggcaaaa
 tgccgcaaaaaagggaataagggcgacacggaaatgtgaatactcactcttcttccatttcaatattatgaagcattatc
 35 aggggtattgtctcatgagcggatacatatttgatgtatttagaaaaataaacaataaggggttccgcgcacatttccccg
 aaaagtgccacctgacgtctaagaaaccattattatcatgacattaacctataaaaaataggcgatcacgaggccctttcg
 tc

40 SEQ ID NO: 19
 pSBT/SV40-GFIP.loxP, sequence

45 SB inverted repeats
 SV40 promoter
 Start codon
 FRT site
 eGFP
 Puro

50 tcgcgcgtttcgggtgatgacggtgaaaacctctgacacatgcagctcccggagacgggtcacagcttgtctgtaagcggat
 gccgggagcagacaagcccgtcagggcgctcagcgggtgttggcgggtgtcggggctggcttaactatgccgcatca
 gagcagattgtactgagagtgacacatatgcgggtgtgaaataccgcacagatgcgtaaggagaaaaataccgcatcagg

cgccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctattacgccagctggcgaa
agggggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacgacgttgtaaacgacggccagt
gaattcgagctcggtagcctacagttgaagtcggaagttacatacacttaagttggagtcattaaaactcgttttcaactac
5 tccacaaatttctgttaacaaacaatagtttggcaagtcagttaggacatctacttgtgcatgacacaagtcattttccaa
caattgtttacagacagattatttcacttataattcactgtatcacaattccagttgggtcagaagttacatacactaagttgact
gtgcctttaaacagcttggaataattccagaaaatgatgtcatggctttagaagcttctgtagactaattgacatcattgagt
caattggagggtgtacctgtggatgtattcaaggaattctgtggaatgtgtgtagttagggtgtggaagtcctccaggctc
10 cccaggcaggcagaagtatgcaaagcatcaggatgtacgggcccagatatacgcgataacttcgtataatgtatgctat
acgaagttatcgctgagggtttaccgctatcacgaaacgcgcgaggcagctgtggaatgtgtgtagttagggtgtgg
aaagtcctccaggctcccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccagggtgtggaaagtc
cccaggctcccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcctcgcccctaactcc
gcccattcccggcccctaactccgcccagttccgcccatttccgcccattggctgactaattttttattatgtagaggccga
ggccgcctcgccctctgagctattccagaagtagtgaggaggctttttggaggctaccatggagaagttactattccgaa
gttcctattctctagaaagtataggaactcaagcttggcactgggtgagcaagggcgaggagctgtaccgggggtgtg
15 ccatctgtgtcagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgaggggcgaggggcgatgccac
ctacggcaagctgacctgaagttcatctgcaccaccggcaagctgcccgtgcccggcccaccctctgaccaccctg
acctacggcgtgcagtgcttaccgctaccccgaccacatgaagcagcagacttctcaagtcggccatgccgaag
gctacgtccaggagcgcaccatcttctcaaggacgacggcaactacaagaccgcgcgagggtgaagttcgagggc
gacaccctgtgtaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatctggggcacaagctgg
20 agtacaactacaacagccacaacgtctatcatgcccagacaagcagaagaacggcatcaagggtgaacttcaagatc
cgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggcccc
gtgtgctgcccagacaaccactacgtgagcaccagtcggccctgagcaaagaccccaacgagaagcgcgatcacat
ggctctgtgtggagttctgtagccgcccggggtcactctcgccatggacgagctgtacaagtaaacggccgcccga
attggggccaccgggtgtgtagccccctaacgttactggccgaagccgcttgaataaggccggtgtgctgttctatgttat
25 tttccaccatattgccgtcttttggcaatgtgagggcccgaaacctggccctgtcttctgacgagcattctaggggtcttc
ccctctgcccgaaggaatgcaaggtctgtgaatgtctgaaggaagcagttcctctggaagcttctgaagacaacaa
cgtctgtagcgaccttgcaggcagcgaacccccacctggcgacagggtcctctgcccgaacaaagccacgtgtat
aagatacacctgcaaaggcggcacaacccccagtgccacgtgtgagttggatagtttggaagagtc aaatggctctc
ctcaagcgtattcaacaaggggtgaaggatgccagaaggtacccattgtatgggatctgctggtggccctcggtgc
30 acatgctttacatgtgttagtcgagggttaaaaaacgtctagggcccccgaaaccacggggacgtggttttctttgaaaaac
acgataataccatgaccgagtacaagcccacgggtgcgctcgccaccgacgacgacgtccccggggccgtacgcac
cctcgccgcccgttcgcccactaccccgccacgcgcccacacgctcgatccggaccgcccacatcgagcgggtcaccg
agctgcaagaactcttctcaccgcgctcgggctcgacatcggcaaggtgtgggtcgccggacgacggcgccgcggtg
gcggtctggaccacgcccggagagcgtcgaagcggggcggtgttcgcccagatcgcccgcgcatggccgagttga
35 gcggttcccgggtggccgagcagcaacagatggaaggcctcctggcgccgacccggcccaaggagcccgcgtggtt
cctggccaccgtcggtctcgcggaccaccagggaaggggtcgggcagcgcgctgctgctccccggagtgagg
cggccgagcgcgcccgggtgcccgccttctggagacctcgcgccccgcaacctcccccttctacgagcggctcggtt
caccgtcacgcgcgacgtcgagggtgccgaaggaccgcgacctgggtcatgaccgcaagcccgggtgctgacgc
ccgcccacaagaccgcagcgcggcaccgaaaggagcgcacgaccccatgcatcgaatcgatcgccggccgca
40 ctctagatcataatcagcccgggggtgatcagcctcgactgtgccttctagttgccagccatctgtgttgccttccccgt
gccttcttgaccttggaagggtgccactcccactgtccttcttaataaaaatgaggaaattgcatcgcatgtctgagtaggt
gtcattctattctgggggtgggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgtggg
gatgcggtggggtctatggaaccagctggggcgcgattaacttcgtataaagtcctctatcgaagttatcgcgccattct
gttggtgttctcaaaactcatcaatgtatcttatcatgtctggatccatcacaagctctgacctaatcctatagaaagga
45 ggaatgagccaaaattcaccaacttattgtgggaagctgtgtgaaggctactcgaaatgtttgacccaagttaaacaatt
aaaggcaatgtaccaataactaattgagtgatgttaacttctgaccactgggaatgtgatgaagaaataaaagctg
aatgaatcattctctactatttctgatattcacattcttaaaataaagttggatcctaactgaccttaagacagggaat
cttactcggattaaatgtcaggaattgtgaaaaagtgagtttaaatgtatttgctaagggtgatgtaaacttccgacttaac
tgtagggtatccttagagtcgacctgcaggcatgcaagcttggcgtaatcatggatagctgttctctgtgtgaaattgtat
50 ccgctcacaattccacacaacatacagccggaagcataaagtgtaaagcctgggggtccctaagtgagtgagtaactc
acattaattgctgtgcgtcactgcccgtttccagtcgggaacacgtctgtgccagctgcattaatgaatcgcccaacgcg
cggggagaggcggttgcgtattggcgctcttccgcttctcgctcactgactcgctgcgtcgggtcggttcgggtcgccg

agcggatcagctcactcaaaggcggtaatacgggtatccacagaatcaggggataacgcaggaaagaacatgtgag
 caaaaggccagcaaaaggccaggaaccgtaaaaaggccgctgtgctggcgttttccataggctccgccccctgacg
 agcatcacaaaaatcgacgctcaagtcagaggtggcgaaaccgacaggactataaagataaccaggcgtttccccct
 5 ggaagctccctcgtgcgctctcctgttccgacctgcccgttaccggataacctgtccgcctttcccttcgggaagcgtggc
 gcttttcaatgctcacgctgtaggtatctcagttcgggtgtaggtcgttccgctcaagctgggctgtgtgcacgaacccccgt
 tcagcccagccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatgccactggcag
 cagccactggtaacaggattagcagagcgaggtatgtaggcgggtgctacagagttctgaagtgggtggcctaactacgg
 ctacactagaaggacagatatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctctgatcc
 ggcaaacaaaccaccgctggttagcgggtggtttttggttgaagcagcagattacgcgcagaaaaaaggatctcaag
 10 aagatcctttgatcttttacggggtcgtacgctcagtggaacgaaaactcacgttaagggatttgggtcatgagattatcaa
 aaaggatcttcacctagatccttttaataaaaaatgaagtttaatacaatctaaagtatatatgagtaaacttggtctgaca
 gttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgta
 gataactacgatacgggaggggttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctcc
 agatttatcagcaataaaccagccagccggaagggccgagcgcagaagtgggtcctgcaactttatccgcctccatcca
 15 gtctattaattgttgcgggaagctagagtaagtagttcgcagtaaatagtttgcgcaacgttgttgccattgctacaggcat
 cgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatccccatggt
 gtgcaaaaaagcggtagctccttcggtcctccgatcgtgtcagaagtaagttggccgagtggtatcactcatggttatgg
 cagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactgggtgagtactcaaccaagtcattctgaga
 atagtgatgcccgcagccaggtgtcttgcggcgctcaatacgggataataccgcgccacatagcagaactttaaaag
 20 tgcctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccaggtcagtgtaaccact
 cgtgcaccaactgatcttcagcatcttttactttaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgca
 aaaaagggaataagggcgacacggaaatgtgaatactcatacttctcttttcaatattatgaagcatttatcagggttat
 tgtctcatgagcggatacatattgaatgtatttagaaaaataaacaataaggggtccgcgcacatttccccgaaaagtgc
 cacctgacgtctaagaaaccattattatcatgacattaacctataaaaaataggcgatcacgaggccctttcgtc

25

SEQ ID NO: 20

FRThygro cassette

CTATTCCTTTGCCCTCGGACGAGTGCTGGGGCGTCGGTTTCCACTATCGGCGAGTACTTCTACACAG
 CCATCGGTCCAGACGGCCGCGCTTCTGCGGGCGATTTGTGTACGCCCGACAGTCCCGGCTCCGGAT
 30 CGGACGATTGCGTCGCATCGACCTGCGCCCAAGCTGCATCATCGAAATTGCCGTCAACCAAGCTCT
 GATAGAGTTGGTCAAGACCAATGCGGAGCATATACGCCCGGAGCCGCGGCGATCCTGCAAGCTCCG
 GATGCCTCCGCTCGAAGTAGCGCGTCTGCTGCTCCATACAAGCCAACCACGGCCTCCAGAAGAAGAT
 GTTGGCGACCTCGTATTGGGAATCCCCGAACATCGCCTCGCTCCAGTCAATGACCGCTGTTATGCGG
 CCATTGTCCGTCAGGACATTGTTGGAGCCGAAATCCGCGTGCACGAGGTGCCGGACTTCGGGGCAG
 35 TCCTCGGCCCAAAGCATCAGCTCATCGAGAGCCTGCGCGACGGACGCACTGACGGTGTCTGTCATC
 ACAGTTTGCCAGTGATACACATGGGGATCAGCAATCGCGCATATGAAATCACGCCATGTAGTGTATTG
 ACCGATTCTTGCGGTCCGAATGGGCCGAACCCGCTCGTCTGGCTAAGATCGGCCGACGATCGC
 ATCCATGGCCTCCGCGACCGGCTGCAGAACAGCGGGCAGTTTCGGTTTCAGGCAGGTCTTGCAACGT
 GACACCCTGTGCACGGCGGGAGATGCAATAGGTCAGGCTCTCGCTGAATTCCCCAATGTCAAGCACT
 40 TCCGGAATCGGGAGCGCGGCCGATGCAAAGTGCCGATAAACATAACGATCTTTGTAGAAACCATCGG
 CGCAGCTATTTACCCGACAGGACATATCCACGCCCTCTACATCGAAGCTGAAAGCACGAGATTCTTC
 GCCCTCCGAGAGCTGCATCAGGTGCGAGACGCTGTGCAACTTTTCGATCAGAACTTCTCGACAGAC
 GTCGCGGTGAGTTCAGGCTTTTT

45

SEQ ID NO: 21

Sequence of pLV/FRThygro.PGKpuro (FRThygro cassette indicated in green)

AAGCTTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATT
 50 ACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAG
 CCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACCGCCCAACGAC
 CCCC GCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACG

TCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTA
CGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTATG
GGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGC
AGTACATCAATGGGCGTGATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCAATTGACGT
5 CAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTGCGTAACAACTCCGCCCCAT
TGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG
GGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTA
AGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAAC
10 TAGAGATCCCTCAGACCCTTTTAGTCAGTGTGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCT
GAAAGCGAAAGGGAAACCAGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAG
AGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTGACTAGCGGAGGCTAGAAGGAGAGAGA
TGGGTGCGAGAGCGTCAGTATTAAGCGGGGAGAAATTAGATCGCGATGGGAAAAAATTCGGTTAAGG
CCAGGGGGGAAAGAAAAAATATAAATTAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCCG
AGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCC
15 TTCAGACAGGATCAGAAGAAGCTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAA
GGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAC
CACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAA
GTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAA
GAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCTTGGGTTCTTGGGAGCAGC
20 AGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATA
GTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCT
GGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGAAAGATACCTAAAGGATCAACAGCTCCT
GGGGATTTGGGTTGCTCTGGAAGAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGT
AATAAATCTCTGGAACAGATTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTAC
25 ACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTG
GAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTA
TTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGTCTGACTTTCTATAGTGAATAGA
GTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGC
CCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTGATTAGTGAACGGATC
30 TCGACGGTATCGGTTCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAAT
TAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGT
GTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAG
CTAGAGGTCGACGGTATACAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAAGTGAATG
CAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCA
35 ATAACAAGTTGGGGTGGGCGAAGAACTCCAGCATGAGATCCCCGCGCTGGAGGATCATCCAGCCG
GCGTCCCGGAAAACGATTCCGAAGCCCAACCTTTATAGAAAGCGGCGGTGGAATCGAAATCTCGTA
GTACGTGCTATTCTTTGCCCTCGGACGAGTGCTGGGGCGTGGTTTCCACTATCGGCGAGTACTTC
TACACAGCCATCGGTCCAGACGGCCGCGCTTCTGCGGGCGATTTGTGTACGCCCGACAGTCCCGGC
TCCGGATCGGACGATTGCGTCGCATCGACCCTGCGCCCAAGCTGCATCATCGAAATTGCCGTCAACC
40 AAGCTCTGATAGAGTTGGTCAAGACCAATGCGGAGCATATACGCCCGAGCCGCGGCGATCCTGCA
AGCTCCGGATGCCTCCGCTCGAAGTAGCGCGTCTGCTGCTCCATACAAGCCAACCACGGCCTCCAG
AAGAAGATGTTGGCGACCTCGTATTGGGAATCCCCGAACATCGCCTCGCTCCAGTCAATGACCGCTG
TTATGCGGCCATTGTCCGTGAGGACATTGTTGGAGCCGAAATCCGCGTGCACGAGGTGCCGGACTTC
GGGCGAGTCTCGGCCCAAAGCATCAGCTCATCGAGAGCCTGCGCGACGGACGCACTGACGGTGTC
45 GTCCATCACAGTTTGCCAGTGATACACATGGGGATCAGCAATCGCGCATATGAAATCACGCCATGTAG
TGTATTGACCGATTCTTGGCGGTCCGAATGGGCCGAACCCGCTCGTCTGGCTAAGATCGGCCGAGC
GATCGCATCCATGGCCTCCGCGACCGGCTGCAGAACAGCGGGCAGTTCCGTTTTAGGCAGGTCTTG
CAACGTGACACCCTGTGCACGGCGGGAGATGCAATAGGTGAGGCTCTCGCTGAATCCCCAATGTCA
AGCACTTCCGGAATCGGGAGCGCGGCCGATGCAAAGTGCCGATAAACATAACGATCTTTGTAGAAAC
50 CATCGGCGCAGCTATTTACCCGCGAGGACATATCCACGCCCTCCTACATCGAAGCTGAAAGCACGAGA
TTCTTCGCCCTCCGAGAGCTGCATCAGGTGCGGAGACGCTGTGCAACTTTTCGATCAGAAACTTCTCGA
CAGACGTGCGGGTGAAGTTCAGGCTTTTTGGCCAAGGAAGTTCCTATACTTTCTAGAGAATAGGAAGT

CGGAATAGGAACTTCTAGGTACGTGAACCATCACCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAA
AGCACTAAATCGGAACCCTAAAGGGACCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTG
GCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTAC
GCTGCGCGTAACCAACACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTGGGGATACCCCT
5 AGAGCCCCAGAACTTTTAAAAGAAAAGGGGGGATTGGGGGTACAGTGCAGGGGAAAGAATAGTAG
ACATAATAGCAACAGACATACAACTAAAGAATTACAAAACAAATTACAAAATTCAAATTTTATCGA
TCACGAGACTAGCCTCGACGATGGTCGAGTACCGGGTAGGGGAGGCGCTTTTCCCAAGGCAGTCTG
GAGCATGCGCTTTAGCAGCCCCGCTGGGCACTTGCGCTACACAAGTGGCCTCTGGCCTCGCACAC
ATTCACATCCACCGGTAGGCGCCAACCGGCTCCGTTCTTTGGTGGCCCCCTTCGCGCCACCTTCTAC
10 TCCTCCCCTAGTCAGGAAGTTCCCCCGCCCCGAGCTCGCGTCGTGCAGGACGTGACAAATGGA
AGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGCACCGCTGAGCAATGGAAGCGGGTAGGCCTT
TGGGGCAGCGGCCAATAGCAGCTTTGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGAAGGGGTGGG
TCCGGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGCGGGCGCCGAAGGTCCTCCGGAGGC
CCGGCATTCTGCACGCTTCAAAGCGCACGTCTGCCGCGCTGTTCTCTCTCTCATCTCCGGGCC
15 TTTGACCTCTAGCGGGATCCAAGCTTACCATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCC
GCGACGAGCTCCCCCGGGCCGTACGCACCCTCGCCGCCGCTTCGCCGACTACCCCGCCACGCGC
CACACCGTCGACCCGGACCGCCACATCGAGCGGGTACCGAGCTGCAAGAACTCTTCTCACGCGC
GTCGGGCTCGACATCGCAAGGTGTGGTTCGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCAC
GCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCCGCGAGATCGGCCCGCGCATGGCCGAGTTGAGCG
20 GTTCCCGGTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGACCGGCCCAAGGAGCCC
GCGTGGTTCTGGCCACCGTCGGCGTCTCGCCGACCAACAGGGCAAGGGTCTGGGCAGCGCCGT
CGTGCTCCCCGAGTGGAGGCGGCCGAGCGCGCCGGGTGCCCGCCTTCTGGAGACCTCCGCGC
CCCCGAACCTCCCCTTCTACGAGCGGCTCGGCTTACCGTCACCGCCGACGTGAGGTGCCGAAG
GACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACTCGAGGGAATTCCGATAATCAACC
25 TCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAATATGTTGCTCCTTTTACGCTATGTGA
TACGCTGCTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGATA
AATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTGAGGCAACGTGGCGTGGTGTGCAC
TGTGTTTGTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTCCGGGACT
TTCGCTTCCCCCTCCCTATTGCCACGGCGGAATCATCGCCGCTGCCTTGCCTGCTGCTGGACAG
30 GGGCTCGGCTGTTGGGCACTGACAATCCGTGGTGTGTGCGGGGAAGCTGACGTCCTTCCATGGCT
GCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCTTCTGCTACGTCCTTCCGGCCCTCAAT
CCAGCGGACCTTCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCCGCTTCGC
CCTCAGACGAGTCGGATCTCCCTTTGGGCCGCTCCCCGCATCGGGAATTCGAGCTCGGTACCTTTA
AGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAG
35 GGCTAATCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAG
ATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTG
AGTGCTTCAAGTAGTGTGTGCCGTCTGTTGTGTGACTCTGGTAAGTACGATCCCTCAGACCCTTTT
AGTCAGTGTGGAATCTCTAGCAGCATCTAGCTAGAATTAATTCCGTGTATTCTATAGTGTACCTAA
ATCGTATGTGTATGATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTAACGACAATATGTACAAGC
40 CTAATTGTGTAGCATCTGGCTTACTGAAGCAGACCCTATCATCTCTCTCGTAAACTGCCGTCAGAGTC
GGTTTGGTTGGACGAACCTTCTGAGTTTCTGGTAACGCGCTCCCGCACCCGGAATGGTCAGCGAAC
CAATCAGCAGGGTCATCGCTAGCCTAGGCTTTTGGTTCGAGACGTACCCAATTGCCCCATAGTGAG
TCGTATTACGCGCGCTCACTGGCCGTGTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTACCC
AACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGA
45 TCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGGACGCGCCCTGTAGCGGCGCATT
AAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCG
CTCCTTTCGCTTCTTCCCTTCTTCTCGCCACGTTGCGCGGCTTCCCCGTCAAGCTCTAAATCGG
GGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTAGGGTGA
TGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTCGCTTGGAGTCCACGTTCT
50 TTAATAGTGGACTCTTGTTCCAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTATTATA
AGGGATTTTGGCGATTTCCGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTAACGCGAATTT
TAACAAAATATTAACGTTTACAATTTCCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTAT

TTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAA
TAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCA
TTTTGCCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAAGTAAAAGATGCTGAAGATCAGTTGGG
TGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAA
5 GAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGC
CGGGCAAGAGCAACTCGGTGCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTC
ACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGA
TAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGACA
10 ACATGGGGGATCATGTAACGCGCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGA
CGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAAGTGGCGAACTA
CTTACTCTAGCTTCCCGGCAACAATTAAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCT
GCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCG
CGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGG
AGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTG
15 GTAAGTGTGACAGCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTAAATTTAAAAGGA
TCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAG
CGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGC
TTGCAACAAAAAAACCACCGCTACCAGCGGTGGTTTGGTTGCGCGATCAAGAGCTACCAACTCTTTT
TCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAG
20 GCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCT
GCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGAAGTCAAGACGATAGTTACCGGATAAGGCGC
AGCGGTGCGGCTGAACGGGGGGTTCGTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAAC
TGAGATACCTACAGCGTGAGCTATGAGAAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGT
ATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGG
25 TATCTTTATAGTCCTGTGCGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGG
GGGCGGAGCCTATGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCT
TTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGA
GCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGA
GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCAATTAATGCAGCTGGCACGACAG
30 GTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCA
CCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCA
CACAGGAAACAGCTATGACCATGATTACGCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAG
CTGGAGCTGC

Claims

1. A genetically modified pig, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.
5
2. A genetically modified porcine blastocyst derived from the genetically modified pig model as defined in claim 1
and/or
a genetically modified porcine blastocyst, wherein the genetically modified genome
10 comprises at least one site for integration of at least one transgene.
3. A genetically modified porcine embryo derived from the genetically modified pig model as defined in claim 1
and/or
15 a genetically modified porcine embryo, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.
4. A genetically modified porcine fetus derived from the genetically modified pig model as defined in claim 1
20 and/or
a genetically modified porcine fetus, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.
5. A genetically modified porcine donor cell and/or cell nucleus derived from the
25 genetically modified pig model as defined in claim 1
and/or
a genetically modified porcine donor cell and/or cell nucleus, wherein the
genetically modified genome comprises at least one site for integration of at least
one transgene.
30
6. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to any of the preceding claims, wherein said at least one site for integration of at least one transgene is a heterologous recombination site.

7. The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, according to any of the preceding claims, wherein the pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus is a mini-pig.
- 5 8. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to claim 6, wherein the mini-pig is selected from the group consisting of Goettingen, Yucatan, Bama Xiang Zhu, Wuzhishan and Xi Shuang Banna, including any combination thereof.
- 10 9. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to claim 8, wherein said pig is a a Goettingen mini-pig.
10. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according any of the preceding claims, wherein the pig is not a mini-pig.
- 15
11. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to any of the preceding claims, wherein the pig belongs to the species of *S. domesticus*.
- 20
12. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to claim 10, wherein the pig is selected from the group consisting of Landrace, Yorkshire, Hampshire, Duroc, Chinese Meishan, Berkshire and Piétrain, including any combination thereof.
- 25
13. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to any of the preceding claims, wherein the pig is an inbred pig.
- 30 14. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to any of the preceding claims, wherein the genetically modified genome comprises at least one recombination site for site-specific gene insertion.

15. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to claim 14, wherein said at least one recombination site is a recombination site for Flp, Flpe, Flpx9, Φ C31 and/or Cre recombinase.
- 5 16. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to claim 14, wherein said at least one recombination site is selected from the group consisting of attB, attP, loxP and FRT.
- 10 17. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to claim 14, wherein said at least one recombination site is a FRT site.
- 15 18. The genetically modified pig, porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus according to claim 15, wherein said at least one recombination site is a recombination site for Flp.
- 20 19. The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, according to any of the preceding claims, wherein said pig, porcine embryo, blastocyst, fetus and/or donor cell, comprises a transposon tagged genome.
- 25 20. The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, according to any of the preceding claims, wherein said pig, porcine embryo, blastocyst, fetus and/or donor cell, comprises a transposon tagged genome is obtained by integration of the target vector of claim 27.
- 30 21. The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, according to any of the preceding claims, wherein said pig, porcine embryo, blastocyst, fetus and/or donor cell, comprises a transposon tagged genome by use of the system of any of claims 43 to 45.
22. The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, according to any of the preceding claims further comprising at least one transgene.

23. The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, according to claim 22, wherein said transgene is inserted into at least one recombination site.
- 5 24. The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, according to claim 22, displaying a phenotype associated with disease.
25. A genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, wherein the genetically modified genome comprises at least one gene of interest
10 obtained by recombination into the at least one site for integration.
26. The genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, according to any of the preceding claims, obtainable by the use of the recombinant vector of claim 27 and/or the system of claim 43.
15
27. A recombinant target vector comprising a DNA-transposon-based construct comprising a bicistronic gene cassette comprising (i) at least one recombination site and (ii) an IRES-driven selection gene.
- 20 28. The recombinant vector according to claim 27, wherein said DNA transposon is selected from the group consisting of the Sleeping Beauty (SB) transposon, Frog Prince (FP) transposon, Piggybac transposon, Tol2 transposon, Himar 1 transposon and passport transposon.
- 25 29. The recombinant vector according to claim 27, wherein said DNA transposon is the Sleeping Beauty (SB) DNA transposon vector.
30. The recombinant vector according to claim 27, wherein said at least one recombination site is a FRT, attB/P, attB, attP and/or LoxP recombination site.
30
31. The recombinant vector according to claim 27, wherein said at least one recombination site is a FRT recombination site.

32. The recombinant vector according to any of claims 27-31, wherein said recombination site is embedded in the coding sequence of a reporter gene and/or selection gene.
- 5 33. The recombinant vector according to claim 32, wherein said recombination site is embedded in the coding sequence selected from the group consisting of the enhanced green fluorescent protein (eGFP), lac Z, dsRed, enhanced yellow fluorescent protein (eYFP), enhanced cyan fluorescent protein (eCFP), enhanced blue fluorescent protein (eBFP) and the human alpha-1-antitrypsin (hAAT).
- 10 34. The recombinant vector according to claim 32, wherein said recombination site is embedded in the coding sequence of eGFP.
- 15 35. The recombinant vector according to claim 31, wherein said FRT recombination site is embedded in a SV40 promoter driven fusion variant of eGFP.
36. The recombinant vector according to claim 31, wherein said FRT recombination site is embedded in a RSV promoter driven fusion variant of eGFP.
- 20 37. The recombinant vector according to claim 31, wherein said FRT recombination site is embedded in a ubiquitin promoter driven fusion variant of eGFP.
38. The recombinant vector according to claim 27, wherein said IRES- driven selection gene is a gene conferring resistance to a drug.
- 25 39. The recombinant vector according to claim 38, wherein said IRES- driven selection gene is a puromycin resistance gene.
40. The recombinant vector according to claim 27 further comprising at least one recognition site for a Cre recombinase and/or Φ C31 recombinase.
- 30 41. The recombinant vector according to claim 40, wherein said at least one recognition site for Cre recombinase is located between the upper inverted repeat of the vector and the SV40 promoter.
- 35

42. The recombinant vector according to claim 40, wherein said at least one recognition site for Cre recombinase is located between the poly A sequence and the lower inverted repeat of the vector.
- 5 43. A bi-phase system comprising a recombinant target vector of claim 27 and a recombination substrate.
44. The bi-phase system of claim 43, wherein said recombination substrate comprises a fusion of at least one recognition site for a recombinase and a gene of interest.
- 10 45. The bi-phase system of claim 44, wherein said recombination substrate is present in a plasmid, an in vitro generated plasmid-derived minicircle and/or a lentiviral circle.
- 15 46. A mammalian cell comprising a DNA transposon tagged genome containing at least one recombination target site for site-specific gene integration of at least one gene of interest.
- 20 47. A mammalian cell comprising at least one gene of interest, obtained by the use of the system of claim 43.
48. The cell according to claim 46 or 47, wherein said cell comprises a DNA transposon tagged genome by a recombinant vector as defined any of claims 27-31 or by the system of claims 43 to 45.
- 25 49. The cell according to claim 46 or 47, wherein the genome further contains at least one recognition site for Cre-recombinase.
50. The cell according to claim 46 or 47, wherein said cell is a mammalian cell.
- 30 51. The cell according to claim 46 or 47 wherein said cell is a somatic cell.
52. The cell according to claim 46 or 47, wherein said cell is of porcine origin.
- 35 53. The cell according to claim 52, wherein said somatic cell is a fibroblast.

54. The cell according to claim 52, wherein said somatic cell is a primary somatic cell.
55. The cell according to claim 54 , wherein primary somatic cell is a porcine primary
5 fibroblast.
56. A method for producing a mammalian cell comprising a DNA transposon tagged
genome comprising at least one recombination target site for site-specific gene
insertion comprising the steps of
10 a) providing a mammalian cell, b) transfecting the cell of a) with a plasmid expressing a
transposase and a recombinant vector comprising a DNA transposon-based construct
carrying a bicistronic gene cassette comprising (i) a recombination site and ii) an IRES-
driven selection gene, c) selecting DNA transposon tagged cells.
- 15 57. The method of claim 56 further comprising a step of recombination using the
recombination substrate of claim 43.
58. The method of claim 56, wherein said recombinant vector is defined in any of the
claims 27-42.
20
59. The method of claim 56, wherein said mammalian cell is a somatic cell.
60. The method of claim 56, wherein said cell is of porcine origin.
- 25 61. The method of claim 59, wherein said somatic cell is a fibroblast.
62. The method of claim 59, wherein said somatic cell is primary somatic cell.
63. The method of claim 59, wherein said primary cell is a fibroblast.
30
64. A method for obtaining the genetically modified pig, porcine embryo, blastocyst,
fetus and/or donor cell according to any of the preceding claims comprising the
steps of
i) providing a donor cell

- ii) genetically modifying the donor cell of i) by inserting the recombinant vector as defined in any of claims 27 to 42 into the genome of said donor cell
- iii) transferring the modified genome of the donor cell obtained in ii) into a host cell
- iv) obtaining a reconstructed embryo forming an embryo
- v) culturing said embryo; and
- vii) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus,
- wherein said genetically modified embryo obtainable by nuclear transfer comprises steps i) to v) and/or vi),
- wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii),
- wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii).
65. The method of claim 64, wherein said donor cell is a somatic cell.
66. The method of claim 64, wherein said donor cell is a fibroblast.
67. The method of claim 64, wherein said fibroblast is a primary fibroblast.
68. The method of claim 64, wherein said fibroblast is of porcine origin.
69. The method of claim 64, wherein the host cell is an enucleated oocyte cell.
70. The genetically modified pig model, porcine embryo, blastocyst, fetus and/or donor cell according to any of claims 27 to 42 obtainable by nuclear transfer comprising the steps of
- i) establishing at least one oocyte having at least a part of a modified zona pellucida,
- ii) separating the oocyte into at least two parts obtaining an oocyte having a nucleus and at least one cytoplasm,
- iii) establishing a donor cell or cell nucleus with desired genetic properties,

- iv) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus,
v) obtaining a reconstructed embryo,
vi) activating the reconstructed embryo to form an embryo;
5 culturing said embryo; and
vii) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus,
wherein said genetically modified embryo obtainable by nuclear transfer comprises steps i) to v) and/or vi),
10 wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii),
wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii).
- 15 71. A method for producing a genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell, comprising at least one recombination site comprising:
i) establishing at least one oocyte
ii) separating the oocyte into at least three parts obtaining at least one cytoplasm,
20 iii) establishing a donor cell or cell nucleus having desired genetic properties,
iv) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus,
v) obtaining a reconstructed embryo,
25 vi) activating the reconstructed embryo to form an embryo; culturing said embryo; and
vii) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus
wherein said genetically modified embryo obtainable by nuclear transfer
30 comprises steps i) to v) and/or vi) ,
wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii),
wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii).
- 35

72. A method for producing a genetically modified pig, porcine embryo, blastocyst, fetus and/or donor cell comprising:

- i) establishing at least one oocyte
 - 5 ii) separating the oocyte into at least three parts obtaining at least one cytoplasm,
 - iii) establishing a donor cell or cell nucleus having desired genetic properties, wherein the donor cell is established from a genetically modified pig carrying in its genome at least one site for integration of at least one transgene
 - 10 iv) providing a transgene and integrating said transgene into the donor cell of iii)
 - v) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus,
 - vi) obtaining a reconstructed embryo,
 - 15 vii) activating the reconstructed embryo to form an embryo;
 - viii) culturing said embryo; and
 - ix) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus,
- wherein said genetically modified embryo obtainable by nuclear transfer comprises steps i) to v) and/or vi),
- 20 wherein said genetically modified blastocyst obtainable by nuclear transfer comprises steps i) to vi) and/or vii),
- wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to vii).

25 73. The genetically modified pig model, porcine embryo, blastocyst, fetus and/or donor cell according to any of claims 1 to 26 obtainable by nuclear transfer comprising the steps of

- 30 i) establishing at least one oocyte having at least a part of a modified zona pellucida,
- ii) separating the oocyte into at least two parts obtaining an oocyte having a nucleus and at least one cytoplasm,
- iii) establishing a donor cell or cell nucleus with desired genetic properties, wherein the donor cell is established from a genetically

- modified pig carrying in its genome at least one site for integration of at least one transgene
- iv) providing a transgene and integrating said transgene into the donor cell of iii)
- 5 v) fusing at least one cytoplasm with the donor cell or membrane surrounded cell nucleus,
- vi) obtaining a reconstructed embryo,
- vii) activating the reconstructed embryo to form an embryo;
- 10 culturing said embryo; and
- viii) transferring said cultured embryo to a host mammal such that the embryo develops into a genetically modified fetus,
- wherein said genetically modified embryo obtainable by nuclear transfer comprises steps i) to vi) and/or vii),
- wherein said genetically modified blastocyst obtainable by nuclear transfer
- 15 comprises steps i) to vi) and/or vii) and/or viii),
- wherein said genetically modified fetus obtainable by nuclear transfer comprises steps i) to viii).
74. The method according to any of claims 64-73 said method comprising one or more
- 20 of the features as defined in any of the preceding claims, wherein the method for activation of the reconstructed embryo is selected from the group of methods consisting of electric pulse, chemically induced shock, increasing intracellular levels of divalent cations and reducing phosphorylation.
75. The method according to claim any of claims 64-73, said method comprising one or
- 25 more of the features as defined in any of the preceding claims, wherein steps d) and f) are performed sequentially or simultaneously.
76. The method according to any of claims 64-73, said method comprising one or more
- 30 of the features as defined in any of the preceding claims, wherein the embryo is cultured in vitro.
77. The method according to claim 76, wherein the embryo is cultured in sequential
- 35 culture.

78. The method according to any of claims 64-73 said method comprising one or more of the features as defined in any of the preceding claims, wherein the embryo is cryopreserved prior to transfer to a host mammal.
- 5 79. The method according to claim 78, wherein the embryo is at a blastocyst stage.
80. The method according to any of claims 64-73, wherein the pig is not a mini-pig.
- 10 81. The method according to any of claims 64-73, wherein the pig belongs to the species of *S. domesticus*.
82. The method according to any of claims 64-73, wherein the pig is selected from the group consisting of Landrace, Yorkshire, Hampshire, Duroc, Chinese Meishan, Berkshire and Piétrain, including any combination thereof.
- 15 83. The method according to any of claims 64-73, wherein the pig is an inbred pig.
84. The method according to any of claims 64-73, wherein the pig is a mini-pig.
- 20 85. The method of claim 84, wherein the mini-pig is selected from the group consisting of Goettingen, Yucatan, Bama Xiang Zhu, Wuzhishan and Xi Shuang Banna, including any combination thereof.
- 25 86. Use of the vector as defined in any of claims 27 to 42 for the production of genetically modified mammalian cells, genetically modified pig, embryo, blastocyst, fetus and/or cells thereof, comprising at least one site for integration.




Fig. 1




Fig. 2




Fig. 3

4 / 28




Fig. 4

5 / 28




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10

11 / 28




Fig. 11




Fig. 12




Fig. 13

Map of pSBT/RSV-GFIP




Fig. 14




Fig. 15





Fig. 16




Fig. 17

18 / 28




Fig. 18

19 / 28




Fig. 19






Fig. 20

21 / 28



Transposition into minipig cells using a
short PGK- puromycin transposon




Transposition into minipig cells using
the presented transposon

Fig. 21

22 / 28

A colony of green fluorescent minipig cells, containing the presented transposon. The cells were selected with puromycin for 10 days



A green fluorescent blastocyst made from minipig cells containing the presented transposon






Fig. 22




Fig. 23




Fig. 24





Fig. 25

A



B




Fig. 26




Fig. 27




Fig. 28

INTERNATIONAL SEARCH REPORT

International application No
PCT/DK2008/050058

A. CLASSIFICATION OF SUBJECT MATTER INV. A01K67/027 C12N5/10 C12N15/85		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12N A01K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BIOSIS, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VAJTA GÁBOR ET AL: "Somatic cell nuclear transfer in pigs: recent achievements and future possibilities" REPRODUCTION, FERTILITY, AND DEVELOPMENT 2007,, vol. 19, no. 2, 29 January 2007 (2007-01-29), pages 403-423, XP002487378 table 1 page 414, last paragraph - page 415, left-hand column, paragraph 3	1-14, 22, 24, 73-85
X	WO 2007/002372 A (UNIV MINNESOTA [US]; LARUE REBECCA ST CLAIRE [US]; HARRIS REUBEN S [US] 4 January 2007 (2007-01-04) page 5, lines 1-9 claim 4	1-14, 19, 22, 24, 73-85
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents :		
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family		
Date of the actual completion of the international search 31 July 2008		Date of mailing of the international search report 12/08/2008
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Brouns, Gaby

INTERNATIONAL SEARCH REPORT

International application No

PCT/DK2008/050058

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/111252 A (LUDWIG MAXIMILIANS UNI MUENCHE [DE]; PFEIFER ALEXANDER [DE]; WOLF ECKH) 23 December 2004 (2004-12-23) example 1	1-14, 22, 24, 25
X	GEURTS ARON M ET AL: "Conditional gene expression in the mouse using a Sleeping Beauty gene-trap transposon" BMC BIOTECHNOLOGY, vol. 6, June 2006 (2006-06), XP002490455 ISSN: 1472-6750 figure 1	27-30, 40, 42-44, 46-51, 53, 54, 56-59
X	GEURTS ARON M ET AL: "Gene mutations and genomic rearrangements in the mouse as a result of transposon mobilization from chromosomal concatemers" PLOS GENETICS, vol. 2, no. 9, September 2006 (2006-09), pages 1413-1423, XP002490456 ISSN: 1553-7390(print) 1553-7404(ele figure 1	27-30, 40, 42-44, 46-51, 53, 54, 56-59
X	DU Y ET AL: "High overall in vitro efficiency of porcine handmade cloning (HMC) combining partial zona digestion and oocyte trisection with sequential culture" CLONING AND STEM CELLS, MARY ANN LIEBERT, LARCHMONT, US, vol. 7, no. 3, 1 October 2005 (2005-10-01), pages 199-205, XP002413504 ISSN: 1536-2302 the whole document	71-85
A	SORRELL ET AL: "Targeted modification of mammalian genomes" BIOTECHNOLOGY ADVANCES, ELSEVIER PUBLISHING, BARKING, GB, vol. 23, no. 7-8, 1 November 2005 (2005-11-01), pages 431-469, XP005076498 ISSN: 0734-9750 page 459, paragraph 2 - page 461, paragraph 1	6
A	CRAIG NL: "Transposases and integrases" ENCYCLOPEDIA OF LIFE SCIENCES, [Online] 2002, pages 1-7, XP002490457 Retrieved from the Internet: URL: http://mrw.interscience.wiley.com/emrw/9780470015902/els/article/a0000593/current/pdf [retrieved on 2008-07-31] page 1, left-hand column, paragraph 2	

-/--

INTERNATIONAL SEARCH REPORT

International application No

PCT/DK2008/050058

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WIRTH DAGMAR ET AL: "FLP-MEDIATED INTEGRATION OF EXPRESSION CASSETTES INTO FRT-TAGGED CHROMOSOMAL LOCI IN MAMMALIAN CELLS" METHODS IN MOLECULAR BIOLOGY, HUMANA PRESS INC., CLIFTON, NJ, US, vol. 267, 1 January 2004 (2004-01-01), pages 467-476, XP009078530 ISSN: 1064-3745	
A	LARGAESPADA DAVID A: "Generating and manipulating transgenic animals using transposable elements" REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, XX, XX, vol. 1, no. 1, 7 November 2003 (2003-11-07), page 80, XP021009352 ISSN: 1477-7827	
A	SARKAR ABHIMANYU ET AL: "Insulated piggyBac vectors for insect transgenesis" BMC BIOTECHNOLOGY, BIOMED CENTRAL LTD. LONDON, GB, vol. 6, no. 1, 16 June 2006 (2006-06-16), page 27, XP021017053 ISSN: 1472-6750	
P,X	KWAN K M ET AL: "The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs" DEVELOPMENTAL DYNAMICS, WILEY-LISS, INC., NEW YORK, NY, US, vol. 236, no. 11, 1 November 2007 (2007-11-01), pages 3088-3099, XP008094309 ISSN: 1058-8388 figure 1 table 1	27,28,30
P,A	CLARK KARL J ET AL: "Enzymatic engineering of the porcine genome with transposons and recombinases." BMC BIOTECHNOLOGY 2007, vol. 7, 2007, page 42, XP021029482 ISSN: 1472-6750 cited in the application abstract	

-/--

INTERNATIONAL SEARCH REPORT

International application No
PCT/DK2008/050058

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	CLARK KARL J ET AL: "Pigs taking wing with transposons and recombinases." GENOME BIOLOGY 2007, vol. 8 Suppl 1, 2007, page S13, XP002490458 ISSN: 1465-6914 page S13.6, paragraph 3 - page S13.10, paragraph 1 figure 2	
P,A	CLARK K ET AL.: "Transposons and recombinases for engineering the pig genome" TRANSGENIC RESEARCH, vol. 16, 17 October 2007 (2007-10-17), page 840, XP002490459 abstract	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/DK2008/050058

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007002372 A	04-01-2007	AU 2006262020 A1	04-01-2007
		CA 2613008 A1	04-01-2007
		EP 1895835 A2	12-03-2008
		KR 20080025172 A	19-03-2008
WO 2004111252 A	23-12-2004	NONE	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK2008/050058

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - ☒ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material
 - ☒ on paper
 - ☒ in electronic form
 - c. time of filing/furnishing
 - ☐ contained in the international application as filed
 - ☐ filed together with the international application in electronic form
 - ☒ furnished subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments: